

BMJ Open

BMJ Open is committed to open peer review. As part of this commitment we make the peer review history of every article we publish publicly available.

When an article is published we post the peer reviewers' comments and the authors' responses online. We also post the versions of the paper that were used during peer review. These are the versions that the peer review comments apply to.

The versions of the paper that follow are the versions that were submitted during the peer review process. They are not the versions of record or the final published versions. They should not be cited or distributed as the published version of this manuscript.

BMJ Open is an open access journal and the full, final, typeset and author-corrected version of record of the manuscript is available on our site with no access controls, subscription charges or pay-per-view fees (<http://bmjopen.bmj.com>).

If you have any questions on BMJ Open's open peer review process please email info.bmjopen@bmj.com

BMJ Open

What can we learn from top-cited articles in inflammatory bowel disease? A bibliometric analysis and assessment of the level of evidence

Journal:	<i>BMJ Open</i>
Manuscript ID	bmjopen-2017-021233
Article Type:	Research
Date Submitted by the Author:	29-Dec-2017
Complete List of Authors:	Azer, Samy; King Saud University, Medical Education; Australian Professional Teaching, Azer, Sarah; St Vincent Hospital
Keywords:	Inflammatory bowel disease (IBD), Ulcerative colitis (UC), Crohn's disease (CD), Bibliometric analysis, Top-cited articles, Quality of evidence

SCHOLARONE™
Manuscripts

Peer Review Only

1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

What can we learn from top-cited articles in inflammatory bowel disease? A bibliometric analysis and assessment of the level of evidence

FOR PEER REVIEW ONLY

Samy A. Azer¹ and Sarah Azer²

Dr Azer is consultant gastroenterologist and a professor of medical education and the chair of Curriculum Development and Research Unit, College of Medicine, King Saud University, Riyadh, Saudi Arabia¹

Registrar, St Vincent Hospital, University of Melbourne, Victoria, Australia²

Correspondence and requests for reprints should be addressed to Dr Azer:
Curriculum Development and Research Unit,
College of Medicine, King Saud University
P O Box 2925, Riyadh 11461
Saudi Arabia
Telephone: (966) 11-4699178
Fax: (966) 11-4699174

Email: azer2000@optusnet.com.au

SHORT TITLE: Top-cited Inflammatory Bowel Disease

ABSTRACT

Objectives: Our objectives were to identifying the top-cited articles in inflammatory bowel disease (IBD), assessing their characteristics, and identifying the quality of evidence provided by these articles.

Design and outcome measures: The most frequently cited articles in IBD were searched in November 2016 in the Science Citation Index Expanded database. Eligible articles were reviewed for these characteristics- number of years since publication, journal impact factor (JIF), the number of authors, number of females in authorship, number of institutes, countries involved and grants received. The level of evidence was determined using the Oxford Centre for Evidence-Based Medicine guidelines.

Results: The number of citations varied 804 to 3320, total= 65332, median= 1042.50, (IQR= 596). No correlations were found between the number of citations and number of years since publication ($p=0.532$), JIF ($p=0.179$), number of authors ($p=0.770$), females in authorship ($p=0.368$), number of institutes ($p=0.890$), number of countries ($p=0.959$), or number of grants ($p=0.464$). Countries contributed to the majority of articles were United States, United Kingdom, Germany, France and Canada. The levels of evidence were 10 articles at level 1b, 11 articles at level 3a, and 17 articles at level 3b. The overall agreement between evaluators using Fleiss kappa was 0.8252; 95% CI=0.79-0.85.

Conclusions: research papers represented 68% (basic research 15, 30% and clinical research 19, 38%). Although no article had a level of evidence at 1a, the majority of articles were at reasonable high level of evidence. The study also shows gender gap and the fact that women still compose a minority of authorship in this area.

Key words

Inflammatory bowel disease (IBD), Ulcerative colitis (UC), Crohn's disease (CD), Top-cited articles, Bibliometric analysis, Quality of evidence, Number of authors, Female authors, Grants/funds, Institutes, Countries.

Strengths and limitations of the study

- More than one method was used in searching the Science Citation Index Expanded to maximize the yield of the search.
- The articles represent a historic perspective on key discoveries in the area of inflammatory bowel disease.
- A number of characteristics including number of authors, number of females in authorship, number of institutes, number of countries involved, and grants received have been studied against citations received.
- The level of evidence for each article has been evaluated.
- The search was limited to articles in the English language, raising the possibility of failing to include top-cited articles in other languages.

INTRODUCTION

The number of citations received by an article has been used for several years by universities and grant funding bodies in assessing the quality of research produced by researchers, ranking research performance and in making decisions regarding professional promotion and grant applications [1-4]. Thomson Reuters gather the names of these authors in the Highly Cited Researchers database where they are acknowledged for the quality of their work and the size of their research input in a particular area [5]. However, the number of citations cannot explain why researchers cited a paper nor reflect the quality of the research and the outcomes identified in a manuscript. Recently, three machine learning models were applied to predict the top 10% of articles in terms of number of citations to the article, suggesting that the topic rather than the content may be the reason for the high citations [6]. While one may agree that there is a high correlation between the numbers of papers a researcher has published and the total number of citations received [7] it appears that both indices namely the number of citations and the number of publications are reflective of research performance measurement and both have been represented in the *H-index* [8]. This index has been currently used in quantifying an individual's scientific research output in a much more meaningful way than depending on the number of citations alone.

Another criticism against the number of citations is self-citations, citations because researchers do not agree with the results/the explanations given or they have reached to different conclusions [9]. While this may form an argument, it cannot explain the high citation numbers received, particularly when we talk about top-cited articles. Evidence has shown that the number of self-citation because of disagreement is usually not significant in highly cited

1
2
3 articles [10]. Also it has been shown that journals with lower impact factor tend to have a
4
5 higher self-citation rate [11].
6
7

8
9 Therefore, the number of citations and the reputation of contribution to research in a particular
10
11 field cannot be ignored particularly when there is a pattern of consistency and progressive
12
13 input into a discipline over years (a life experience), and a demonstration from publication
14
15 records and citation history of collaboration with other researchers from other institutes at
16
17 local and international levels. Hence the credits given to an author or a group of authors and
18
19 the impact of the work in a particular area can be proportionally related to the citation records
20
21 [12]. The greater the citation history over years, the more influential they are in their specialty
22
23 [13].
24
25

26
27
28 Inflammatory bowel disease comprises ulcerative colitis (UC) and Crohn's disease (CD); both
29
30 pursue a relapsing and remitting course over years. While the two diseases share several
31
32 similarities, they have a number of differences in regard to structures involved, pathogenesis,
33
34 clinical presentation, and management approaches. UC was first reported briefly in mid 1800
35
36 [14], while CD was reported in *the Journal of the American Medical Association (JAMA)* later
37
38 by Crohn, Ginzburg and Oppenheimer in 1932 [15]; describing it as a chronic inflammatory
39
40 bowel disease of the ilium. Later we learnt that CD can involve any part of the gastrointestinal
41
42 tract from the lips to the anal margin but the ileocolonic disease represents the common
43
44 presentation. Since then both diseases have been extensively researched in their different
45
46 aspects and one would be interested to explore top-cited articles that reflect the topics, aspects,
47
48 authors, and institutes that were behind our current knowledge and practices of these two
49
50
51
52
53 diseases.
54
55
56
57
58
59
60

1
2
3 However, there are no research publications covering top-cited articles in IBD. The
4
5 identification and analysis of the top-cited articles in inflammatory bowel disease bring a
6
7 number of educational and research-related issues that we need to consider:
8
9

10
11 First, these articles can be considered a cornerstone in the field; advanced our knowledge
12
13 about IBD, and enabled us to make definitive progress in understanding its epidemiology,
14
15 pathogenesis, diagnostic procedures, and management.
16
17

18
19 Second, these articles reflect the work of key authors and research teams from particular
20
21 institutes and countries that have made significant contribution to inflammatory bowel disease
22
23 over the last 50-60 years or at least their work was the nucleus of hundreds of other research
24
25 projects.
26
27

28
29 Third, the analysis of the indicators/parameters related to these articles such as number of
30
31 authors, number of female authors, number of institutes, number of countries involved, and
32
33 number of funds/grants received could help in understanding which of these parameters may
34
35 correlate with higher number of citations and explain key features related to a successful or
36
37 influential paper.
38
39

40
41 Therefore, the aims of the present research were: First, identify the top-cited articles in IBD.
42
43 Second, analyze their characteristics and evaluate any correlations between the number of
44
45 citations and the number of years since publications, the number of authors, the number of
46
47 females in authorship, the number of institutes, the number of countries involved and the
48
49 number of funds/grants received. Because of the assumption that researchers tend to cite
50
51 recently published articles, it was decided to compare the yearly mean citations received by
52
53 articles published before the year 2000 compared with the yearly means of those published
54
55
56
57
58
59
60

1
2
3 after the year 2000. Third, assess the quality of evidence provided by articles. The findings
4 from this study could enable clinicians, pathologists, other allied health professionals, post-
5 graduate students, and researchers to explore key articles behind the progress in this topic over
6 the last few decades and identify areas that need further research. As well as explore the
7 characteristics of these articles and what can be learnt from such analysis.
8
9
10
11
12
13
14
15
16
17

18 **METHODS**

19 **Study Design**

20 The database, the Science Citation Index Expanded (SCI-Expanded) database of the Thomson
21 Reuters Web of Science was searched for the identification of the top-cited articles and
22 tracking the citation records of each publication. Although Scopus and Google Scholar also
23 provide citation records, it was decided to limit the search to SCI-Expanded database.
24 Compared to other databases, SCI-Expanded database is regularly updated and the 2015
25 Journal Citation Reports (JCRs) included more than 6,500 journals across 150 disciplines.
26 Although Google Scholar database is freely available, it was not used because it is difficult to
27 search, and it cites textbooks, monographs, conference proceedings, as well as non-peer
28 reviewed publications [16]. It is also not possible to track the yearly records of citations
29 attracted by each article since publication. Scopus database was not used because it is not
30 extensive in its coverage and its records only go back to 1996 [17].
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47

48 To achieve the first two aims of this study we planned to identify the highly cited articles in
49 IBD and assess if there were any correlation between the number of citations and any of the
50 parameters characterizing these highly cited articles- number of authors, percentage of female
51 authors, number of institutes, number of countries involved, and number of grants/funds
52
53
54
55
56
57
58
59
60

1
2
3 received. Regarding the third aim we planned to grade each article against the level of
4
5 evidence hierarchy as per the Oxford Centre for Evidence-Based Medicine (OCEBM-2011
6
7 Levels of Evidence and the accompanying Table of Evidence Glossary) [18, 19].
8
9

10 11 12 13 **Searching the Science Citation Index Expanded Database**

14
15 On 5th to 9th of November 2016, two researchers (the author who is a professor of medical
16
17 education, consultant gastroenterologist, and a fellow of the American College of
18
19 Gastroenterology together with a research assistant who has medical background) searched the
20
21 SCI-Expanded database to retrieve top-cited articles in inflammatory bowel disease. The
22
23 search words used were the following: “Inflammatory bowel disease”, “Ulcerative colitis”,
24
25 “Crohn’s disease”, “IBD”, “Experimental colitis”, “Animal models for Colitis”, “Animal
26
27 models for inflammatory bowel disease”, “Pathology IBD”, “Pathology UC”, “Pathology CD”,
28
29 “Pathogenesis IBD”, “Pathogenesis UC”, “Pathogenesis CD”, “Treatment IBD”, “Treatment
30
31 UC”, “Treatment CD”, “Investigation IBD” and “Regional ileitis”. To increase the yield of the
32
33 search, we used the full terms- inflammatory bowel disease, ulcerative colitis, and Crohn’s
34
35 disease for the abbreviations IBD, UC, and CD, respectively. These search words were
36
37 identified from the terminology used in gastroenterology journals and the proceedings of
38
39 major conferences on inflammatory bowel disease and gastroenterology such as the British
40
41 Society of Gastroenterology (BSG), the American Gastroenterological Association (AGA),
42
43 American College of Gastroenterology (ACG), Canadian Association of Gastroenterology
44
45 (CAG), Scottish Society of Gastroenterology (SSG), and Gastroenterological Society of
46
47 Australia (GESA). For each search word, the results were arranged using a link on the Science
48
49 Citation Index Expanded database system “sort-by” – “Time Cited- highest to lowest”. The
50
51
52
53
54
55
56
57
58
59
60

1
2
3 results showed the articles organized in a descending order with the articles most frequently
4 cited on the top. A copy of the results was printed out for further analysis. The findings from
5 each search word were then arranged on one Excel sheet (Microsoft Excel 2010, Microsoft
6 Corp, Redmond, WA) in a descending order based on the number of citations. Duplicate
7 articles and articles not in the English language were excluded. Articles with identical
8 absolute number of citations were identified and were ranked on the basis of average citation
9 per year. The average number of citations per year is the ratio calculated from the number of
10 citations obtained by an article divided by the number of years since published [20]. A copy of
11 all papers included in the list was obtained and read by the two evaluators.
12
13
14
15
16
17
18
19
20
21
22
23

24 Using the above mentioned search words, we conducted another search of major
25 gastroenterology journals and the 2015-JCR under the category “Gastroenterology and
26 Hepatology”. This category comprises 76 journals at the time of conducting the search; of
27 these seven journals were in languages other than English and were not searched.
28 Gastroenterology journals publishing articles not in the English language were excluded
29 because neither the author nor the assistant researchers are competent in the Spanish, Italian or
30 German languages. Since the language recommended by the journal publishing this work is
31 English and its readers are most likely interested in research publications in the English
32 language, we decided not to search these journals.
33
34
35
36
37
38
39
40
41
42
43
44
45

46 Interestingly, after identifying the list of top-cited articles in IBD, and again checking these
47 seven non-English journals, none had a paper with a citation higher than the paper ranked
48 number 50 in the list.
49
50
51

52 Also these key words were used in searching the websites of major general medicine, surgery
53 and research journals including the *New England Journal of Medicine*, *Lancet*, *the British*
54
55
56
57
58
59
60

1
2
3 *Medical Journal, the Journal of the American Medical Association, Annals of Internal*
4 *Medicine, Archives of Medicine, PLOS Medicine, Annals of Surgery, Archives of Surgery,*
5 *British Journal of Surgery, American Journal of Surgical Pathology, Nature, Science, Nature*
6 *Reviews Cancer, Nature Genetics, Nature Medicine, Cell, Nature Reviews Microbiology,*
7 *Immunity, Nature Reviews Immunology, Nature Reviews Molecular Cell Biology, and Journal*
8 *of Immunology.*
9

10
11
12 A list identifying the 50 top-cited articles was reviewed again and checked regarding
13 authorship, year of publication, title of the article, journal publishing the work, the Journal
14 Impact Factor (JIF) at the time of the search, the number of citations and the institution of the
15 first author (Appendix 1). Two articles shared the same citation number and the average
16 citation per year was used to justify their ranking order. The average citation per year is
17 calculated using this equation= total number of citations obtained/number of years calculated
18 from the year of publication to the time of the research.
19
20
21
22
23
24
25
26
27
28
29
30
31
32

33
34
35
36
37 =====Add Appendix 1 =====
38
39
40
41

42 **Inclusion And Exclusion Criteria**

43
44 The inclusion criteria were: (i) papers focusing on inflammatory bowel disease (ulcerative
45 colitis or Crohn's disease) in the English language, and (ii) articles, reviews, research papers,
46 reports, meta-analysis on any aspect related to inflammatory bowel disease in the English
47 language (aetiology, contributing factors, incidence, population studies, pathology,
48 pathogenesis, investigations, treatment/management, medications, nutrition, health promotion,
49 patient education, animal studies, clinical studies, *in vitro* or *in vivo* studies or any related
50
51
52
53
54
55
56
57
58
59
60

1
2
3 clinical, healthcare, research issues). The exclusion criteria were: (i) articles on inflammatory
4 bowel disease in languages other than English, (ii) articles that focused on other diseases and
5 inflammatory bowel disease was not the main focus, and (iii) studies that focus on other types
6 of colitis and not inflammatory bowel disease.
7
8
9
10
11

12 **Assessing Articles**

13
14
15 The full text of the identified 50-top cited articles was obtained and a copy was given to each
16 researcher. The following information was collected for each article: (i) the authors' names,
17 the number of authors, their affiliations, and the number of females contributing to authorship,
18 (ii) the number of institutes involved in the publication, (iii) the city and country of the origin
19 of the publication, (iv) the total number of citations obtained up to the day of searching the
20 database, and the number of yearly citations since publication, (v) the year of publication and
21 the calculated number of years since published, and (vi) the number of funds/grants stated in
22 the publication and the Web of Science.
23
24
25
26
27
28
29
30
31
32
33

34 We have not used the classification provided by the Web of Science regarding study type
35 because we noted that the Web of Science allocates publications that are original research,
36 articles, practical guides and reviews and identified them as articles or reviews. For
37 consistency and the purpose of this study, the system we used groups the top-cited articles into
38 four types - article, review paper/meta-analysis, report, and research. A definition of each type
39 is given in the glossary. Two researchers independently allocated each of the top-cited articles
40 under its type as per the definition given. Any differences between the researchers were
41 discussed in a meeting until a decision was reached.
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

1
2
3 The topics covered by the top-cited articles were identified by each researcher independently
4 and were discussed in a meeting to harmonize the grouping into a logical, simple and practical
5 way. Articles that covered more than one topic were classified on the basis of the aim of the
6 study and the main outcomes. For other evaluations of an article including the number of
7 authors, the number of females represented in authorship, the number of institutes, and
8 countries contributing to the work, and the number of grants/funds received we checked the
9 original article for such details. Regarding the identification of females in the authorship we
10 noted that several journals use abbreviations of the first and second name rather than the full
11 name. In order to identify the females in these articles we tried to search the Google database
12 to find the university, personal website of the author, their LinkedIn or ResearchGate
13 accounts. We also tried to identify them by searching the Google Scholar database and
14 identify their account, where we can find other publications under their name and the full first
15 name.

34 **Evaluating the Journals**

35
36 The publishing journals of the top 50 articles in IBD were identified and evaluated in regard to
37 the following: (i) the 2015-Journal Impact Factor (JIF) of each journal, and (ii) the ranking
38 order of each article in comparison to other articles published in that journal. This was based
39 on the number of citations obtained in comparison to the citation numbers received by other
40 articles published in the journal. For example, an article ranked number one, in its publishing
41 journal, means that the article received the highest number of citations in comparison to all
42 other articles published in that journal. This evaluation aimed at assessing the position order of
43 articles identified among the 50 top-cited articles in IBD in regard to their ranking among
44 other articles published in the journal. Such assessment highlights the significance of the
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

1
2
3 inflammatory bowel disease articles among other topics published in gastroenterological
4 journals as well as general medicine journals such as *The New England Journal of Medicine*,
5 *The Lancet*, *the British Medical Journal*, *Medicine*, and top research journals such as *Nature*,
6 *Nature Genetics*, *Science*, *Cell*, and top journals in immunology such as *Nature Reviews*
7 *Immunology*, and *Immunity* (Appendix 1).
8
9
10
11
12
13
14
15
16
17

18 **Assessing Level of Evidence**

19 Two researchers independently used the Oxford Centre for Evidence-Based Medicine
20 (OCEBM-2011 Levels of Evidence and the accompanying Table of Evidence Glossary)
21 [18,19] to rank each article regarding level of evidence. In 1998 this hierarchical of evidence
22 was first produced to make the process of finding relevant evidence feasible. Since then the
23 levels have been reviewed and amended, and the version used in this research is the currently
24 available version. [18,19]. This evaluation aimed at identifying the level of evidence of each
25 article and assessing whether the highly cited articles have received higher scores in regard to
26 level of evidence as per the Oxford hierarchy.
27
28
29
30
31
32
33
34
35
36
37
38
39
40

41 **Statistical Analysis**

42 Pearson's correlation coefficient (r) was calculated to determine if the high citation numbers
43 obtained was related to the age of the article. Other correlations were between the number of
44 citations and the number of authors, the percentage of females in authorship, the number of
45 institutes, the number of countries involved, the number of grants received, and the Journal
46 Impact Factor (JIF) of the journals in which articles were published. Because of the
47 assumption that researchers usually cite recently published articles, it was decided to compare
48
49
50
51
52
53
54
55
56
57
58
59
60

1
2
3 the mean yearly citations received of articles published before the year 2000 and compare
4 them with those published after the year 2000. All analyses were conducted using SPSS
5 Software (IBM SPSS Statistics Premium version 22.0 for Mac OS-SPSS Inc., Chicago, IL,
6 USA) and the results were reported at total, mean, median, IQR, and percentage. The inter-
7 rater agreement between evaluators was calculated using the Fleiss kappa scale [21].
8
9
10
11
12
13
14
15
16

17 **RESULTS**

18 **Top-Cited Papers Identified**

19
20 Appendix 1 summarizes the top-cited articles in IBD identified by searching the Science
21 Citation Index Expanded database [22-71]. The articles are listed in a descending order from 1
22 to 50 with the highest absolute citation number is ranked 1 and the article with the lowest
23 citation ranked 50 as per the day of the search. Articles with the same number of citations
24 were ranked on the basis of average citation per year (the articles ranked 46 and 47 had the
25 same citation number 814, they were allocated to a ranking order based on the calculated
26 citation per year, 50.9 and 30.1, respectively).
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42

43 Table 1 summarizes the year of publication and article type. The articles were published over
44 57 years (from 1955 to 2012). During the period from 1955 to 1976, only 3 articles (6%)
45 were published. However, the number increased significantly from 1977 to 1994 making a
46 total of 13 (26%) articles. The number of publications increased significantly to 34 (68%)
47 during the years from 1995 to 2012. No correlation was found between the number of citations
48 of these papers and the number of years since published (Pearson correlation (r) = 0.090, p =
49
50
51
52
53
54
55
56
57
58
59
60

1
2
3 0.532). To assess if there were differences between old articles (published before the year
4 2000) and those published after the year 2000, it was decided to study the mean number of
5 citations received by top-cited articles in each year after their publications. The year 2000 was
6 taken as a midpoint for comparison because the majority of articles identified were published
7 in the period after the year 1986, and hence the year 2000 could represent such point. As
8 shown from Figures 1A and 1B, the mean numbers of citations were higher for articles
9 published after the year 2000 compared to those published before the year 2000.

10
11
12
13
14
15
16
17
18
19 Approximately one fourth of the top-cited papers were reviews/meta-analysis (n= 13, 26%),
20 two-thirds were research papers (n= 34, 68%), and the remaining were articles (n= 2, 4%) and
21 a report (n=1, 2%).
22
23
24
25
26
27
28
29

30 =====Please Add Table 1 here=====

31
32
33
34
35
36 Table 2 summarizes the distribution of IBD topics covered in the top-cited articles. These can
37 be summarized as follows: Epidemiology and prevalence (n=2, 4%), Crohn's disease genetic
38 susceptibility and NOD2 mutation (n=7, 14%), Animal models (n= 6, 12%), Pathogenesis of
39 IBD (n= 13, 26%), classification and index of disease activity (n= 5, 10%), risk of developing
40 colorectal cancer (n= 2, 4%), extra-intestinal complications (n= 1, 2%), Infliximab in Crohn's
41 disease (n= 6, 12%), corticosteroids in ulcerative colitis (n=1, 2%), drug treatment and
42 cyclosporine in ulcerative colitis (n= 2, 4%), adalimumab in Crohn's disease (n=1, 2%), 5-
43 aminosalicylic acid in ulcerative colitis (n=1, 2%), 6-mercaptopurine in Crohn's disease (n=1,
44 2%), and monoclonal antibiotics, and anti-tumour necrosis factor in Crohn's disease (n=2,
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

1
2
3 4%). As shown in Appendix 1, 15 (30%) were basic research and 19 (38%) were clinical
4
5 research. The level of evidence is discussed later in the results.
6
7
8
9
10

11
12 =====Please Add Table 2 here =====
13
14
15
16
17

18 The articles were published in the following journals: *New England Journal of Medicine* (n=
19 12, 24%), *Gastroenterology* (n= 10, 20%), *Nature* (n=4, 8%), *Nature Genetics* (n=4, 8%), *The*
20 *Lancet* (n= 3, 6%), *Proceedings of the National Academic of Sciences of the United States of*
21 *America* (n=2, 4%), *Cell* (n= 2, 4%), and *Gut* (n= 2, 4%). See Table 3 for more details about
22 the journals publishing these articles.
23
24
25
26
27
28
29
30
31
32

33
34 =====Please Add Table 3 here =====
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

Looking at the ranking of the top-cited articles in IBD in the journals they were published in
could provide a better picture about the influence of these articles. This influence would be
clearly demonstrated when the journal has a relatively higher Journal Impact Factor. The
ranking is based on the number of citations received by an article compared to the number of
citations received by other articles that were published in that journal. The article by Best et al
(1976) [25] is ranked number 4 in the list, and also ranked number 2 among all articles
published in *Gastroenterology* (2015-JIF = 18.187). The article by Eaden et al [42] is ranked
number 21 in the list and also ranked number 1 among all articles published in *Gut* (2015-JIF=

1
2
3 14.921). The ranking of other articles in List and their rankings in the journals in which they
4
5 were published are shown in Appendix 1.
6
7

8
9 The first author of the top-cited articles was from the United States (n= 25, 50%), The United
10
11 Kingdom (n=6, 12%), Germany (n= 6, 12%), France (n= 4, 8%), Canada (n= 3, 6%), Belgium
12
13 (n= 2, 4%), Japan (n=2, 4%), Sweden (n=1, 2%), and the Netherlands (n=1, 2%).
14
15

16
17 Table 4 summarises the 72 authors who have published two papers or more in the top-cited
18
19 IBD. Of these 19 authors were the first author and coauthors of more than two papers in total,
20
21 one was only the first author of two papers, all the remaining, 52 were coauthors of more than
22
23 two papers. Top authors were Rutgeers, P (n=10 papers), Targan, SR (n=8 papers), Schreiber,
24
25 S (n=8 papers), Cho, JH (n=7 papers), Colombel, JF (n=7 papers), Hanauer, SB (n=7 papers),
26
27 Duerr, RH (n=6 papers), Silverberg, MS (n=6 papers), and each of the following authors have
28
29 5 papers: Podolsky, DK, Rioux, JD, Daly MJ, Steinhart, AH, Rotter, JI, Schumm, LP, van
30
31 Deventer, SJ, Taylor, KD, Vermeire, S, Mathew, CG, and Regueiro, M.
32
33
34
35
36
37
38
39

40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60
=====Please Add Table 4 here =====

61
62
63
64
65
66
67
68
69
70
71
72
73
74
75
76
77
78
79
80
81
82
83
84
85
86
87
88
89
90
91
92
93
94
95
96
97
98
99
100
101
102
103
104
105
106
107
108
109
110
111
112
113
114
115
116
117
118
119
120
121
122
123
124
125
126
127
128
129
130
131
132
133
134
135
136
137
138
139
140
141
142
143
144
145
146
147
148
149
150
151
152
153
154
155
156
157
158
159
160
161
162
163
164
165
166
167
168
169
170
171
172
173
174
175
176
177
178
179
180
181
182
183
184
185
186
187
188
189
190
191
192
193
194
195
196
197
198
199
200
201
202
203
204
205
206
207
208
209
210
211
212
213
214
215
216
217
218
219
220
221
222
223
224
225
226
227
228
229
230
231
232
233
234
235
236
237
238
239
240
241
242
243
244
245
246
247
248
249
250
251
252
253
254
255
256
257
258
259
260
261
262
263
264
265
266
267
268
269
270
271
272
273
274
275
276
277
278
279
280
281
282
283
284
285
286
287
288
289
290
291
292
293
294
295
296
297
298
299
300
301
302
303
304
305
306
307
308
309
310
311
312
313
314
315
316
317
318
319
320
321
322
323
324
325
326
327
328
329
330
331
332
333
334
335
336
337
338
339
340
341
342
343
344
345
346
347
348
349
350
351
352
353
354
355
356
357
358
359
360
361
362
363
364
365
366
367
368
369
370
371
372
373
374
375
376
377
378
379
380
381
382
383
384
385
386
387
388
389
390
391
392
393
394
395
396
397
398
399
400
401
402
403
404
405
406
407
408
409
410
411
412
413
414
415
416
417
418
419
420
421
422
423
424
425
426
427
428
429
430
431
432
433
434
435
436
437
438
439
440
441
442
443
444
445
446
447
448
449
450
451
452
453
454
455
456
457
458
459
460
461
462
463
464
465
466
467
468
469
470
471
472
473
474
475
476
477
478
479
480
481
482
483
484
485
486
487
488
489
490
491
492
493
494
495
496
497
498
499
500
501
502
503
504
505
506
507
508
509
510
511
512
513
514
515
516
517
518
519
520
521
522
523
524
525
526
527
528
529
530
531
532
533
534
535
536
537
538
539
540
541
542
543
544
545
546
547
548
549
550
551
552
553
554
555
556
557
558
559
560
561
562
563
564
565
566
567
568
569
570
571
572
573
574
575
576
577
578
579
580
581
582
583
584
585
586
587
588
589
590
591
592
593
594
595
596
597
598
599
600
601
602
603
604
605
606
607
608
609
610
611
612
613
614
615
616
617
618
619
620
621
622
623
624
625
626
627
628
629
630
631
632
633
634
635
636
637
638
639
640
641
642
643
644
645
646
647
648
649
650
651
652
653
654
655
656
657
658
659
660
661
662
663
664
665
666
667
668
669
670
671
672
673
674
675
676
677
678
679
680
681
682
683
684
685
686
687
688
689
690
691
692
693
694
695
696
697
698
699
700
701
702
703
704
705
706
707
708
709
710
711
712
713
714
715
716
717
718
719
720
721
722
723
724
725
726
727
728
729
730
731
732
733
734
735
736
737
738
739
740
741
742
743
744
745
746
747
748
749
750
751
752
753
754
755
756
757
758
759
760
761
762
763
764
765
766
767
768
769
770
771
772
773
774
775
776
777
778
779
780
781
782
783
784
785
786
787
788
789
790
791
792
793
794
795
796
797
798
799
800
801
802
803
804
805
806
807
808
809
810
811
812
813
814
815
816
817
818
819
820
821
822
823
824
825
826
827
828
829
830
831
832
833
834
835
836
837
838
839
840
841
842
843
844
845
846
847
848
849
850
851
852
853
854
855
856
857
858
859
860
861
862
863
864
865
866
867
868
869
870
871
872
873
874
875
876
877
878
879
880
881
882
883
884
885
886
887
888
889
890
891
892
893
894
895
896
897
898
899
900
901
902
903
904
905
906
907
908
909
910
911
912
913
914
915
916
917
918
919
920
921
922
923
924
925
926
927
928
929
930
931
932
933
934
935
936
937
938
939
940
941
942
943
944
945
946
947
948
949
950
951
952
953
954
955
956
957
958
959
960
961
962
963
964
965
966
967
968
969
970
971
972
973
974
975
976
977
978
979
980
981
982
983
984
985
986
987
988
989
990
991
992
993
994
995
996
997
998
999
1000

1
2
3 Illinois, the United States, University of Pittsburgh, Pittsburgh, Pennsylvania, the United
4
5 States, University Hospital of Cleveland Case Western Reserve University School of
6
7 Medicine, Ohio, the United States, Wellcome Trust Centre for Human Genetics, University of
8
9 Oxford, Roosevelt Drive, Oxford, the United Kingdom, Wellcome Trust Sanger Institute,
10
11 Wellcome Trust Genome Campus, Cambridge, the United Kingdom, and Institute of Virology
12
13 and Immunobiology, University of Würzburg, Germany. See Appendix 1 for more detail.
14
15
16

17 18 **Characteristics of the Top-Cited Articles**

19
20 These articles were created by 673 authors, median 7.0, minimum 1, maximum 106, IQR 12;
21
22 the females in authorship were 115, median 1.0, minimum 0, maximum 20, IQR 2. It is worth
23
24 mentioning here that it was difficult to identify the gender of authors in two papers because
25
26 the full first and middle names were not shown and it was difficult to find more information or
27
28 clues to make a decision. The number of institutes involved were 431, median 3.0, minimum
29
30 1, maximum 88, IQR 9; the countries involved were 139, median 1.0, minimum 1, maximum
31
32 16, IQR 2; and the number of grants/funds were 334, median 1.0, minimum 0, maximum 94,
33
34 IQR 3. No correlations were found between the number of citations and the Journal Impact
35
36 Factor (JIF) (Pearson correlation (r) = 0.193; p =0.179), the number of authors (r = -0.042; p =
37
38 0.770), number of females in authorship (r = -0.125; p = 0.368), the number of institutes
39
40 involved (r = -0.020; p = 0.890), the number of countries involved (r = 0.007; p = 0.959), and the
41
42 number of grants received (r = -0.106; p =0.464).
43
44
45
46
47
48

49 **Level of Evidence**

50
51 Table 5 summarizes the grading of articles according to the Oxford Center for evidence-based
52
53 medicine. The table shows that most articles were graded at levels 1b and 3a and 3b evidence
54
55 (10 papers had level 1b evidence, 11 papers at level 3a, and 17 papers had level 3b evidence).
56
57
58
59
60

1
2
3 Only 5 papers had a level of evidence of 4 and one paper at level 5. No papers were at level
4
5 1a. The remaining 3 papers were at level 2b and two papers at level 2c. The overall agreement
6
7 between the evaluators was acceptable; Fleiss kappa= 0.8252; 95% CI 0.79-0.85.
8
9

10
11
12
13
14 =====Please Add Table 5 here =====
15

16 17 18 19 20 **DISCUSSION**

21
22
23 This study aimed at identifying the characteristics of the top 50 most frequently cited papers in
24
25 IBD and assessing the quality of evidence provided. The papers covered a number of key
26
27 topics related to IBD including: epidemiology and prevalence, pathogenesis and genetic
28
29 susceptibility of NOD2 mutation, animal models, clinical classification and indices of disease
30
31 activity, risks of developing colorectal cancer, extra-intestinal complications, and use of
32
33 infliximab, adalimumab, monoclonal antibodies and anti-tumour necrosis factor, and 6-
34
35 mercaptopurine in CD, and use of 5-aminosalicylic acid, corticosteroids, and cyclosporine in
36
37 treating UC. While these topics cover key issues related to IBD, topics related to molecular
38
39 biology, surgical management, patient education, nutritional aspects, radiological and other
40
41 investigations were not represented in the top-cited articles list [72-73].
42
43
44
45
46

47
48 The assessment of the characteristics of the top 50 highly cited articles identified in this study
49
50 reveals the following:
51

52
53 First, the lack of correlations between the number of citations and the number of years since
54
55 publication may indicate that the high citation numbers are not caused by ageing of these
56
57
58
59
60

1
2
3 articles. In fact, only 16 articles (32%) were published in the period from 1955 to 1994 (39
4 years), while the majority 34 (68%) were published in the last 17 years. This paper also shows
5 that the mean number of citations of articles published before the year 2000 were much lower
6 than those of articles after the year 2000. This may be related to the tendency of researchers to
7 cite recently published research and new findings [74] and papers that they have read [20, 75].
8 Also the higher citations have been found to be the strongest predictor of current online
9 availability after long time since publication. Therefore, the higher citation could be a
10 protective mechanism for continued availability of a publication despite aging and hence
11 continuing citation [76].
12
13
14
15
16
17
18
19
20
21
22
23

24 Second, the lack of a correlation between the number of citations and the Journal Impact
25 Factor (JIF). The JIF has been widely used in ranking and evaluating journals. It stands as a
26 proxy for the relative importance of a journal with its field [77]. Although the top-cited
27 articles identified were published in journals with high impact factors, the impact factors of
28 some journals were not necessarily the highest in their fields. For example, *Human Pathology*,
29 *Laboratory Investigation*, *Canadian Journal of Gastroenterology and Hepatology*, *Medicine*
30 *(Baltimore)*, *Journal of Immunology*, *Infection and Immunity*, and *Scandinavian Journal of*
31 *Gastroenterology* had JIFs in the range of 2.1 to 4.9. With this information in mind one may
32 postulate that the high JIF is not necessarily related to the higher citation numbers received.
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

Third, the study showed negative correlation between the number of citations and the number
of authors, the number of female authors, or the number of institutes. The number of authors

1
2
3 and females in authorship varied from one to 106 and from zero to 20, respectively. Also the
4
5 number of institutes involved varied from one to 88. The question that can be raised in this
6
7 regards; are we expecting an increase in number of citations as the number of authors or the
8
9 number institutes involved increased? The work of Garcia-Aroca et al [80] shows that
10
11 collaboration between authors increases their impact and increases citation rates. However,
12
13 they showed that publishing in English in certain journals and collaborating with certain
14
15 authors and institutes increase the visibility of the manuscripts published on the subject.
16
17 Hence it is the quality of collaboration rather than the absolute number of these parameters.
18
19 Recently Tanner-Smith and Polanin showed that studies conducted by more established
20
21 authors (have higher h-indices) and reported in more prestigious journal outlets are more
22
23 likely to be cited by other scholars, even after controlling for various proxies of study quality
24
25 [81].
26
27
28
29
30

31
32 Although the proportion of women in authorship of original research in the United States in
33
34 general has significantly increased in the last four decades, women still compose a minority of
35
36 the authors of original research [82]. In the field of gastroenterology, the percentage of the
37
38 United States female physician authors of original research in the field has relatively increased
39
40 over time, yet the senior author position remains lower than expected [83,84].
41
42
43

44
45 Fourth, the study showed no correlation between the number of citations and the number of
46
47 funds/grants received. This finding is not surprising. Recently it was shown that too many of
48
49 the United States authors of most influential papers in science do not receive NH funding [85].
50
51 Another group of researchers found no association between grant percentile ranking and grant
52
53 outcome as assessed by number of top-10% articles per dollar million spent [86].
54
55
56
57
58
59
60

1
2
3 The United States, the United Kingdom, Germany, France, and Canada contributed to the
4 majority of these articles. The leadership of universities from these countries in
5
6 gastrointestinal research particularly IBD is no surprise, top universities identified from this
7
8 study were Massachusetts General Hospital and Harvard Medical School, Boston,
9
10 Massachusetts, the United States, Mount Sinai School of Medicine, New York, the United
11
12 States, Mayo Clinic, Rochester, Minnesota, the United States, Cedars-Sinai Medical Center,
13
14 Los Angeles, California, the United States, University of Chicago Medical Center, Chicago,
15
16 Illinois, the United States, University of Pittsburgh, Pittsburgh, Pennsylvania, the United
17
18 States, University Hospital of Cleveland Case Western Reserve University School of
19
20 Medicine, Ohio, the United States, Wellcome Trust Centre for Human Genetics, University of
21
22 Oxford, Roosevelt Drive, Oxford, the United Kingdom, Wellcome Trust Sanger Institute,
23
24 Wellcome Trust Genome Campus, Cambridge, the United Kingdom, Institute of Virology and
25
26 Immunobiology, University of Würzburg, Germany, Institute of Clinical Molecular Biology,
27
28 Christian-Albrechts-University Kiel, Kiel, Germany, Hôpital Claude Huriez and Centre
29
30 d'Investigation Clinique, Centre Hospitalier Universitaire de Lill, Université Lille Nord de
31
32 France, Lille, France, Foundation Jean Dausset CEPH, France, University of Toronto,
33
34 Toronto, Ontario, Canada, and University of Montreal, Research Center, Montreal, Quebec,
35
36 Canada
37
38
39
40
41
42
43
44

45 All articles were published in the English language. The most productive journals were the
46
47 *New England Journal of Medicine*, and *Gastroenterology* with a total of 22 articles. Others
48
49 were *Nature*, *Nature Genetics*, *the Lancet*, and *Proceedings of the National Academy of*
50
51 *Sciences of the United States of America*, *Cell*, *Gut*, *British Medical Journal*, *Science*, *Nature*
52
53 *Reviews Immunology*, and *Immunity*, making a total of 21 articles. While these journals have a
54
55
56
57
58
59
60

1
2
3 relatively high JIF, other journals published one article each and had a relatively low JIF
4 compared to journals included in their categories. For example, *Human Pathology* listed
5 number 22 under the category of Pathology, *Canadian Journal of Gastroenterology and*
6 *Hepatology*, listed number 74 under the category Gastroenterology and Hepatology,
7 *Scandinavian Journal of Gastroenterology*, listed number 77 under the category
8 Gastroenterology and Hepatology, and *Infection and Immunity* listed number 67 under the
9 category Immunology. The high level of evidence as outlined in the top-cited articles could be
10 an important contributing factor to the higher number of citations received by these articles
11 [87].
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27

28 CONCLUSIONS

29
30
31 The top 50 top-cited articles in inflammatory bowel disease were identified by searching the
32 Science Citation Index Expanded database; the citation analysis revealed that these articles
33 were published between 1955 and 2012 with the years from 1995 to 2012 representing the
34 best productive period. The citations varied from 804 to 3320 and the yearly mean numbers of
35 citations for papers published after the year 2000 were relatively higher compared to those
36 published before the year 2000. Over two thirds of these papers were research (30% basic
37 research and 38% clinical research), and the remaining were mainly reviews and meta-
38 analysis. Only three were articles and reports. The top-cited articles focused on: epidemiology
39 and prevalence of IBD, pathogenesis and genetic susceptibility of NOD2 mutation, animal
40 models, clinical classification and indices of disease activity, risks of developing colorectal
41 cancer, extra-intestinal complications, and use of infliximab, adalimumab, monoclonal
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

1
2
3 antibodies and anti-tumour necrosis factor, and 6- mercaptopurine in CD, and use of 5-
4 aminosalicylic acid, corticosteroids, and cyclosporine in treating UC. The journals that
5 published top-cited articles were not limited to gastroenterology journals; top general
6 medicine journals such as the *New England Journal of Medicine*, *the Lancet*, *British Medical*
7 *Journal*, and *Medicine (Baltimore)*, as well as top research journals such as *Nature*, *Nature*
8 *Genetics*, *Science* and *Nature Reviews Immunology* contributed to the publication of these
9 papers. On assessing the evidence level, ten articles were at level 1b, eleven articles were at
10 level 3a, and seventeen articles were at level 3b. Countries that contributed to the majority of
11 articles were the United States, the United Kingdom, Germany, France and Canada. There was
12 no significant correlation between the number of citations and the number of years since
13 publication, the Journal Impact Factor (JIF), the number of authors, the number of female
14 authors, the number of institutes, the number of countries involved, or the number of grants
15 received. These findings may be consistent with the concept that it is not the absolute number
16 of collaboration that will make an impact on the citation number or the influence of a
17 publication but rather the quality of such collaboration in regard to the researchers involved,
18 their institutes, and the ongoing contribution to the advances of a particular area in research.
19 The relatively small number of females in the authorship reflects the gender gap and the fact
20 that women still compose a minority of the authors of original research and reviews in
21 gastroenterology. The higher level of evidence demonstrated in most top-cited articles may
22 have contributed to the higher number of citations received by these articles.
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

1
2
3 **Acknowledgement:** The author would like to thank Diana Sanad for her assistance and
4 reviewing the manuscript. Also thank Dr Lily Scott for her assistance in this work.
5
6
7
8
9

10 **Funding support:** This work was funded by the College of Medicine, Research Center
11 Deanship of Scientific Research, King Saud University, Riyadh, Saudi Arabia.
12
13
14

15 **Ethical approval:** Not applicable to this study.
16
17

18 **Contributors** SAA and SA shared equally the different roles and responsibilities to complete
19 the submitted article including, the research idea, the search of databases, the evaluation of
20 data collected, the statistical analysis, the interpretation of findings, the creation of tables and
21 figures, writing the manuscript and the approved the final version of the manuscript.
22
23
24
25

26 **Competing interests:** Both authors (SAA and SA) declare that they have no competing
27 interests and have completed the International Committee of Medical Journal Editors (ICMJE)
28 form
29
30
31

32 **Provenance and peer review:** Not commissioned; externally peer reviewed
33
34
35

36 **Data sharing statement:** No further data available to share
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52

REFERENCES

1. MacMaster FP, Swansburg R, Rittenbach K. Academic Productivity in Psychiatry: Benchmarks for the H-Index. *Acad Psychiatry*. 2017 Apr 18. [Epub ahead of print]
2. Susarla HK, Dhar V, Karimbux NY, Tinanoff N. Do Standard Bibliometric Measures Correlate with Academic Rank of Full-Time Pediatric Dentistry Faculty Members? *J Dent Educ*. 2017 Apr;81(4):427-432.
3. Milone MT, Bernstein J. On Track to Professorship? A Bibliometric Analysis of Early Scholarly Output. *Am J Orthop (Belle Mead NJ)*. 2016 Mar-Apr;45(3):E119-23.
4. Azer SA, Holen A, Wilson I, Skokauskas N. Impact factor of medical education journals and recently developed indices: Can any of them support academic promotion criteria? *J Postgrad Med*. 2016 Jan-Mar;62(1):32-39. doi: 10.4103/0022-3859.173202.
5. Jones AW. Impact of JAT publications 1981-2003: the most prolific authors and the most highly cited articles. *J Anal Toxicol*. 2004 Oct;28(7):541-545.
6. Rosenkrantz AB, Doshi AM, Ginocchio LA, Aphinyanaphongs Y. Use of a Machine-learning Method for Predicting Highly Cited Articles Within General Radiology Journals. *Acad Radiol*. 2016 Dec;23(12):1573-1581. doi: 10.1016/j.acra.2016.08.011. Epub 2016 Sep 28.
7. Bosquet C, Combes PP. Are academics who publish more also more cited? Individual determinants of publication and citation records *Scientometrics* 97 (3), 831-857
8. Hirsch JE. An index to quantify an individual's scientific research output. *Proc Natl Acad Sci U S A*. 2005 Nov 15;102(46):16569-72.

- 1
2
3
4 9. Miyamoto S. Self-citation rate and impact factor in the field of plastic and reconstructive
5 surgery. *J Plast Surg Hand Surg*. 2017 May 9;1-7. doi: 10.1080/2000656X.2017.1319847.
6 [Epub ahead of print]
7
8
9
10
11 10. Ioannidis JP, Klavans R, Boyack KW. Multiple Citation Indicators and Their Composite
12 across Scientific Disciplines. *PLoS Biol*. 2016 Jul 1;14(7):e1002501. doi:
13 10.1371/journal.pbio.1002501. eCollection 2016 Jul.
14
15
16
17 11. Reiter O, Mimouni M, Mimouni D. Analysis of self-citation and impact factor in
18 dermatology journals. *Int J Dermatol*. 2016 Sep;55(9):995-9. doi: 10.1111/ijd.13193. Epub
19 2015 Dec 23.
20
21
22 12. Patsopoulos NA, Ioannidis JP, Analatos AA. Origin and funding of the most frequently
23 cited papers in medicine: database analysis. *BMJ* 2006;332:1061–4.
24
25
26 13. Garfield E. Fortnightly review: how can impact factors be improved? *BMJ* 1996;313:411–
27 413.
28
29
30 14. Wilks S. Morbid appearances in the in- testines of Miss Bankes. *Med Times Gazette*
31 1859;2:264-265.
32
33 15. Crohn BB, Ginzburg L, Oppenheimer GD. Regional ileitis: a pathologic and clinical
34 entity. *JAMA* 1932;99:1323-1329.
35
36
37 16. Van Noorden R, Maher B, Nuzzo R. The top 100 papers. *Nature*. 2014;514(7524):550.
38
39 17. Kulkarni AV, Aziz B, Shams I, Busse JW. Comparisons of citations in Web of Science,
40 Scopus, and Google Scholar for articles published in general medical journals. *JAMA*. 2009
41 Sep 9;302(10):1092-1096.
42
43
44 18. Azer SA. Top-Cited Articles in Problem-Based Learning: A Bibliometric Analysis and
45 Quality of Evidence Assessment. *J Dent Educ*. 2017 Apr;81(4):458-478.
46
47
48 19. Oxford Centre for Evidence-based Medicine – Levels of Evidence (March 2009).
49 Available at: [http://www.cebm.net/oxford-centre-evidence-based-medicine-levels-evidence-](http://www.cebm.net/oxford-centre-evidence-based-medicine-levels-evidence-march-2009)
50 [march-2009](http://www.cebm.net/oxford-centre-evidence-based-medicine-levels-evidence-march-2009) [Accessed 20 May 2017].
51
52
53 20. Azer SA. The top-cited articles in medical education: a bibliometric analysis. *Acad Med*
54 2015;90(8):1147-1161.
55
56
57
58
59
60

- 1
2
3
4 21. D'Antiga L, Betalli P, De Angelis P, et al. Interobserver agreement on endoscopic
5 classification of oesophageal varices in children. *J Pediatr Gastroenterol Nutr* 2015;61(2):176-
6 181.
7
8
9 22. Hugot JP, Chamaillard M, Zouali H, Lesage S, Cézard JP, Belaiche J, Almer S, Tysk C,
10 O'Morain CA, Gassull M, Binder V, Finkel Y, Cortot A, Modigliani R, Laurent-Puig P,
11 Gower-Rousseau C, Macry J, Colombel JF, Sahbatou M, Thomas G. Association of NOD2
12 leucine-rich repeat variants with susceptibility to Crohn's disease. *Nature*. 2001 May
13 31;411(6837):599-603.
14
15
16 23. Ogura Y, Bonen DK, Inohara N, Nicolae DL, Chen FF, Ramos R, Britton H, Moran T,
17 Karaliuskas R, Duerr RH, Achkar JP, Brant SR, Bayless TM, Kirschner BS, Hanauer SB,
18 Nuñez G, Cho JH. A frameshift mutation in NOD2 associated with susceptibility to Crohn's
19 disease. *Nature*. 2001 May 31;411(6837):603-6.
20
21
22 24. Kühn R, Löhler J, Rennick D, Rajewsky K, Müller W. Interleukin-10-deficient mice
23 develop chronic enterocolitis. *Cell*. 1993 Oct 22;75(2):263-74
24
25 25. Best WR, Beckett JM, Singleton JW, Kern F Jr. Development of a Crohn's disease activity
26 index. National Cooperative Crohn's Disease Study. *Gastroenterology*. 1976 Mar;70(3):439-
27 44.
28
29
30 26. Podolsky DK. Inflammatory bowel disease. *N Engl J Med*. 2002 Aug 8;347(6):417-429.
31
32 27. Targan SR, Hanauer SB, van Deventer SJ, Mayer L, Present DH, Braakman T, DeWoody
33 KL, Schaible TF, Rutgeerts PJ. A short-term study of chimeric monoclonal antibody cA2 to
34 tumor necrosis factor alpha for Crohn's disease. Crohn's Disease cA2 Study Group. *N Engl J*
35 *Med*. 1997 Oct 9;337(15):1029-35.
36
37
38
39 28. Hanauer SB, Feagan BG, Lichtenstein GR, Mayer LF, Schreiber S, Colombel JF,
40 Rachmilewitz D, Wolf DC, Olson A, Bao W, Rutgeerts P; ACCENT I Study Group.
41 Maintenance infliximab for Crohn's disease: the ACCENT I randomised trial. *Lancet*. 2002
42 May 4;359(9317):1541-1549.
43
44
45
46 29. Truelove SC and Witts LJ. Cortisone in ulcerative colitis; final report on a therapeutic
47 trial. *Br Med J*. 1955 Oct 29;2(4947):1041-1048.
48
49
50 30. Xavier RJ, Podolsky DK. Unravelling the pathogenesis of inflammatory bowel disease.
51 *Nature*. 2007 Jul 26;448(7152):427-434.
52
53 31. Duerr RH, Taylor KD, Brant SR, Rioux JD, Silverberg MS, Daly MJ, Steinhart AH,
54 Abraham C, Regueiro M, Griffiths A, Dassopoulos T, Bitton A, Yang H, Targan S, Datta LW,
55 Kistner EO, Schumm LP, Lee AT, Gregersen PK, Barmada MM, Rotter JI, Nicolae DL, Cho
56 JH. A genome-wide association study identifies IL23R as an inflammatory bowel disease
57
58
59
60

1
2
3 gene. *Science*. 2006 Dec 1;314(5804):1461-1463.
4

5
6 32. Present DH, Rutgeerts P, Targan S, Hanauer SB, Mayer L, van Hogezaand RA, Podolsky
7 DK, Sands BE, Braakman T, DeWoody KL, Schaible TF, van Deventer SJ. Infliximab for the
8 treatment of fistulas in patients with Crohn's disease. *N Engl J Med*. 1999 May
9 6;340(18):1398-405.
10

11 33. Rutgeerts P, Sandborn WJ, Feagan BG, Reinisch W, Olson A, Johanns J, Travers S,
12 Rachmilewitz D, Hanauer SB, Lichtenstein GR, de Villiers WJ, Present D, Sands BE,
13 Colombel JF. Infliximab for induction and maintenance therapy for ulcerative colitis. *N Engl J*
14 *Med*. 2005 Dec 8;353(23):2462-76.
15

16
17
18 34. Fiocchi C. Inflammatory bowel disease: etiology and pathogenesis. *Gastroenterology*.
19 1998 Jul;115(1):182-205.
20

21
22
23 35. Barrett JC, Hansoul S, Nicolae DL, Cho JH, Duerr RH, Rioux JD, Brant SR, Silverberg
24 MS, Taylor KD, Barmada MM, Bitton A, Dassopoulos T, Datta LW, Green T, Griffiths AM,
25 Kistner EO, Murtha MT, Regueiro MD, Rotter JI, Schumm LP, Steinhart AH, Targan SR,
26 Xavier RJ; NIDDK IBD Genetics Consortium, Libioulle C, Sandor C, Lathrop M, Belaiche J,
27 Dewit O, Gut I, Heath S, Laukens D, Mni M, Rutgeerts P, Van Gossum A, Zelenika D,
28 Franchimont D, Hugot JP, de Vos M, Vermeire S, Louis E; Belgian-French IBD Consortium;
29 Wellcome Trust Case Control Consortium, Cardon LR, Anderson CA, Drummond H, Nimmo
30 E, Ahmad T, Prescott NJ, Onnie CM, Fisher SA, Marchini J, Ghorri J, Bumpstead S, Gwilliam
31 R, Tremelling M, Deloukas P, Mansfield J, Jewell D, Satsangi J, Mathew CG, Parkes M,
32 Georges M, Daly MJ. Genome-wide association defines more than 30 distinct susceptibility
33 loci for Crohn's disease. *Nat Genet*. 2008 Aug;40(8):955-962.
34
35

36
37
38 36. Riddell RH, Goldman H, Ransohoff DF, Appelman HD, Fenoglio CM, Haggitt RC, Ahren
39 C, Correa P, Hamilton SR, Morson BC, et al. Dysplasia in inflammatory bowel disease:
40 standardized classification with provisional clinical applications. *Hum Pathol*. 1983
41 Nov;14(11):931-968.
42

43 37. Sadlack B, Merz H, Schorle H, Schimpl A, Feller AC, Horak I. Ulcerative colitis-like
44 disease in mice with a disrupted interleukin-2 gene. *Cell*. 1993 Oct 22;75(2):253-261.
45
46

47
48 38. Loftus EV Jr. Clinical epidemiology of inflammatory bowel disease: Incidence,
49 prevalence, and environmental influences. *Gastroenterology*. 2004 May;126(6):1504-1517.
50

51 39. Okayasu I, Hatakeyama S, Yamada M, Ohkusa T, Inagaki Y, Nakaya R A novel method
52 in the induction of reliable experimental acute and chronic ulcerative colitis in mice.
53 *Gastroenterology*. 1990 Mar;98(3):694-702.
54
55

- 1
2
3 40. Harvey RF, Bradshaw JM. A simple index of Crohn's-disease activity. *Lancet*. 1980 Mar
4 8;1(8167):514.
5
6
7
8 41. Frank DN, St Amand AL, Feldman RA, Boedeker EC, Harpaz N, Pace NR. Molecular-
9 phylogenetic characterization of microbial community imbalances in human inflammatory
10 bowel diseases. *Proc Natl Acad Sci U S A*. 2007 Aug 21;104(34):13780-13785
11
12
13 42. Eaden JA, Abrams KR, Mayberry JF. The risk of colorectal cancer in ulcerative colitis: a
14 meta-analysis. *Gut*. 2001 Apr;48(4):526-535.
15
16
17
18 43. Baert F, Noman M, Vermeire S, Van Assche G, D' Haens G, Carbonez A, Rutgeerts P.
19 Influence of immunogenicity on the long-term efficacy of infliximab in Crohn's disease. *N*
20 *Engl J Med*. 2003 Feb 13;348(7):601-608.
21
22
23
24 44. Cooper HS, Murthy SN, Shah RS, Sedergran DJ. Clinicopathologic study of dextran
25 sulfate sodium experimental murine colitis. *Lab Invest*. 1993 Aug;69(2):238-249.
26
27
28
29 45. Ekblom A, Helmick C, Zack M, Adami HO. Ulcerative colitis and colorectal cancer. A
30 population-based study. *N Engl J Med*. 1990 Nov 1;323(18):1228-1233.
31
32
33 46. Silverberg MS, Satsangi J, Ahmad T, Arnott ID, Bernstein CN, Brant SR, Caprilli R,
34 Colombel JF, Gasche C, Geboes K, Jewell DP, Karban A, Loftus EV Jr, Peña AS, Riddell
35 RH, Sachar DB, Schreiber S, Steinhart AH, Targan SR, Vermeire S, Warren BF. Toward an
36 integrated clinical, molecular and serological classification of inflammatory bowel disease:
37 report of a Working Party of the 2005 Montreal World Congress of Gastroenterology. *Can J*
38 *Gastroenterol*. 2005 Sep;19 Suppl A:5A-36A
39
40
41
42 47. Rioux JD, Xavier RJ, Taylor KD, Silverberg MS, Goyette P, Huett A, Green T, Kuballa P,
43 Barmada MM, Datta LW, Shugart YY, Griffiths AM, Targan SR, Ippoliti AF, Bernard EJ,
44 Mei L, Nicolae DL, Regueiro M, Schumm LP, Steinhart AH, Rotter JI, Duerr RH, Cho JH,
45 Daly MJ, Brant SR. Genome-wide association study identifies new susceptibility loci for
46 Crohn disease and implicates autophagy in disease pathogenesis. *Nat Genet*. 2007
47 May;39(5):596-604.
48
49
50
51 48. Bouma G, Strober W. The immunological and genetic basis of inflammatory bowel
52 disease. *Nat Rev Immunol*. 2003 Jul;3(7):521-533.
53
54
55 49. Lichtiger S, Present DH, Kornbluth A, Gelernt I, Bauer J, Galler G, Michelassi F, Hanauer
56 S. Cyclosporine in severe ulcerative colitis refractory to steroid therapy. *N Engl J Med*. 1994
57
58
59
60

1
2
3 Jun 30;330(26):1841-1845.
4
5

6
7 50. Summers RW, Switz DM, Sessions JT Jr, Bechtel JM, Best WR, Kern F Jr, Singleton JW.
8 National Cooperative Crohn's Disease Study: results of drug treatment. *Gastroenterology*.
9 1979 Oct;77(4 Pt 2):847-869
10

11 51. Franke A, McGovern DP, Barrett JC, Wang K, Radford-Smith GL, Ahmad T, Lees CW,
12 Balschun T, Lee J, Roberts R, Anderson CA, Bis JC, Bumpstead S, Ellinghaus D, Festen EM,
13 Georges M, Green T, Haritunians T, Jostins L, Latiano A, Mathew CG, Montgomery GW,
14 Prescott NJ, Raychaudhuri S, Rotter JI, Schumm P, Sharma Y, Simms LA, Taylor KD,
15 Whiteman D, Wijmenga C, Baldassano RN, Barclay M, Bayless TM, Brand S, Büning C,
16 Cohen A, Colombel JF, Cottone M, Stronati L, Denson T, De Vos M, D'Inca R, Dubinsky M,
17 Edwards C, Florin T, Franchimont D, Geary R, Glas J, Van Gossum A, Guthery SL,
18 Halfvarson J, Verspaget HW, Hugot JP, Karban A, Laukens D, Lawrance I, Lemann M,
19 Levine A, Libioulle C, Louis E, Mowat C, Newman W, Panés J, Phillips A, Proctor DD,
20 Regueiro M, Russell R, Rutgeerts P, Sanderson J, Sans M, Seibold F, Steinhardt AH, Stokkers
21 PC, Torkvist L, Kullak-Ublick G, Wilson D, Walters T, Targan SR, Brant SR, Rioux JD,
22 D'Amato M, Weersma RK, Kugathasan S, Griffiths AM, Mansfield JC, Vermeire S, Duerr
23 RH, Silverberg MS, Satsangi J, Schreiber S, Cho JH, Annese V, Hakonarson H, Daly MJ,
24 Parkes M. Genome-wide meta-analysis increases to 71 the number of confirmed Crohn's
25 disease susceptibility loci. *Nat Genet*. 2010 Dec;42(12):1118-1125.
26
27
28
29
30

31 52. Sands BE, Anderson FH, Bernstein CN, Chey WY, Feagan BG, Fedorak RN, Kamm MA,
32 Korzenik JR, Lashner BA, Onken JE, Rachmilewitz D, Rutgeerts P, Wild G, Wolf DC,
33 Marsters PA, Travers SB, Blank MA, van Deventer SJ. Infliximab maintenance therapy for
34 fistulizing Crohn's disease. *N Engl J Med*. 2004 Feb 26;350(9):876-85.
35
36

37
38 53. Jostins L, Ripke S, Weersma RK, Duerr RH, McGovern DP, Hui KY, Lee JC, Schumm
39 LP, Sharma Y, Anderson CA, Essers J, Mitrovic M, Ning K, Cleynen I, Theatre E, Spain SL,
40 Raychaudhuri S, Goyette P, Wei Z, Abraham C, Achkar JP, Ahmad T, Amininejad L,
41 Ananthakrishnan AN, Andersen V, Andrews JM, Baidoo L, Balschun T, Bampton PA, Bitton
42 A, Boucher G, Brand S, Büning C, Cohain A, Cichon S, D'Amato M, De Jong D, Devaney
43 KL, Dubinsky M, Edwards C, Ellinghaus D, Ferguson LR, Franchimont D, Fransen K, Geary
44 R, Georges M, Gieger C, Glas J, Haritunians T, Hart A, Hawkey C, Hedl M, Hu X, Karlsen
45 TH, Kupcinkas L, Kugathasan S, Latiano A, Laukens D, Lawrance IC, Lees CW, Louis E,
46 Mahy G, Mansfield J, Morgan AR, Mowat C, Newman W, Palmieri O, Ponsioen CY,
47 Potocnik U, Prescott NJ, Regueiro M, Rotter JI, Russell RK, Sanderson JD, Sans M, Satsangi
48 J, Schreiber S, Simms LA, Sventoraityte J, Targan SR, Taylor KD, Tremelling M, Verspaget
49 HW, De Vos M, Wijmenga C, Wilson DC, Winkelmann J, Xavier RJ, Zeissig S, Zhang B,
50 Zhang CK, Zhao H; International IBD Genetics Consortium (IIBDGC)., Silverberg MS,
51 Annese V, Hakonarson H, Brant SR, Radford-Smith G, Mathew CG, Rioux JD, Schadt EE,
52 Daly MJ, Franke A, Parkes M, Vermeire S, Barrett JC, Cho JH. Host-microbe interactions
53 have shaped the genetic architecture of inflammatory bowel disease. *Nature*. 2012 Nov
54 1;491(7422):119-24.
55
56
57
58
59
60

1
2
3
4
5
6 54. Sokol H, Pigneur B, Watterlot L, Lakhdari O, Bermúdez-Humarán LG, Gratadoux JJ,
7 Blugeon S, Bridonneau C, Furet JP, Corthier G, Grangette C, Vasquez N, Pochart P, Trugnan
8 G, Thomas G, Blottière HM, Doré J, Marteau P, Seksik P, Langella P. Faecalibacterium
9 prausnitzii is an anti-inflammatory commensal bacterium identified by gut microbiota analysis
10 of Crohn disease patients. *Proc Natl Acad Sci U S A*. 2008 Oct 28;105(43):16731-16736.
11

12
13
14 55. Hampe J, Franke A, Rosenstiel P, Till A, Teuber M, Huse K, Albrecht M, Mayr G, De La
15 Vega FM, Briggs J, Günther S, Prescott NJ, Onnie CM, Häsler R, Sipos B, Fölsch UR,
16 Lengauer T, Platzer M, Mathew CG, Krawczak M, Schreiber S. A genome-wide association
17 scan of nonsynonymous SNPs identifies a susceptibility variant for Crohn disease in
18 ATG16L1. *Nat Genet*. 2007 Feb;39(2):207-211.
19

20
21 56. Colombel JF, Sandborn WJ, Reinisch W, Mantzaris GJ, Kornbluth A, Rachmilewitz D,
22 Lichtiger S, D'Haens G, Diamond RH, Broussard DL, Tang KL, van der Woude CJ, Rutgeerts
23 P; SONIC Study Group. Infliximab, azathioprine, or combination therapy for Crohn's disease.
24 *N Engl J Med*. 2010 Apr 15;362(15):1383-1395.
25

26
27 57. Elson CO, Sartor RB, Tennyson GS, Riddell RH. Experimental models of inflammatory
28 bowel disease. *Gastroenterology*. 1995 Oct;109(4):1344-1367.
29

30
31
32 58. Colombel JF, Sandborn WJ, Rutgeerts P, Enns R, Hanauer SB, Panaccione R, Schreiber S,
33 Byczkowski D, Li J, Kent JD, Pollack PF. Adalimumab for maintenance of clinical response
34 and remission in patients with Crohn's disease: the CHARM trial. *Gastroenterology*. 2007
35 Jan;132(1):52-65.
36

37
38
39 59. Greenstein AJ, Janowitz HD, Sachar DB. The extra-intestinal complications of Crohn's
40 disease and ulcerative colitis: a study of 700 patients. *Medicine (Baltimore)*. 1976
41 Sep;55(5):401-412.
42

43
44 60. Schroeder KW, Tremaine WJ, Ilstrup DM. Coated oral 5-aminosalicylic acid therapy for
45 mildly to moderately active ulcerative colitis. A randomized study. *N Engl J Med*. 1987 Dec
46 24;317(26):1625-1629.
47

48
49 61. Fujino S, Andoh A, Bamba S, Ogawa A, Hata K, Araki Y, Bamba T, Fujiyama Y.
50 Increased expression of interleukin 17 in inflammatory bowel disease. *Gut*. 2003
51 Jan;52(1):65-70.
52

53
54
55 62. van Dullemen HM, van Deventer SJ, Hommes DW, Bijl HA, Jansen J, Tytgat GN, Woody
56 J. Treatment of Crohn's disease with anti-tumor necrosis factor chimeric monoclonal antibody
57
58
59

1
2
3 (cA2). *Gastroenterology*. 1995 Jul;109(1):129-135.
4
5

6
7 63. Fuss IJ, Neurath M, Boirivant M, Klein JS, de la Motte C, Strong SA, Fiocchi C, Strober
8 W. Disparate CD4+ lamina propria (LP) lymphokine secretion profiles in inflammatory bowel
9 disease. Crohn's disease LP cells manifest increased secretion of IFN-gamma, whereas
10 ulcerative colitis LP cells manifest increased secretion of IL-5. *J Immunol*. 1996 Aug
11 1;157(3):1261-1270.
12

13
14
15 64. Hampe J, Cuthbert A, Croucher PJ, Mirza MM, Mascheretti S, Fisher S, Frenzel H, King
16 K, Hasselmeyer A, MacPherson AJ, Bridger S, van Deventer S, Forbes A, Nikolaus S,
17 Lennard-Jones JE, Foelsch UR, Krawczak M, Lewis C, Schreiber S, Mathew CG. Association
18 between insertion mutation in NOD2 gene and Crohn's disease in German and British
19 populations. *Lancet*. 2001 Jun 16;357(9272):1925-1928.
20

21
22
23 65. Present DH, Korelitz BI, Wisch N, Glass JL, Sachar DB, Pasternack BS. Treatment of
24 Crohn's disease with 6-mercaptopurine. A long-term, randomized, double-blind study. *N Engl*
25 *J Med*. 1980 May 1;302(18):981-987.
26

27
28
29 66. Abraham C, Cho JH. Inflammatory bowel disease. *N Engl J Med*. 2009 Nov
30 19;361(21):2066-2078.
31

32
33 67. Cario E, Podolsky DK. Differential alteration in intestinal epithelial cell expression of toll-
34 like receptor 3 (TLR3) and TLR4 in inflammatory bowel disease. *Infect Immun*. 2000
35 Dec;68(12):7010-7017.
36

37
38
39 68. Lennard-Jones JE. Classification of inflammatory bowel disease. *Scand J Gastroenterol*
40 *Suppl*. 1989;170:2-6.
41

42
43
44 69. Molodecky NA, Soon IS, Rabi DM, Ghali WA, Ferris M, Chernoff G, Benchimol EI,
45 Panaccione R, Ghosh S, Barkema HW, Kaplan GG. Increasing incidence and prevalence of the
46 inflammatory bowel diseases with time, based on systematic review. *Gastroenterology*. 2012
47 Jan;142(1):46-54.
48

49
50
51 70. Swidsinski A, Ladhoff A, Pernthaler A, Swidsinski S, Loening-Baucke V, Ortner M,
52 Weber J, Hoffmann U, Schreiber S, Dietel M, Lochs H. Mucosal flora in inflammatory bowel
53 disease. *Gastroenterology*. 2002 Jan;122(1):44-54.
54

55
56 71. Powrie F, Leach MW, Mauze S, Menon S, Caddle LB, Coffman RL. Inhibition of Th1
57
58
59

1
2
3 responses prevents inflammatory bowel disease in scid mice reconstituted with CD45RBhi
4 CD4+ T cells. *Immunity*. 1994 Oct;1(7):553-562.

6
7 72. Azer SA. Overview of molecular pathways in inflammatory bowel disease associated with
8 colorectal cancer development. *Eur J Gastroenterol Hepatol*. 2013 Mar;25(3):271-281.

10
11 73. Azer SA, AlOlayan TI, AlGhamdi MA, AlSanea MA. Inflammatory bowel disease: An
12 evaluation of health information on the internet. *World J Gastroenterol*. 2017 Mar
13 7;23(9):1676-1696.

15
16 74. Börner K, Maru JT, Goldstone RL. The simultaneous evolution of author and paper
17 networks. *Proc Natl Acad Sci U S A*. 2004 Apr 6;101 Suppl 1:5266-73.

19
20 75. Azer SA. Exploring the Top-Cited and Most Influential Articles in Medical Education.
21 *J Contin Educ Health Prof*. 2016 Summer;36 Suppl 1:S32-S41.

23
24 76. Wren JD, Georgescu C, Giles CB, Hennessey J. Use it or lose it: citations predict the
25 continued online availability of published bioinformatics resources. *Nucleic Acids*
26 *Res*. 2017 Apr 20;45(7):3627-3633.

28
29 77. Shanahan DR. Auto-correlation of journal impact factor for consensus research reporting
30 statements: a cohort study. *PeerJ*. 2016 Mar 31;4:e1887.

32
33 78. Royle P, Kandala NB, Barnard K, Waugh N. Bibliometrics of systematic reviews: analysis
34 of citation rates and journal impact factors. *Syst Rev*. 2013 Sep 12;2:74.

35
36 79. Falagas ME, Kouranos VD, Michalopoulos A, Rodopoulou SP, Batsiou
37 MA, Karageorgopoulos DE. Comparison of the distribution of citations received by articles
38 published in high, moderate, and low impact factor journals in clinical medicine. *Intern Med*
39 *J*. 2010 Aug;40(8):587-591.

41
42 80. García-Aroca MÁ, Pandiella-Dominique A, Navarro-Suay R, Alonso-Arroyo A, Granda-
43 Orive JI, Anguita-Rodríguez F, López-García A. Analysis of Production, Impact, and
44 Scientific Collaboration on Difficult Airway Through the Web of Science and Scopus (1981-
45 2013). *Anesth Analg*. 2017 Jun;124(6):1886-1896.

47
48 81. Tanner-Smith EE, Polanin JR. Brief alcohol intervention trials conducted by higher
49 prestige authors and published in higher impact factor journals are cited more frequently. *J*
50 *Clin Epidemiol*. 2016 Feb 6.

1
2
3
4 82. Jagsi R, Guancial EA, Worobey CC, Henault LE, Chang Y, Starr R, Tarbell NJ, Hylek
5 EM. The "gender gap" in authorship of academic medical literature--a 35-year perspective. *N*
6 *Engl J Med*. 2006 Jul 20;355(3):281-287.
7

8
9
10 83. Long MT, Leszczynski A, Thompson KD, Wasan SK, Calderwood AH. Female
11 authorship in major academic gastroenterology journals: a look over 20 years. *Gastrointest*
12 *Endosc*. 2015;81(6):1440-1447.
13

14
15 84. Diamond SJ, Thomas CR Jr, Desai S, Holliday EB, Jagsi R, Schmitt C, Enestvedt BK.
16 Gender Differences in Publication Productivity, Academic Rank, and Career Duration Among
17 U.S. Academic Gastroenterology Faculty. *Acad Med*. 2016 Aug;91(8):1158-1163.
18

19
20
21 85. Nicholson JM, Ioannidis JP. Research grants: Conform and be funded. *Nature*. 2012 Dec
22 6;492(7427):34-36.
23

24
25
26 86. Lauer MS, Danthi NS, Kaltman J, Wu C. Predicting Productivity Returns on Investment:
27 Thirty Years of Peer Review, Grant Funding, and Publication of Highly Cited Papers at the
28 National Heart, Lung, and Blood Institute. *Circ Res*. 2015 Jul 17;117(3):239-243.
29

30
31
32 87. Cheng K, Dodson TB, Egbert MA, Susarla SM. Which Factors Affect Citation Rates in
33 the Oral and Maxillofacial Surgery Literature? *J Oral Maxillofac Surg*. 2017 Apr 1. pii:
34 S0278-2391(17)30361-0.
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

Glossary

Articles are scientific written composition representing a substantial advance in the understanding of a topic or problem. They raise questions, provide thoughtful, critical analysis and aim at establishing new directions.

Basic research is defined as fundamental research, which aims at improving scientific theories and our understanding of a phenomenon. Basic research may use animal models and include in vivo and in-vitro studies that target advances of fundamental knowledge.

Clinical research is defined as research applied to a clinical condition/disease with the aim to test an intervention or make a change to a phenomenon. Basic research usually fuels clinical research.

Reports are defined as brief articles with conclusions, results, and recommendations. They report on a substantial advance in an area/topic or a problem and aim at reporting findings and standardization of practice.

Review and meta-analysis are defined as an article reviewing the progress of knowledge in a particular topic, critically analysing the current status of knowledge and presenting an understanding of the subject by discussing related literature. A review should identify gaps in the literature and highlight future directions for further research. A **meta-analysis** is defined as a statistical analysis that combines the results from different scientific studies to provide conclusive evidence.

1
2
3
4
5
6
7
8
9
10 **Figure Legend**

11
12 **Figure 1A:** Number of citations of papers published before the year 2000 (mean±SD)

13
14
15 **Figure 1B:** Number of citations of papers published after the year 2000 (mean±SD)

16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

For peer review only

1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

For peer review only

1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47

Table 1 Top cited papers in inflammatory bowel disease identified by searching the Web of Knowledge, summarized by year of publication and category

Article type	Year of publication: no of articles [References]							
	1950-1958	1959-1967	1968-1976	1977-1985	1986-1994	1995-2003	2004-2012	Total (%)
Article				1 [36]	1 [68]			2 [4%]
Review/Meta-analysis			1 [59]			5 [26,34,42,48,57]	7 [30,35,38,51,53,66,69]	13 [26%]
Report							1 [46]	1 [2%]
Research	1 [29]		1 [25]	3 [40,50,65]	8 [24,37,39,44,45,49,60,71]	12 [22,23,27,28,32,43,61,62,63,64,67,70]	9 [31,33,41,47,52,54,55,56,58]	34 [68%]
Total (%)	1 [2%]	0 [0%]	2 [4%]	4 [8%]	9 [18%]	17 [34%]	17 [34%]	50 [100%]

Table 2 Top-cited papers in inflammatory bowel disease (IBD) identified by searching the Web of Knowledge, summarized by category and topic

Topics on IBD	Category: no of articles [References]				Total (%)
	Article	Review/ Meta-analysis	Report	Research	
Epidemiology, prevalence		2 [38,69]			2 [4%]
CD genetic susceptibility and NOD2 mutation		2 [35,51]		5 [22,23,47,55,64]	7 [14%]
Animal models for IBD		1 [57]		5 [24,37,39,44,71]	6 [12%]
Pathogenesis of IBD		6 [26,30,34,48,53,66]		7 [31,41,54,61,63,67,70]	13 [26%]
Classification, index of disease activity	2 [36,68]		1 [46]	2 [25,40]	5 [10%]
Risk of developing colorectal cancer		1 [42]		1 [45]	2 [4%]
Extra-intestinal complications		1 [59]			1 [2%]
Infliximab in CD				6 [28,32,33,43,52,56]	6 [12%]
Corticosteroids in UC				1 [29]	1 [2%]
Drug treatment and cyclosporine in UC				2 [49,50]	2 [4%]
Adalimumab in CD				1 [58]	1 [2%]
5-aminosalicylic acid in UC				1 [60]	1 [2%]
6-mercaptopurine in CD				1 [65]	1 [2%]

1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47

Monoclonal antibodies, anti-tumor necrosis factor in CD				2 [27,62]	2 [4%]
Total (%)	2 [4%]	13 [26%]	1 [2%]	34 [68%]	50 [100%]

For peer review only

Table 3. The journals that published the top-cited inflammatory bowel disease (IBD) articles included in the study, the journal impact factor, and the number of papers published and reference number.

Journal*	2015-Journal Impact Factor (JIF)	Number of papers published [References]
<i>New England Journal of Medicine</i>	59.558	12 [26,27,32,33,43,45,49,52,56,60,65,66]
<i>Gastroenterology</i>	18.187	10 [25,34,38,39,50,57,58,62,69,70]
<i>Nature</i>	38.138	4 [22,23,30,53]
<i>Nature Genetics</i>	31.616	4 [35,47,51,55]
<i>The Lancet</i>	44.002	3 [28,40,64]
<i>Proceedings of the National Academy of Sciences of the United States of America</i>	9.423	2 [41,54]
<i>Cell</i>	28.710	2 [24,37]
<i>Gut</i>	14.921	2 [42,61]
<i>British Medical Journal</i>	19.697	1 [29]
<i>Science</i>	34.661	1 [31]
<i>Human Pathology</i>	2.791	1 [36]
<i>Laboratory Investigation</i>	4.202	1 [44]
<i>Canadian Journal of Gastroenterology and Hepatology</i>	2.307	1 [46]
<i>Nature Reviews Immunology</i>	39.416	1 [48]
<i>Medicine (Baltimore)</i>	2.133	1 [59]
<i>Journal of Immunology</i>	4.985	1 [63]
<i>Infection and Immunity</i>	3.603	1 [67]
<i>Scandinavian Journal of Gastroenterology</i>	2.199	1 [68]
<i>Immunity</i>	24.082	1 [71]

- Gastroenterology related journals (Gastroenterology, Gut, and the Scandinavian Journal of Gastroenterology) only published 13 articles out of the top highly cited 50 articles (26%)

1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47

Table 4 Authors and co-authors of two or more articles of the top-cited articles in inflammatory bowel disease identified by searching the Web of Science

Author's name**	Number [References]		Author's Name**	Number [References]	
	First author	Coauthor		First author	Coauthor
Hugot, JP	1 [22]	2 [35,51]	Daly,MJ	-	5[31,35,47,51,53]
Podolsky, DK	1 [26]	4 [29,30,32,67]	Steinhart,AH	-	5[31,35,46,47,51]
Targan, SR	1 [27]	7 [31,32,35,46,47,51,53]	Griffiths,A	-	4[31,35,47,51]
Hanauer,SB	1 [28]	6 [23,27,32,33,49,58]	Dassopoulos,T	-	2[31,35]
Xavier,RJ	1 [30]	3 [35,47,53]	Bitton,A	-	3[31,35,53]
Duerr,RH	1 [31]	5 [23,35,51,53]	Datta,LW	-	3[31,35,47]
Present,DH	2 [32,65]	3 [27,33,49]	Kistner,EO	-	2[31,35]
Rutgeerts, P	1 [33]	9 [27,28,32,35,43,51,52,56,58]	Rotter,JI	-	5[31,35,47,51,53]
Fiocchi,C	1 [34]	1 [63]	Schumm,LP	-	5[31,35,47,51,52]
Barrett,JC	1 [35]	2 [51,53]	Lee,J	-	2[51,53]
Riddell,RH	1 [36]	2 [46,57]	Lees,CW	-	2[51,53]
Loftus,EV Jr	1 [38]	1 [46]	Sandborn,WJ	-	3[33,56,58]
Franke,A	1 [51]	2 [53,55]	Barmada,MM	-	3[31,35,47]
Silverberg,MS	1 [46]	5 [31,35,47,51,53]	Nicolae,DL	-	4[23,31,35,47]
Rioux,JD	1 [47]	4 [31,35,51,53]	Sands,BE	-	3[32,33,52]
Lichtiger,S	1 [49]	1 [56]	Belaiche,J	-	2[22,35]
Colombel,JF	2 [56,58]	5 [22,28,33,46,51]	Laukens,D	-	3[35,51,53]
Hampe,J	2 [55,64]	-	Lawrance,I	-	2[51,53]
Abraham,C	1 [66]	2 [31,53]	Louis,E	-	3[35,53,51]

Lennard-Jones,JE	1 [68]	1 [64]	Vos,M	-	3[35,51,53]
Becktel, JM	-	2 [25,50]	Vermeire,S	-	5[35,43,46,51,53]
Singleton, JW	-	2 [25,50]	Satsangi, J	-	4[35,46,51,53]
Kern, F Jr	-	2 [25,50]	Bernstein, CN	-	2[46,52]
Van Deventer, SJ	-	5 [27,32,52,62,64]	Tremelling, M	-	2[35,53]
Mayer, L	-	3 [27,28,32]	Mansfield, J	-	3[35,51,53]
Braakman, T	-	2 [27,32]	Jewell, D	-	2[35,46]
DeWoody, KL	-	2 [27,32]	Mathew, CG	-	5[35,51,53,55,64]
Schaible, TF	-	2 [27,32]	Parkes, M	-	3[35,51,53]
Feagan, BG	-	3 [28,33,52]	Georges, M	-	3[35,51,53]
Lichtenstein, GR	-	2 [28,33]	Karban, A	-	2[46,51]
Schreiber, S	-	8 [28,46,51,53,55,58,64,70]	Gossum, A	-	2[35,51]
Rachmilewitz, D	-	4 [28,33,52,56]	Franchimont, D	-	3[35,51,53]
Wolf, DC	-	2 [28,52]	Newman, W	-	2[51,53]
Olson, A	-	2 [28,33]	Regueiro, M	-	5[31,35,47,51,53]
Taylor, KD	-	5 [31,35,47,51,53]	Kornbluth, A	-	2[49,56]
Bayless, TM	-	2 [23,51]			
Cho, JH	-	7 [23,31,35,47,51,53,66]			

*The table is limited to authors and coauthors of two or more articles regardless to the category of the article.

**Author's name= family name, abbreviations of first or first and second names.

1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47

Table 5 Grading the top-cited articles in inflammatory bowel disease according to the Oxford Centre for Evidence-based Medicine – Levels of Evidence.

Level	Characteristics and description	Articles number [References]
1a	Systematic reviews of RCTs (with consistent results from individual studies)	-
1b	Individual RCT (with narrow confidence intervals)	10 [27,28,33,49,50,52,56,58,60,65]
2a	Systematic review of cohort studies (with consistent results from individual studies)	1 [35]
2b	Individual cohort study (including low quality RCT; e.g., <80% follow-up)	3 [32,43,45]
2c	Outcome studies (analysis of large registries)	2 [59,69]
3a	Systemic reviews of case-control studies (with consistent results from individual studies)	11 [26,30,34,38,42,46,48,51,52,56,66]
3b	Individual case-control study	17 [22,23,24,29,31,37,39,41,47,54,55,61,63,64,67,70,71]
4	Case series (studies without control group, including poor quality cohort studies)	5 [25,36,40,44,62]
5	Expert opinion without explicit critical appraisal or based on research evidence.	1 [68]

1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47

For peer review only

1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60





Figure 1A and 1B

209x296mm (300 x 300 DPI)

Appendix 1.Top-cited articles on inflammatory bowel disease identified by searching the Science Citation Index Expanded database^a

Rank	Authors, Year [Reference]	Article (<i>Journal</i>)	2015-JIF	Category	Number of citations, Web of Knowledge	Average citation per year ^b	Rank of the article in the journal publishing it ^c	Origin: First author's organization, location (country)
1	Hugot et al, 2001 ²²	Association of NOD2 leucine-rich repeat variants with susceptibility to Crohn's disease. (<i>NATURE</i>).	38.138	Basic research	3,320	221.3	128	Fondation Jean Dausset CEPH (France)
2	Ogura et al, 2001 ²³	A frameshift mutation in NOD2 associated with susceptibility to Crohn's disease. (<i>NATURE</i>).	38.138	Basic research	3,105	207.0	151	The University of Michigan Medical School, Michigan (United States).
3	Kuhn et al, 1993 ²⁴	Interleukin-10-deficient mice develop chronic enterocolitis. (<i>CELL</i>)	28.710	Basic research	2,804	121.9	62	Institute for Genetics, University of Cologne, (Germany)
4	Best et al, 1976 ²⁵	Development of a Crohns-disease activity index-National cooperative Chrons-disease study (<i>Gastroenterology</i>).	18.187	Clinical research	2,362	59.0	2	Hines Veterans Administration Cooperative Studies Support Center, University of Colorado Medical Center, Denver, Colorado, (United States).
5	Podolsky, 2002 ²⁶	Inflammatory bowel disease. (<i>New England Journal of Medicine</i>)	59.558	Review	2,261	161.5	151	Massachusetts General Hospital and Harvard Medical School, Boston, Massachusetts (United States).
6	Targan et al, 1997 ²⁷	A short-term study of chimeric monoclonal antibody cA2 to tumor necrosis factor alpha for Crohn's disease (<i>New England Journal of</i>	59.558	Clinical research	2,242	118.0	153	Cedars-Sinai Medical Center, Los Angeles, California (United States)

		<i>Medicine)</i>						
7	Hanauer et al, 2002 ²⁸	Maintenance infliximab for Crohn's disease: the ACCENT I randomized trial (<i>Lancet</i>)	44.002	Clinical research	2,126	151.8	47	University of Chicago Medical Center, Chicago, IL (United States).
8	Truelove and Witts, 1955 ²⁹	Cortisone in ulcerative colitis- Final report on a therapeutic trial (<i>British Medical Journal</i>).	19.697	Clinical research	1,756	28.8	17	Nuffield Department of Clinical Medicine, Oxford (United Kingdom)
9	Xavier and Podolsky, 2007 ³⁰	Unravelling the pathogenesis of inflammatory bowel disease (<i>NATURE</i>)	38.138	Review	1,693	188.1	501	Massachusetts General Hospital, Harvard Medical School, Boston, Massachusetts (United States).
10	Duerr et al, 2006 ³¹	A genome-wide association study identifies IL23R as an inflammatory bowel disease gene. (<i>SCIENCE</i>).	34.661	Clinical research	1,683	168.3	554	Department of Medicine, School of Medicine, University of Pittsburgh, Pittsburgh, PA (United States).
11	Present et al, 1999 ³²	Infliximab for treatment of fistulas in patients with Crohn's disease (<i>New England Journal of Medicine</i>)	59.558	Clinical research	1,615	95	315	Mount Sinai Medical Center, New York, NY, (United States)
12	Rutgeerts et al, 2005 ³³	Infliximab for induction and maintenance therapy for ulcerative colitis (<i>New England Journal of Medicine</i>)	59.558	Clinical research	1,506	136.9	318	University Hospital Gasthuisberg, Leuven, (Belgium).
13	Fiocchi, 1998 ³⁴	Inflammatory bowel disease: Etiology and pathogenesis (<i>Gastroenterology</i>)	18.187	Review	1,490	82.8	8	University Hospitals of Cleveland Case Western Reserve University School of Medicine, Ohio (United States)

14	Barrett et al, 2008 ³⁵	Genome-wide association defines more than 30 distinct susceptibility loci for Crohn's disease. (<i>Nature Genetics</i>)	31.616	Review Meta-analysis	1,440	180	28	Wellcome Trust Centre for Human Genetics, University of Oxford, Roosevelt Drive, Oxford (United Kingdom)
15	Riddell et al, 1983 ³⁶	Dysplasia in inflammatory bowel disease- Standardized classification with provisional clinical applications (<i>Human Pathology</i>)	2.791	Article	1,335	40.4	2	National Foundation for Ileitis and Colitis, New York, (United States).
16	Sadlack et al, 1993 ³⁷	Ulcerative colitis-like disease in mice with a disrupted interleukin-2 gene (<i>CELL</i>)	28.710	Basic research	1,328	57.7	370	Institute of Virology and Immunobiology, University of Würzburg, (Germany)
17	Loftus, 2004 ³⁸	Clinical epidemiology of inflammatory bowel disease: Incidence, prevalence, and environmental influences (<i>Gastroenterology</i>)	18.187	Review	1,295	107.9	15	Mayo Clinic, Rochester, Minnesota, (United States)
18	Okayasu et al, 1990 ³⁹	A novel method in the induction of reliable experimental acute and chronic ulcerative-colitis in mice (<i>Gastroenterology</i>)	18.187	Basic research	1,266	48.7	19	School of Medicine, Tokyo Medical and Dental University, (Japan).
19	Harvey and Bradshaw, 1980 ⁴⁰	A simple index of Crohns-disease activity (<i>Lancet</i>)	44.002	Clinical research	1,239	34.4	173	Bristol Royal Infirmary and Frenchay Hospital, Bristol (United Kingdom)
20	Frank et al, 2007 ⁴¹	Molecular-phylogenetic characterization of microbial community imbalances in human inflammatory bowel diseases. (<i>Proceedings of the National Academy of Sciences of the United States of America</i>)	9.423	Basic research	1,231	136.8	221	University of Colorado, Boulder, CO (United States)
21	Eaden et al, 2001 ⁴²	The risk of colorectal cancer in ulcerative colitis: a meta-analysis. (<i>Gut</i>).	14.921	Review Meta-analysis	1,178	78.5	1	Leicester General Hospital, Gwendolen Road, Leicester (United Kingdom)

22	Baert et al, 2003 ⁴³	Influence of immunogenicity on the long-term efficacy of infliximab in Crohn's disease. (<i>New England Journal of Medicine</i>)	59.558	Clinical research	1,112	85.5	584	University Hospital Gasthuisberg, Leuven, (Belgium).
23	Cooper et al, 1993 ⁴⁴	Clinicopathologic study of dextran sulfate sodium experimental murine colitis. (<i>Laboratory Investigation</i>)	4.202	Basic research	1,088	47.3	4	Hahnemann University, Philadelphia, Pennsylvania. (United States)
24	Ekbom et al, 1990 ⁴⁵	Ulcerative colitis and colorectal cancer. A population-based study. (<i>New England Journal of Medicine</i>)	59.558	Clinical research	1,061	40.8	651	University Hospital, Uppsala, (Sweden).
25	Silverberg et al, 2005 ⁴⁶	Toward an integrated clinical, molecular and serological classification of inflammatory bowel disease: report of a Working Party of the 2005 Montreal World Congress of Gastroenterology. (<i>Canadian Journal of Gastroenterology and Hepatology</i>)	2.307	Report	1,043	94.8	1	Mount Sinai Hospital IBD Centre, University of Toronto, Toronto, Ontario (Canada)
26	Rioux et al, 2007 ⁴⁷	Genome-wide association study identifies new susceptibility loci for Crohn disease and implicates autophagy in disease pathogenesis. (<i>Nature Genetics</i>)	31.616	Basic research	1,042	115.8	90	Université de Montréal and the Montreal Heart Institute, Research Center, Montreal, Quebec (Canada).
27	Bouma and Strober, 2003 ⁴⁸	The immunological and genetic basis of inflammatory bowel disease. (<i>Nature Reviews Immunology</i>)	39.416	Review	1,028	79.1	32	National Institutes of Health, and National Institutes of Allergy and Infectious Diseases, Bethesda, Maryland (United States)

28	Lichtiger et al, 1994 ⁴⁹	Cyclosporine in severe ulcerative colitis refractory to steroid therapy. (<i>New England Journal of Medicine</i>)	59.558	Clinical research	1,026	46.6	714	Mount Sinai School of Medicine, New York (United States).
29	Summers et al, 1979 ⁵⁰	National Cooperative Crohn's Disease Study: results of drug treatment (<i>Gastroenterology</i>)	18.187	Clinical research	1,020	27.6	33	Division of gastroenterology, University of Iowa Medical Center, Iowa City, Virginia, (United States).
30	Frank et al, 2010 ⁵¹	Genome-wide meta-analysis increases to 71 the number of confirmed Crohn's disease susceptibility loci. (<i>Nature Genetics</i>)	31.616	Review Meta-analysis	1,019	169.8	91	Institute of Clinical Molecular Biology, Christian-Albrechts-University Kiel, Kiel, (Germany).
31	Sands et al, 2004 ⁵²	Infliximab maintenance therapy for fistulizing Crohn's disease. (<i>New England Journal of Medicine</i>)	59.558	Clinical research	1,004	83.7	737	Massachusetts General Hospital, and Harvard Medical School, Boston (United States)
32	Jostins et al, 2012 ⁵³	Host-microbe interactions have shaped the genetic architecture of inflammatory bowel disease. (<i>Nature</i>)	38.138	Review Meta-analysis	997	249.2	938	Wellcome Trust Sanger Institute, Wellcome Trust Genome Campus, Hinxton, Cambridge, (<i>United Kingdom</i>)
33	Sokol et al, 2008 ⁵⁴	Faecalibacterium prausnitzii is an anti-inflammatory commensal bacterium identified by gut microbiota analysis of Crohn disease patients. <i>Proceedings of the National Academy of Sciences of the United</i>	9.423	Basic research	994	124.2	318	Institut National de la Recherche Agronomique U910, Domaine de Vilvert, Jouy-en-Josas, (France).

		<i>States of America)</i>						
34	Hampe et al, 2007 ⁵⁵	A genome-wide association scan of nonsynonymous SNPs identifies a susceptibility variant for Crohn disease in ATG16L1. (<i>Nature Genetics</i>)	31.616	Basic research	989	109.9	95	Institute for Clinical Molecular Biology, Christian-Albrechts University Kiel, University Hospital Schleswig-Holstein, (Germany).
35	Colombel et al, 2010 ⁵⁶	Infliximab, azathioprine, or combination therapy for Crohn's disease (<i>New England Journal of Medicine</i>)	59.558	Clinical research	955	159.2	738	Hôpital Claude Huriez and Centre d'Investigation Clinique, Centre Hospitalier Universitaire de Lille, Université Lille Nord de France, Lille, (France).
36	Elson CO et al, 1995 ⁵⁷	Experimental models of inflammatory bowel disease. (<i>Gastroenterology</i>).	18.187	Review	913	43.5	35	Department of Medicine, University of Alabama Hospital at Birmingham, AL, (United States).
37	Colombel et al, 2007 ⁵⁸	Adalimumab for maintenance of clinical response and remission in patients with Crohn's disease: the CHARM trial. (<i>Gastroenterology</i>).	18.187	Clinical research	900	100	36	Hôpital Claude Huriez, Centre Hospitalier Universitaire de Lille, Rue Michel Polonovski, Lille, (France)
38	Greenstein et al, 1976 ⁵⁹	The extra-intestinal complications of Crohn's disease and ulcerative colitis: a study of 700 patients. <i>Medicine (Baltimore)</i> .	2.133	Review	899	22.5	10	Department of Surgery, Mount Sinai School of Medicine and the City University of New York, New York, (United States.)

39	Schroeder et al, 1987 ⁶⁰	Coated oral 5-aminosalicylic acid therapy for mildly to moderately active ulcerative colitis. A randomized study (<i>New England Journal of Medicine</i>)	59.558	Clinical research	897	30.9	775	Mayo Clinic, Rochester, MN (United States)
40	Fujino et al, 2003 ⁶¹	Increased expression of interleukin 17 in inflammatory bowel disease. (<i>Gut</i>).	14.921	Basic research	850	65.4	13	Shiga University of Medical Science, Seta-Tukinowa, Otsu, (Japan).
41	Vandullem en et al, 1995 ⁶²	Treatment of Crohn's disease with anti-tumor necrosis factor chimeric monoclonal antibody (cA2). (<i>Gastroenterology</i>).	18.187	Clinical research	845	40.2	44	Academic Medical Center, Amsterdam, (The Netherlands).
42	Fuss et al 1996 ⁶³	Disparate CD4+ lamina propria (LP) lymphokine secretion profiles in inflammatory bowel disease. Crohn's disease LP cells manifest increased secretion of IFN-gamma, whereas ulcerative colitis LP cells manifest increased secretion of IL-5. (<i>Journal of Immunology</i>)	4.985	Basic research	842	42.1	69	National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, MD, (United States)
43	Hampe et al, 2001 ⁶⁴	Association between insertion mutation in NOD2 gene and Crohn's disease in German and British populations. (<i>Lancet</i>).	44.002	Clinical research	835	55.7	444	Christian-Albrechts-University, Kiel, (Germany).
44	Present et al, 1980 ⁶⁵	Treatment of Crohn's disease with 6-mercaptopurine. A long-term, randomized, double-blind study. (<i>New England Journal of Medicine</i>)	59.558	Clinical research	834	23.2	1054	Lenox Hill Hospital and the Mount Sinai School of Medicine of City University of New York (United States)

45	Abraham et al, 2009 ⁶⁶	Inflammatory bowel disease. (<i>New England Journal of Medicine</i>)	59.558	Review	817	116.7	1099	Yale University School of Medicine, New Haven, CT (United States)
46	Cario and Podolsky, 2000 ⁶⁷	Differential alteration in intestinal epithelial cell expression of toll-like receptor 3 (TLR3) and TLR4 in inflammatory bowel disease. (<i>Infection and Immunity</i>)	3.603	Basic research	814	50.9	6	Massachusetts General Hospital, and Harvard Medical School, Center for the Study of Inflammatory Bowel Disease, Boston, Massachusetts (United States)
47	Lennard-Jones, 1989 ⁶⁸	Classification of inflammatory bowel disease. (<i>Scandinavian Journal of Gastroenterology</i>)	2.199	Article	814	30.1	2	St Mark's Hospital, London, (United Kingdom)
48	Molodecky et al, 2012 ⁶⁹	Increasing incidence and prevalence of the inflammatory bowel diseases with time, based on systematic review. (<i>Gastroenterology</i>).	18.187	Review	809	202.2	45	University of Calgary, Calgary, Alberta, (Canada).
49	Swidsinski et al, 2002 ⁷⁰	Mucosal flora in inflammatory bowel disease. (<i>Gastroenterology</i>).	18.187	Basic research	806	57.6	49	Charité Humboldt Universität, Berlin, (Germany).
50	Powrie et al, 1994 ⁷¹	Inhibition of Th1 responses prevents inflammatory bowel disease in scid mice reconstituted with CD45RBhi CD4+ T cells. (<i>Immunity</i>).	24.082	Basic research	804	36.5	41	DNAX Research Institute of Molecular and Cellular Biology Incorporated, Palo Alto, California (United States).

1
2
3
4
5
6 ^a The search was conducted in November 2016 by searching the Web of Knowledge (1900 to 2016).

7 ^b Because the article by Cario and Podolsky (2000) and the article by Lennard-Jones (1989) had the same absolute number of citations, the paper with higher
8 average citation per year was ranked higher. The average citation per year for Cario and Podolsky was 50.9 (ranked 46) and the paper by Lennard-Jones had
9 an average citation per year of 30.1 (ranked 47).

10 ^c This ranking was identified by searching each journal for a top-cited article and identifying its ranking based on the number of citations received in
11 comparison to the number of citations received by other articles published in that journal.
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46

For peer review only

1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46

For peer review only

BMJ Open

What can we learn from top-cited articles in inflammatory bowel disease? A bibliometric analysis and assessment of the level of evidence

Journal:	<i>BMJ Open</i>
Manuscript ID	bmjopen-2017-021233.R1
Article Type:	Research
Date Submitted by the Author:	01-May-2018
Complete List of Authors:	Azer, Samy; King Saud University, Medical Education; Australian Professional Teaching, Azer, Sarah; St Vincent Hospital
Primary Subject Heading:	Gastroenterology and hepatology
Secondary Subject Heading:	Gastroenterology and hepatology, Medical education and training, Medical publishing and peer review
Keywords:	Inflammatory bowel disease (IBD), Ulcerative colitis (UC), Crohn's disease (CD), Bibliometric analysis, Top-cited articles, Quality of evidence

SCHOLARONE™
Manuscripts

1
2
3 Amended version
4
5
6
7
8

9
10 **What can we learn from top-cited articles in**
11 **inflammatory bowel disease? A bibliometric analysis**
12 **and assessment of the level of evidence**
13
14

15
16
17
18 Samy A. Azer¹ and Sarah Azer²
19

20
21 Dr Azer is a Consultant Gastroenterologist and Professor of Medical
22 Education and the chair of Curriculum Development and Research Unit,
23 College of Medicine, King Saud University, Riyadh, Saudi Arabia¹
24
25

26
27
28 Registrar, St Vincent Hospital, University of Melbourne, Victoria,
29 Australia²
30
31

32
33
34 Correspondence and requests for reprints should be addressed to:

35 Professor Samy Azer
36 Curriculum Development and Research Unit,
37 College of Medicine, King Saud University
38 P O Box 2925, Riyadh 11461
39 Saudi Arabia
40 Telephone: (966) 11-4699178
41 Fax: (966) 11-4699174
42
43
44
45

46 Email:azer2000@optusnet.com.au
47
48
49
50
51

52 SHORT TITLE: Top-cited Inflammatory Bowel Disease
53
54
55
56
57
58
59
60

ABSTRACT

Background and Objectives: Despite increasing number of publications in inflammatory bowel disease (IBD) no bibliometric analysis has been conducted to evaluate the significance of highly-cited articles. Our objectives were to identify the top-cited articles in IBD, assessing their characteristics, and determining the quality of evidence provided by these articles.

Design and outcome measures: IBD and related terms were used in searching the Web of Science to identify English language articles. The 50 top-cited articles were analyzed by year, journal impact factor (JIF), authorship, females in authorship, institute, country, and grants received. The level of evidence was determined using the Oxford Centre for Evidence-Based Medicine guidelines.

Results: The number of citations varied from 871 to 3555 with a total of 74638, and a median 1339.50, (IQR= 587). No correlations were found between the number of citations and number of years since publication ($r=0.042$, $p=0.771$), JIF ($r= 0.186$, $p=0.196$), number of authors ($r= 0.061$, $p=0.674$), females in authorship ($r=0.064$, $p=0.661$), number of institutes ($r= 0.076$, $p=0.602$), number of countries ($r= 0.101$, $p=0.483$), or number of grants ($r= - 0.015$, $p=0.915$). The first authors were from the United States ($n= 24$), United Kingdom ($n= 6$), Germany ($n=5$), France ($n=5$), Belgium ($n=3$), and Canada ($n=3$). The levels of evidence were 12 articles at level 1b, 9 articles at level 3a, and 15 articles at level 3b and fewer were at other levels.

Conclusions: Research papers represented 66% of articles. The majority of items have reasonably high levels of evidence; which may have contributed to the higher number of citations. The study also shows a gender gap in authorship in this area.

Key words

Inflammatory bowel disease (IBD), Ulcerative colitis (UC), Crohn's disease (CD), Top-cited articles, Bibliometric analysis, Quality of evidence, Number of authors, Female authors, Grants/funds, Institutes, Countries.

Strengths and limitations of the study

- More than one method was used in searching the Web of Science to maximize the yield of the search.
- The articles represent a historic perspective on key discoveries in the area of inflammatory bowel disease.
- A number of characteristics including journal impact factor, number of authors, number of females in authorship, number of institutes, number of countries involved, and grants received have been studied against citations received.
- The level of evidence for each article has been evaluated.
- The search was limited to articles in the English language, raising the possibility of failing to include top-cited articles in other languages.

INTRODUCTION

The number of citations received by an article has been used for several years by universities and grant funding bodies in assessing the quality of research produced by researchers, ranking research performance and in making decisions regarding professional promotion and grant applications [1-4]. Thomson Reuters gather the names of these authors in the Highly Cited Researchers database where they are acknowledged for the quality of their work and the size of their research input in a particular area [5]. Although the number of citations cannot explain why researchers cited a particular paper nor reflect the quality of the research and the outcomes identified in a manuscript, the number of citations and the reputation of contribution to research in a particular field cannot be ignored. This is particularly important when there is a pattern of consistency and progressive input into a discipline over years (a life experience), and a demonstration from publication records and citation history of collaboration with other researchers from other institutes at local and international levels. Hence the credits given to an author or a group of authors and the impact of the work in a particular area can be proportionally related to the citation records [6]. The greater the citation history over years, the more influential they are in their specialty [7]. In this study, we hypothesized that examining the most cited in IBD may provide more insight into the significance of these articles and the level of evidence they present [8]. Considering the fact that there are over 91,000 articles on IBD in the literature as per our preliminary search of Web of Science, it is important to consider the characteristics of highly cited articles.

1
2
3 Inflammatory bowel disease comprises ulcerative colitis (UC) and Crohn's disease
4 (CD); both pursue a relapsing and remitting course over years. While the two
5
6 diseases share several similarities, they have a number of differences with regard to
7
8 structures involved, pathogenesis, clinical presentation, and management
9
10 approaches. UC was first reported briefly in mid 1800 [9], while CD was reported in
11
12 *the Journal of the American Medical Association (JAMA)* later by Crohn, Ginzburg
13
14 and Oppenheimer in 1932 [10]; describing it as a chronic inflammatory bowel disease
15
16 of the ileum. Later, it was discovered that CD can involve any part of the
17
18 gastrointestinal tract from the lips to the anal margin but the ileocolonic disease
19
20 represents the common presentation. Since then both diseases have been
21
22 extensively researched in their different aspects.
23
24
25
26
27
28

29 We assumed that these articles may be a cornerstone in IBD, and may enable
30
31 researchers in understanding a range of aspects related to IBD. Therefore, the
32
33 bibliometric analysis of these articles including journal impact factor, authorship,
34
35 females in authorship, institute, country and grants received may explain key features
36
37 of a successful or influential article in IBD. The aims of the present research were (1)
38
39 identify the top-cited articles in IBD, and analyze their characteristics and (2) assess
40
41 the quality of evidence provided by articles.
42
43
44
45

46 **METHODS**

47 **Study Design**

48
49
50 The Web of Science database was searched for the identification of the top-cited
51
52 articles and tracking the citation records of each publication. Although Scopus and
53
54
55
56
57
58
59
60

1
2
3 Google Scholar also provide citation records, it was decided to limit the search to
4
5 Web of Science database. Compared to other databases, the Web of Science is
6
7 regularly updated and the 2015 Journal Citation Reports (JCRs) included more than
8
9 6,500 journals across 150 disciplines. Although Google Scholar database is freely
10
11 available, it was not used because it is difficult to search, and it cites textbooks,
12
13 monographs, conference proceedings, as well as non-peer reviewed publications
14
15 [11]. It is also not possible to track the yearly records of citations attracted by each
16
17 article since publication. Scopus database was not used because it is not extensive in
18
19 its coverage and its records only go back to 1996 [12]. Furthermore, several other
20
21 researchers have used Web of Science to identify top-cited articles [13,14,15]
22
23
24
25

26
27 To achieve the aims of this study we planned to identify the highly cited articles in IBD
28
29 and assess if there were any correlation between the number of citations and any of
30
31 the parameters characterizing these highly cited articles. We also aim to grade each
32
33 article against the level of evidence hierarchy as per the Oxford Centre for Evidence-
34
35 Based Medicine (OCEBM-2011 Levels of Evidence and the accompanying Table of
36
37 Evidence Glossary) [16,17].
38
39
40

41 **Searching the Web of Science database**

42
43
44 On 15 and 16 April 2018, the authors searched the Web of Science database to
45
46 retrieve top-cited articles in inflammatory bowel disease. The search words used
47
48 were the following: “Inflammatory bowel disease”, “Ulcerative colitis”, “Crohn’s
49
50 disease”, “IBD”, “Experimental colitis”, “Animal models for Colitis”, “Animal models for
51
52 inflammatory bowel disease”, “Pathology IBD”, “Pathology UC”, “Pathology CD”,
53
54
55
56
57
58
59
60

1
2
3 “Pathogenesis IBD”, “Pathogenesis UC”, “Pathogenesis CD”, “Treatment IBD”,
4
5 “Treatment UC”, “Treatment CD”, “Investigation IBD” and “Regional ileitis”. To
6
7 increase the yield of the search, we used the full terms- inflammatory bowel disease,
8
9 ulcerative colitis, and Crohn’s disease for the abbreviations IBD, UC, and CD,
10
11 respectively. These search words were identified from the terminology used in
12
13 gastroenterology journals and the proceedings of major conferences on inflammatory
14
15 bowel disease and gastroenterology such as the British Society of Gastroenterology
16
17 (BSG), the American Gastroenterological Association (AGA), American College of
18
19 Gastroenterology (ACG), Canadian Association of Gastroenterology (CAG), Scottish
20
21 Society of Gastroenterology (SSG), and Gastroenterological Society of Australia
22
23 (GESA). For each search word, the results were arranged using a link on the Web of
24
25 Science system, “sort-by” – “Time Cited- highest to lowest”. The results showed the
26
27 articles organized in a descending order with the articles most frequently cited at the
28
29 top. A copy of the results was printed out for further analysis. The findings from each
30
31 search word were then arranged on one Excel sheet (Microsoft Excel 2010, Microsoft
32
33 Corp, Redmond, WA) in descending order based on the number of citations.
34
35 Duplicate articles and articles not in the English language were excluded. In addition
36
37 to the absolute number of citations, we calculated the average citations per year for
38
39 each article. The average number of citations per year is the ratio calculated from the
40
41 number of citations obtained by an article divided by the number of years since
42
43 publication [18].
44
45
46
47
48
49
50
51

52 Using the above mentioned search words, we conducted another search of major
53
54 gastroenterology journals and the 2016-JCR under the category “Gastroenterology
55
56
57
58
59
60

1
2
3 and Hepatology". This category comprises 76 journals at the time of conducting the
4 search; of these seven journals were in languages other than English and were not
5 searched. Gastroenterology journals publishing articles not in the English language
6 were excluded because neither the author nor the assistant researchers are
7 competent in the Spanish, Italian or German languages. Since the language
8 recommended by the journal publishing this work is English and its readers are most
9 likely interested in research publications in the English language, we decided not to
10 search these journals.
11

12 Interestingly, after identifying the list of top-cited articles in IBD, and again checking
13 these seven non-English journals, none had a paper with a citation higher than the
14 paper ranked number 50 on the list.
15

16 These key words were also used in searching the websites of major general
17 medicine, surgery and research journals including the *New England Journal of*
18 *Medicine*, *Lancet*, *the British Medical Journal*, *the Journal of the American Medical*
19 *Association*, *Annals of Internal Medicine*, *Archives of Medicine*, *PLOS Medicine*,
20 *Annals of Surgery*, *Archives of Surgery*, *British Journal of Surgery*, *American Journal*
21 *of Surgical Pathology*, *Nature*, *Science*, *Nature Reviews Cancer*, *Nature Genetics*,
22 *Nature Medicine*, *Cell*, *Nature Reviews Microbiology*, *Immunity*, *Nature Reviews*
23 *Immunology*, *Nature Reviews Molecular Cell Biology*, and *Journal of Immunology*.
24

25 A list identifying the 50 top-cited articles was reviewed again and checked regarding
26 authorship, year of publication, title of the article, journal publishing the work, the
27 Journal Impact Factor (JIF) at the time of the search, the number of citations and the
28 institution of the first author (Appendix 1).
29

1
2
3 =====Add Appendix 1 =====
4
5

6 **Inclusion And Exclusion Criteria**

7
8

9 The inclusion criteria were: papers focusing on IBD (ulcerative colitis or Crohn's
10 disease) written in the English language. The exclusion criteria were: (i) articles on
11 inflammatory bowel disease in languages other than English, (ii) articles that focused
12 on other diseases and inflammatory bowel disease was not the main focus, and (iii)
13 studies that focus on other types of colitis and not inflammatory bowel disease.
14
15
16
17
18
19
20

21 **Assessing Articles**

22
23

24 The full text of the identified 50-top cited articles was obtained and a copy was given
25 to each researcher. The following information was collected for each article: (i) the
26 authors' names, the number of authors, their affiliations, and the number of females
27 contributing to authorship, (ii) the number of institutes involved in the publication, (iii)
28 the city and country of the origin of the publication, (iv) the total number of citations
29 obtained up to the day of searching the database, and the number of yearly citations
30 since publication, (v) the year of publication and the calculated number of years since
31 publication, and (vi) the number of funds/grants stated in the publication and the Web
32 of Science.
33
34
35
36
37
38
39
40
41
42
43
44
45

46 We have not used the classification provided by the Web of Science regarding study
47 type because we noted that the Web of Science groups publications as original
48 research, articles, practical guides and reviews and identifies them as articles or
49 reviews. For consistency and the purpose of this study, the top-cited articles were
50 grouped into four types - article, review paper/meta-analysis, report, and research. A
51
52
53
54
55
56
57
58
59
60

1
2
3 definition of each type is given in the glossary. Two researchers independently
4 allocated each of the top-cited articles under its type as per the definition given. Any
5 differences between the researchers were discussed in a meeting until a decision
6 was reached.
7
8
9
10
11
12

13 The topics covered by the top-cited articles were identified by each researcher
14 independently and were discussed in a meeting to harmonize the grouping into a
15 logical, simple and practical way. Articles that covered more than one topic were
16 classified on the basis of the aim of the study and the main outcomes. For other
17 evaluations of an article including the number of authors, the number of females
18 represented in authorship, the number of institutes, and countries contributing to the
19 work, and the number of grants/funds received we checked the original article for
20 such details. Institute was defined as the university where an author belonged. If an
21 author belonged to two universities, this was considered to be two different institutes.
22 Regarding the identification of females in the authorship we noted that several
23 journals use abbreviations of the first and second name rather than the full name. In
24 order to identify the females in these articles we tried to search the Google database
25 to find the university, personal website of the author, their LinkedIn or ResearchGate
26 accounts. We also tried to identify them by searching the Google Scholar database
27 and identify their account, where we can find other publications under their name and
28 the full first name. In two papers, despite our efforts, we failed to identify the gender
29 of five authors and we contacted the corresponding authors. We received a response
30 from one correspondence, making us unable to identify the gender of three authors in
31 the second paper.
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

Evaluating the Journals

The publishing journals of the top 50 articles in IBD were identified and evaluated in regard to the following: (i) the 2016-Journal Impact Factor (JIF) of each journal, and (ii) the ranking order of each article in comparison to other articles published in that journal. This was based on the number of citations obtained in comparison to the citation numbers received by other articles published in the journal. For example, an article ranked number one, in its publishing journal, means that the article received the highest number of citations in comparison to all other articles published in that journal. This evaluation aimed at assessing the position order of articles identified among the 50 top-cited articles in IBD in regard to their ranking among other articles published in the journal. Such assessment highlights the significance of the inflammatory bowel disease articles among other topics published in gastroenterological journals as well as general medicine journals such as *The New England Journal of Medicine*, *The Lancet*, *the British Medical Journal*, *Medicine*, and top research journals such as *Nature*, *Nature Genetics*, *Science*, *Cell*, and top journals in immunology such as *Nature Reviews Immunology* (Appendix 1).

Assessing Level of Evidence

Two researchers independently used the Oxford Centre for Evidence-Based Medicine (OCEBM-2011 Levels of Evidence and the accompanying Table of Evidence Glossary) [16,17] to rank each article regarding level of evidence. In 1998 this hierarchical of evidence was first produced to make the process of finding relevant evidence feasible. Since then the levels have been reviewed and amended, and the

1
2
3 version used in this research is the currently available version. This evaluation aimed
4
5 at identifying the level of evidence of each article and assessing whether the highly
6
7 cited articles have received higher scores in regard to level of evidence as per the
8
9 Oxford hierarchy. The assessment required extensive review of each article since
10
11 quality descriptors exist for different types of studies and level of evidence vary
12
13 depending on therapeutic, prevention, prognostic, diagnostic, or prevalence design
14
15 [13,14].
16
17
18
19

20 **Statistical Analysis**

21
22
23 Pearson's correlation coefficient (r) was calculated to determine if the high citation
24
25 numbers obtained was related to the age of the article. Other correlations were
26
27 between the number of citations and the number of authors, the percentage of
28
29 females in authorship, the number of institutes, the number of countries involved, the
30
31 number of grants received, and the Journal Impact Factor (JIF) of the journals in
32
33 which articles were published. Because of the assumption that researchers usually
34
35 cite recently published articles, it was decided to compare the mean yearly citations
36
37 received of articles published before the year 2000 and compare them with those
38
39 published after the year 2000. All analyses were conducted using SPSS Software
40
41 (IBM SPSS Statistics Premium version 22.0 for Mac OS-SPSS Inc., Chicago, IL,
42
43 USA) and the results were reported at total, mean, median, IQR, and percentage.
44
45
46 The inter-rater agreement between evaluators was calculated using the Fleiss kappa
47
48 scale [19].
49
50
51
52
53
54
55
56
57
58
59
60

Patient and Public involvement

This study did not involve patients or the public.

RESULTS

Top-Cited Papers Identified

Appendix 1 summarizes the top-cited articles in IBD identified by searching the Web of Science [20-69]. The articles are listed in a descending order from 1 to 50 with the highest absolute citation number is ranked 1 and the article with the lowest citation ranked 50 as per the day of the search.

Table 1 summarizes the year of publication and article type. The articles were published over 57 years (from 1955 to 2012). During the period from 1955 to 1976, only 3 articles (6%) were published. However, the number increased significantly from 1977 to 1994 making a total of 12 (24%) articles. The number of publications increased significantly to 35 (70%) during the years from 1995 to 2012. No correlation was found between the number of citations of these papers and the number of years since published (Pearson correlation (r) = 0.042, p = 0.771). To assess if there were differences between old articles (published before the year 2000) and those published after the year 2000, it was decided to study the mean number of citations received by top-cited articles in each year after their publications. The year 2000 was taken as a midpoint for comparison because the majority of articles identified were published in the period after the year 1986, and hence the year 2000 could represent such point. As shown from Figures 1A and 1B, the mean numbers of citations were higher for articles published after the year 2000 compared to those published before

1
2
3 the year 2000. Approximately one fourth of the top-cited papers were reviews/meta-
4 analysis (n= 14, 28%), two-thirds were research papers (n= 33, 66%), and the
5
6 remaining were an article (n= 1, 2%) and two reports (n=2, 4%).
7
8
9

10
11 =====Please Add Table 1 here =====
12

13
14 Table 2 summarizes the distribution of IBD topics covered in the top-cited articles.
15

16 These can be summarized as follows: epidemiology and prevalence (n=2, 4%),
17
18 Crohn's disease genetic susceptibility and NOD2 mutation (n=6, 12%), Animal
19
20 models (n= 5, 10%), Pathogenesis of IBD (n= 15, 30%), classification and index of
21
22 disease activity (n= 5, 10%), risk of developing colorectal cancer (n= 2, 4%), extra-
23
24 intestinal complications (n= 1, 2%), Infliximab in Crohn's disease (n= 6, 12%),
25
26 corticosteroids in ulcerative colitis (n=1, 2%), drug treatment and cyclosporine in
27
28 ulcerative colitis (n= 2, 4%), adalimumab in Crohn's disease (n=1, 2%), 5-
29
30 aminosalicylic acid in ulcerative colitis (n=1, 2%), 6-mercaptopurine in Crohn's
31
32 disease (n=1, 2%), and monoclonal antibiotics, and anti-tumour necrosis factor in
33
34 Crohn's disease (n=2, 4%). As shown in Appendix 1, 14 (28%) were basic research
35
36 and 19 (38%) were clinical research. The level of evidence is discussed later in the
37
38 results.
39
40
41
42
43
44

45 =====Please Add Table 2 here =====
46

47
48 The articles were published in the following journals: *New England Journal of*
49
50 *Medicine* (n= 12, 24%), *Gastroenterology* (n= 12, 24%), *Nature* (n=4, 8%), *Nature*
51
52 *Genetics* (n=4, 8%), *The Lancet* (n= 2, 4%), *Proceedings of the National Academic of*
53
54
55
56
57
58
59
60

1
2
3 *Sciences of the United States of America* (n=2, 4%), *Cell* (n= 2, 4%), and *Gut* (n= 4,
4
5 8%). See Table 3 for more details about the journals publishing these articles.
6
7
8
9
10

11
12 =====Please Add Table 3 here =====
13

14
15 Looking at the ranking of the top-cited articles in IBD in the journals they were
16
17 published in could provide a better picture about the influence of these articles. This
18
19 influence would be clearly demonstrated when the journal has a relatively higher
20
21 Journal Impact Factor. The ranking is based on the number of citations received by
22
23 an article compared to the number of citations received by other articles that were
24
25 published in that journal. The article by Best et al (1976) [23] is ranked number 4 in
26
27 the list, and also ranked number 2 among all articles published in *Gastroenterology*
28
29 (2016-JIF = 18.392). The article by Eaden et al [41] is ranked number 22 in the list
30
31 and also ranked number 1 among all articles published in *Gut* (2016-JIF= 16.658).
32
33 The ranking of other articles in List and their rankings in the journals in which they
34
35 were published are shown in Appendix 1.
36
37
38
39
40

41 The first authors of the top-cited articles were from the United States (n= 24, 48%),
42
43 the United Kingdom (n=6, 12%), Germany (n= 5, 10%), France (n= 5, 10%), Belgium
44
45 (n= 3, 6%), Canada (n= 3, 6%), Japan (n=2, 4%), Sweden (n=1, 2%), and the
46
47 Netherlands (n=1, 2%).
48
49
50

51 Table 4 summarises the 70 authors who have published two papers or more in the
52
53 top-cited IBD. Of these 18 authors were the first author and coauthors of more than
54
55 two papers in total, all the remaining, 52 were coauthors of more than two papers.
56
57
58
59
60

1
2
3 Top authors were Rutgeers, P (n=10 papers), Targan, SR (n=8 papers), Schreiber, S
4 (n=7 papers), Cho, JH (n=7 papers), Colombel, JF (n=7 papers), Hanauer, SB (n=7
5 papers), Silverberg, MS (n=6 papers), and each of the following authors have 5
6 papers: Podolsky, DK, Rioux, JD, Daly MJ, Steinhart, AH, Rotter, JI, Schumm, LP,
7 Taylor, KD, Vermeire, S, Duerr, RH, and Regueiro, M.
8
9

10
11
12
13
14
15 =====Please Add Table 4 here =====
16

17
18 The leadership of universities and institutes that have contributed to the creation of
19 these publications were Massachusetts General Hospital and Harvard Medical
20 School, Boston, Massachusetts, the United States, Mount Sinai School of Medicine,
21 New York, the United States, Mayo Clinic, Rochester, Minnesota, the United States,
22 Cedars-Sinai Medical Center, Los Angeles, California, the United States, University of
23 Chicago Medical Center, Chicago, Illinois, the United States, University of Pittsburgh,
24 Pittsburgh, Pennsylvania, the United States, University Hospital of Cleveland Case
25 Western Reserve University School of Medicine, Ohio, the United States, Wellcome
26 Trust Centre for Human Genetics, University of Oxford, Roosevelt Drive, Oxford, the
27 United Kingdom, Wellcome Trust Sanger Institute, Wellcome Trust Genome Campus,
28 Cambridge, the United Kingdom, and Institute of Virology and Immunobiology,
29 University of Würzburg, Germany. See Appendix 1 for more detail.
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45

46 47 **Characteristics of the Top-Cited Articles** 48

49
50 These articles were created by 667 authors, median 7.0, minimum 1, maximum 106,
51 IQR 9.5; the females in authorship were 111, median 1.0, minimum 0, maximum 20,
52 IQR 2. It is worth mentioning here that it was difficult to identify the gender of some
53
54
55
56
57
58
59
60

1
2
3 authors in two papers because the full first and middle names were not shown and it
4 was difficult to find more information or clues to make a decision. We contacted the
5
6 corresponding authors of these two articles; we received information for one article
7
8 but we had no response from the corresponding author of the second article. Thus
9
10 the gender of three authors could not be identified. The number of institutes involved
11
12 were 436, median 3.0, minimum 1, maximum 88, IQR 9; the countries involved were
13
14 141, median 1.0, minimum 1, maximum 16, IQR 2.75; and the number of grants/funds
15
16 were 328, median 1.0, minimum 0, maximum 94, IQR 2.75. No correlations were
17
18 found between the number of citations and the Journal Impact Factor (JIF) (Pearson
19
20 correlation ($r = 0.186$; $p=0.196$), the number of authors ($r =0.061$; $p= 0.674$), number
21
22 of females in authorship ($r =0.064$; $p= 0.661$), the number of institutes involved (r
23
24 $=0.076$; $p= 0.602$), the number of countries involved ($r =0.101$; $p= 0.483$), and the
25
26 number of grants received ($r= - 0.015$; $p=0.915$).

33 34 **Level of Evidence**

35
36
37 Table 5 summarizes the grading of articles according to the Oxford Center for
38
39 evidence-based medicine. The table shows that most articles were graded at levels
40
41 1b and 3a and 3b evidence (12 papers had level 1b evidence, 9 papers at level 3a,
42
43 and 15 papers had level 3b evidence). Five articles had a level of evidence of 4 and
44
45 no article at level 5. The remaining articles were at levels 1a, 2a, 2b and 2c. The
46
47 overall agreement between the evaluators was acceptable; Fleiss kappa= 0.8252;
48
49 95% CI 0.79-0.85.
50
51
52
53
54
55
56
57
58
59
60

1
2
3 =====Please Add Table 5 here =====
4
5
6
7

8 9 **DISCUSSION**

10
11
12 This study aimed at identifying the characteristics of the top 50 most frequently cited
13 papers in IBD and assessing the quality of evidence provided. The papers covered a
14 number of key topics related to IBD including: epidemiology and prevalence,
15 pathogenesis and genetic susceptibility, animal models, clinical classification and
16 indices of disease activity, risks of developing colorectal cancer, extra-intestinal
17 complications, and use of infliximab, adalimumab, monoclonal antibodies and anti-
18 tumour necrosis factor, and 6- mercaptopurine in CD, and use of 5-aminosalicylic
19 acid, corticosteroids, and cyclosporine in treating UC. While these topics cover key
20 issues related to IBD, topics related to molecular biology, surgical management,
21 patient education, nutritional aspects, radiological and other investigations were not
22 represented in the top-cited articles list [70,71].
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37

38
39 The assessment of the characteristics of the top 50 highly cited articles identified in
40 this study reveals the following:
41
42
43

44 First, the lack of correlations between the number of citations and the number of
45 years since publication may indicate that the high-citations is not caused by ageing of
46 these articles. In fact, only 15 articles (30%) were published in the period from 1955
47 to 1994 (39 years), while the majority, 35 (70%) were published in the last 17 years.
48
49
50

51 No papers were published after 2012. This article also shows that the mean number
52 of citations of articles published before the year 2000 were much lower than those of
53
54
55
56
57
58
59
60

1
2
3 articles after the year 2000. This may be related to the tendency of researchers to cite
4 recently published research and new findings [72] and papers that they have read
5
6 [18]. Also the number of citations and the papers' age might be attributed to the
7
8 changes in citation behaviour over time. For example, in the 50s and 60s, the authors
9
10 used to cite fewer papers compared to what was practiced over the last 20 years [73].
11
12 The higher citations have been found to be the strongest predictor of current online
13
14 availability after a long time since publication. Therefore, the higher citation could be
15
16 a protective mechanism for continued availability of a publication despite aging and
17
18 hence continuing citation [74].
19
20
21
22
23

24
25 Second, the lack of a correlation between the number of citations and the Journal
26
27 Impact Factor (JIF). The JIF has been widely used in ranking and evaluating journals.
28
29 It stands as a proxy for the relative importance of a journal with its field [75]. Although
30
31 the top-cited articles identified were published in journals with high impact factors, the
32
33 impact factors of some journals were not necessarily the highest in their fields. For
34
35 example, *Laboratory Investigation*, *Canadian Journal of Gastroenterology and*
36
37 *Hepatology*, *Medicine (Baltimore)*, and *Journal of Immunology* had JIFs in the range
38
39 of 1.804 to 4.857. With this information in mind one may postulate that the high JIF is
40
41 not necessarily related to the higher citation numbers received. Two recent works
42
43 showed that the JIF is not an accurate indicator of citations an average article
44
45 receives, articles published in low impact factor journals can still be highly cited and
46
47 vice versa [76,77].
48
49
50
51
52

53
54 Third, the study showed negative correlation between the number of citations and the
55
56 number of authors, the number of female authors, or the number of institutes. The
57
58
59
60

1
2
3 number of authors and females in authorship varied from one to 106 and from zero to
4
5 20, respectively. Also the number of institutes involved varied from one to 88. The
6
7 question that can be raised in this regards; are we expecting an increase in number
8
9 of citations as the number of authors or the number institutes involved increased?

10
11
12 The work of Garcia-Aroca et al [78] shows that collaboration between authors
13
14 increases their impact and increases citation rates. However, they showed that
15
16 publishing in English in certain journals and collaborating with certain authors and
17
18 institutes increase the visibility of the manuscripts published on the subject. Hence it
19
20 is the quality of collaboration rather than the absolute number of these parameters.
21
22
23 Recently Tanner-Smith and Polanin showed that studies conducted by more
24
25 established authors (have higher h-indices) and reported in more prestigious journal
26
27 outlets are more likely to be cited by other scholars, even after controlling for various
28
29 proxies of study quality [79].
30
31
32

33
34 Although the proportion of women in authorship of original research in the United
35
36 States in general has significantly increased in the last four decades, women still
37
38 compose a minority of the authors of original research [80]. In the field of
39
40 gastroenterology, the percentage of the United States female physician authors of
41
42 original research in the field has relatively increased over time, yet the senior author
43
44 position remains lower than expected [81,82].
45
46
47

48
49 Fourth, the study showed no correlation between the number of citations and the
50
51 number of funds/grants received. This finding is not surprising. Recently it was shown
52
53 that too many of the United States authors of most influential papers in science do not
54
55 receive NH funding [83]. Another group of researchers found no association between
56
57
58
59
60

1
2
3 grant percentile ranking and grant outcome as assessed by number of top-10%
4 articles per dollar million spent [84].
5
6
7

8 The United States, the United Kingdom, Germany, France, Belgium, and Canada
9 contributed to the majority of these articles. The leadership of universities from these
10 countries in gastrointestinal research particularly IBD is no surprise, top universities
11 identified from this study were Massachusetts General Hospital and Harvard Medical
12 School, Boston, Massachusetts, the United States, Mount Sinai School of Medicine,
13 New York, the United States, Mayo Clinic, Rochester, Minnesota, the United States,
14 Cedars-Sinai Medical Center, Los Angeles, California, the United States, University of
15 Chicago Medical Center, Chicago, Illinois, the United States. Other institutes and
16 research centres that had lead these studies are shown in Appendix 1.
17
18
19
20
21
22
23
24
25
26
27
28
29

30 All articles were published in the English language. The most productive journals
31 were the *New England Journal of Medicine*, and *Gastroenterology* with a total of 24
32 articles. Others were *Nature*, *Nature Genetics*, *the Lancet*, and *Proceedings of the*
33 *National Academy of Sciences of the United States of America*, *Cell*, *Gut*, *British*
34 *Medical Journal*, *Science*, and *Nature Reviews Immunology* making a total of 20
35 articles. While these journals have a relatively high JIF, other journals published one
36 article each and had a relatively low JIF compared to journals included in their
37 categories. For example, *Human Pathology* listed number 22 under the category of
38 Pathology, and *Canadian Journal of Gastroenterology and Hepatology*, listed number
39 74 under the category Gastroenterology and Hepatology. The high level of evidence
40 as outlined in the top-cited articles could be an important contributing factor to the
41 higher number of citations received by these articles [85].
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

1
2
3 After the submission of our study we came across the study by Connelly et al [86] on
4 top 100 articles on IBD. While they indicated that their findings covered the period
5 between 1955-2012 which is consistent with our findings, our study has examined a
6 range of parameters including correlation of citation numbers with JIF, number of
7 years since publication, number of authors, females in authorship, institutes, and
8 number of countries and grants, which were not addressed by Connelly's work. Also
9 we have examined the level of evidence of highly cited articles.
10
11
12
13
14
15
16
17
18
19

20 **CONCLUSIONS**

21
22
23 Our list of top-cited articles in IBD highlights key contributions that based the
24 foundation of research and examination of different aspects of the disease over 57
25 years. This scholarly contribution came from universities and research centres in the
26 United States, the United Kingdom, Germany, France, Belgium and Canada. The
27 findings may be consistent with the concept that it is not the absolute number of
28 collaborators that makes an impact on the citation number or the influence of a
29 publication but rather the quality of such collaboration with regard to the researchers
30 involved, their institutes, and the ongoing contribution to the advances of research.
31 The relatively small number of females in the authorship reflects the gender gap and
32 the fact that women still compose a minority of the authors of original research and
33 reviews in gastroenterology. The higher level of evidence demonstrated in most top-
34 cited articles may have contributed to the higher number of citations received by
35 these articles.
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

1
2
3 **Acknowledgement:** The author would like to thank Diana Sanad for her assistance
4
5 and reviewing the manuscript.
6
7

8 **Funding support:** This work was funded by the College of Medicine, Research
9
10 Center Deanship of Scientific Research, King Saud University, Riyadh, Saudi Arabia.
11
12

13 **Ethical approval:** Not applicable to this study.
14
15

16 **Contributors** SAA and SA shared equally the different roles and responsibilities to
17
18 complete the submitted article including, the research idea, the search of databases,
19
20 the evaluation of data collected, the statistical analysis, the interpretation of findings,
21
22 the creation of tables and figures, writing the manuscript and the approved the final
23
24 version of the manuscript.
25
26
27

28 **Competing interests:** Both authors (SAA and SA) declare that they have no
29
30 competing interests and have completed the International Committee of Medical
31
32 Journal Editors (ICMJE) form
33
34
35

36 **Provenance and peer review:** Not commissioned; externally peer reviewed
37
38

39 **Data sharing statement:** No further data available to share
40
41

REFERENCES

1. MacMaster FP, Swansburg R, Rittenbach K. Academic Productivity in Psychiatry: Benchmarks for the H-Index. *Acad Psychiatry*. 2017 Apr 18. [Epub ahead of print]
2. Susarla HK, Dhar V, Karimbux NY, Tinanoff N. Do Standard Bibliometric Measures Correlate with Academic Rank of Full-Time Pediatric Dentistry Faculty Members? *J Dent Educ*. 2017 Apr;81(4):427-432.
3. Milone MT, Bernstein J. On Track to Professorship? A Bibliometric Analysis of Early Scholarly Output. *Am J Orthop (Belle Mead NJ)*. 2016 Mar-Apr;45(3):E119-23.
4. Azer SA, Holen A, Wilson I, Skokauskas N. Impact factor of medical education journals and recently developed indices: Can any of them support academic promotion criteria? *J Postgrad Med*. 2016 Jan-Mar;62(1):32-39. doi: 10.4103/0022-3859.173202.
5. Jones AW. Impact of JAT publications 1981-2003: the most prolific authors and the most highly cited articles. *J Anal Toxicol*. 2004 Oct;28(7):541-545.
6. Patsopoulos NA, Ioannidis JP, Analatos AA. Origin and funding of the most frequently cited papers in medicine: database analysis. *BMJ* 2006;332:1061–1064.
7. Garfield E. Fortnightly review: how can impact factors be improved? *BMJ* 1996;313:411–413.
8. Azer SA. Exploring the Top-Cited and Most Influential Articles in Medical Education. *J Contin Educ Health Prof*. 2016 Summer;36 Suppl 1:S32-41.
9. Wilks S. Morbid appearances in the intestines of Miss Bankes. *Med Times Gazette* 1859;2:264-265.
10. Crohn BB, Ginzburg L, Oppenheimer GD. Regional ileitis: a pathologic and clinical entity. *JAMA* 1932;99:1323-1329.
11. Van Noorden R, Maher B, Nuzzo R. The top 100 papers. *Nature*. 2014;514(7524):550.

- 1
2
3
4 12. Kulkarni AV, Aziz B, Shams I, Busse JW. Comparisons of citations in Web of
5 Science, Scopus, and Google Scholar for articles published in general medical
6 journals. *JAMA*. 2009 Sep 9;302(10):1092-1096.
7
- 8 13. Powell AGMT, Bevan V, Brown C, Lewis WG. Altmetric Versus Bibliometric
9 Perspective Regarding Publication Impact and Force. *World J Surg*. 2018 Mar 13.
10
11
12
- 13 14. Yi F, Ma J, Ni W, Chang R, Liu W, Han X, Pan D, Liu X, Qiu J. The top
14 cited articles on glioma stem cells in Web of Science. *Neural Regen Res*. 2013 May
15 25;8(15):1431-8. doi: 10.3969/j.issn.1673-5374.2013.15.011.
16
- 17 15. Mu Y, Li N, Guan L, Wang C, Shang S, Wang Y. Therapies for children with
18 cerebral palsy: A Web of Science-based literature analysis. *Neural Regen Res*. 2012
19 Nov 25;7(33):2632-9. doi: 10.3969/j.issn.1673-5374.2012.33.009.
20
21
- 22 16. Azer SA. Top-Cited Articles in Problem-Based Learning: A Bibliometric Analysis
23 and Quality of Evidence Assessment. *J Dent Educ*. 2017 Apr;81(4):458-478.
24
25
- 26 17. Oxford Centre for Evidence-based Medicine – Levels of Evidence (March 2009).
27 Available at: [http://www.cebm.net/oxford-centre-evidence-based-medicine-levels-](http://www.cebm.net/oxford-centre-evidence-based-medicine-levels-evidence-march-2009)
28 [evidence-march-2009](http://www.cebm.net/oxford-centre-evidence-based-medicine-levels-evidence-march-2009) [Accessed 20 May 2017].
29
30
- 31 18. Azer SA. The top-cited articles in medical education: a bibliometric analysis. *Acad*
32 *Med* 2015;90(8):1147-1161.
33
34
35
- 36 19. D'Antiga L, Betalli P, De Angelis P, et al. Interobserver agreement on endoscopic
37 classification of oesophageal varices in children. *J Pediatr Gastroenterol Nutr*
38 2015;61(2):176-181.
39
40
- 41 20. Hugot JP, Chamaillard M, Zouali H, Lesage S, Cézard JP, Belaiche J, Almer S,
42 Tysk C, O'Morain CA, Gassull M, Binder V, Finkel Y, Cortot A, Modigliani R, Laurent-
43 Puig P, Gower-Rousseau C, Macry J, Colombel JF, Sahbatou M, Thomas G.
44 Association of NOD2 leucine-rich repeat variants with susceptibility to Crohn's
45 disease. *Nature*. 2001 May 31;411(6837):599-603.
46
47
- 48 21. Ogura Y, Bonen DK, Inohara N, Nicolae DL, Chen FF, Ramos R, Britton H, Moran
49 T, Karaliuskas R, Duerr RH, Achkar JP, Brant SR, Bayless TM, Kirschner BS,
50 Hanauer SB, Nuñez G, Cho JH. A frameshift mutation in NOD2 associated with
51 susceptibility to Crohn's disease. *Nature*. 2001 May 31;411(6837):603-6.
52
53
- 54 22. Kühn R, Löhler J, Rennick D, Rajewsky K, Müller W. Interleukin-10-deficient mice
55 develop chronic enterocolitis. *Cell*. 1993 Oct 22;75(2):263-74
56
57
58
59
60

- 1
2
3 23. Best WR, Becktel JM, Singleton JW, Kern F Jr. Development of a Crohn's
4 disease activity index. National Cooperative Crohn's Disease Study.
5 Gastroenterology. 1976 Mar;70(3):439-44.
6
7
8 24. Hanauer SB, Feagan BG, Lichtenstein GR, Mayer LF, Schreiber S, Colombel JF,
9 Rachmilewitz D, Wolf DC, Olson A, Bao W, Rutgeerts P; ACCENT I Study Group.
10 Maintenance infliximab for Crohn's disease: the ACCENT I randomised trial. Lancet.
11 2002 May 4;359(9317):1541-1549.
12
13 25. Podolsky DK. Inflammatory bowel disease. N Engl J Med. 2002 Aug
14 8;347(6):417-429.
15
16
17 26. Targan SR, Hanauer SB, van Deventer SJ, Mayer L, Present DH, Braakman T,
18 DeWoody KL, Schaible TF, Rutgeerts PJ. A short-term study of chimeric monoclonal
19 antibody cA2 to tumor necrosis factor alpha for Crohn's disease. Crohn's Disease
20 cA2 Study Group. N Engl J Med. 1997 Oct 9;337(15):1029-35.
21
22
23
24 27. Xavier RJ, Podolsky DK. Unravelling the pathogenesis of inflammatory bowel
25 disease. Nature. 2007 Jul 26;448(7152):427-434.
26
27
28 28. Truelove SC and Witts LJ. Cortisone in ulcerative colitis; final report on a
29 therapeutic trial. Br Med J. 1955 Oct 29;2(4947):1041-1048.
30
31
32 29. Duerr RH, Taylor KD, Brant SR, Rioux JD, Silverberg MS, Daly MJ, Steinhart AH,
33 Abraham C, Regueiro M, Griffiths A, Dassopoulos T, Bitton A, Yang H, Targan S,
34 Datta LW, Kistner EO, Schumm LP, Lee AT, Gregersen PK, Barmada MM, Rotter JI,
35 Nicolae DL, Cho JH. A genome-wide association study identifies IL23R as an
36 inflammatory bowel disease gene. Science. 2006 Dec 1;314(5804):1461-1463.
37
38
39 30. Rutgeerts P, Sandborn WJ, Feagan BG, Reinisch W, Olson A, Johanns J,
40 Travers S, Rachmilewitz D, Hanauer SB, Lichtenstein GR, de Villiers WJ, Present D,
41 Sands BE, Colombel JF. Infliximab for induction and maintenance therapy for
42 ulcerative colitis. N Engl J Med. 2005 Dec 8;353(23):2462-76.
43
44
45 31. Present DH, Rutgeerts P, Targan S, Hanauer SB, Mayer L, van Hogezaand RA,
46 Podolsky DK, Sands BE, Braakman T, DeWoody KL, Schaible TF, van Deventer SJ.
47 Infliximab for the treatment of fistulas in patients with Crohn's disease. N Engl J Med.
48 1999 May 6;340(18):1398-405.
49
50
51 32. Frank DN, St Amand AL, Feldman RA, Boedeker EC, Harpaz N, Pace NR.
52 Molecular-phylogenetic characterization of microbial community imbalances in human
53 inflammatory bowel diseases. Proc Natl Acad Sci U S A. 2007 Aug
54 21;104(34):13780-13785
55
56 33. Jostins L, Ripke S, Weersma RK, Duerr RH, McGovern DP, Hui KY, Lee JC,

1
2
3 Schumm LP, Sharma Y, Anderson CA, Essers J, Mitrovic M, Ning K, Cleynen I,
4 Theatre E, Spain SL, Raychaudhuri S, Goyette P, Wei Z, Abraham C, Achkar JP,
5 Ahmad T, Amininejad L, Ananthakrishnan AN, Andersen V, Andrews JM, Baidoo L,
6 Balschun T, Bampton PA, Bitton A, Boucher G, Brand S, Büning C, Cohain A, Cichon
7 S, D'Amato M, De Jong D, Devaney KL, Dubinsky M, Edwards C, Ellinghaus D,
8 Ferguson LR, Franchimont D, Fransen K, Garry R, Georges M, Gieger C, Glas J,
9 Ferguson LR, Franchimont D, Fransen K, Garry R, Georges M, Gieger C, Glas J,
10 Haritunians T, Hart A, Hawkey C, Hedl M, Hu X, Karlsen TH, Kupcinskas L,
11 Kugathasan S, Latiano A, Laukens D, Lawrance IC, Lees CW, Louis E, Mahy G,
12 Mansfield J, Morgan AR, Mowat C, Newman W, Palmieri O, Ponsioen CY, Potocnik
13 U, Prescott NJ, Regueiro M, Rotter JI, Russell RK, Sanderson JD, Sans M, Satsangi
14 J, Schreiber S, Simms LA, Sventoraityte J, Targan SR, Taylor KD, Tremelling M,
15 Verspaget HW, De Vos M, Wijmenga C, Wilson DC, Winkelmann J, Xavier RJ,
16 Zeissig S, Zhang B, Zhang CK, Zhao H; International IBD Genetics Consortium
17 (IIBDGC)., Silverberg MS, Annese V, Hakonarson H, Brant SR, Radford-Smith G,
18 Mathew CG, Rioux JD, Schadt EE, Daly MJ, Franke A, Parkes M, Vermeire S, Barrett
19 JC, Cho JH. Host-microbe interactions have shaped the genetic architecture of
20 inflammatory bowel disease. *Nature*. 2012 Nov 1;491(7422):119-24.
21
22

23
24 34. Barrett JC, Hansoul S, Nicolae DL, Cho JH, Duerr RH, Rioux JD, Brant SR,
25 Silverberg MS, Taylor KD, Barmada MM, Bitton A, Dassopoulos T, Datta LW, Green
26 T, Griffiths AM, Kistner EO, Murtha MT, Regueiro MD, Rotter JI, Schumm LP,
27 Steinhart AH, Targan SR, Xavier RJ; NIDDK IBD Genetics Consortium, Libioulle C,
28 Sandor C, Lathrop M, Belaiche J, Dewit O, Gut I, Heath S, Laukens D, Mni M,
29 Rutgeerts P, Van Gossum A, Zelenika D, Franchimont D, Hugot JP, de Vos M,
30 Vermeire S, Louis E; Belgian-French IBD Consortium; Wellcome Trust Case Control
31 Consortium, Cardon LR, Anderson CA, Drummond H, Nimmo E, Ahmad T, Prescott
32 NJ, Onnie CM, Fisher SA, Marchini J, Ghorji J, Bumpstead S, Gwilliam R, Tremelling
33 M, Deloukas P, Mansfield J, Jewell D, Satsangi J, Mathew CG, Parkes M, Georges
34 M, Daly MJ. Genome-wide association defines more than 30 distinct susceptibility loci
35 for Crohn's disease. *Nat Genet*. 2008 Aug;40(8):955-962.
36
37

38
39 35. Loftus EV Jr. Clinical epidemiology of inflammatory bowel disease: Incidence,
40 prevalence, and environmental influences. *Gastroenterology*. 2004 May;126(6):1504-
41 1517.
42

43 36. Fiocchi C. Inflammatory bowel disease: etiology and pathogenesis.
44 *Gastroenterology*. 1998 Jul;115(1):182-205.
45

46
47 37. Harvey RF, Bradshaw JM. A simple index of Crohn's-disease activity. *Lancet*.
48 1980 Mar 8;1(8167):514.
49

50 38. Molodecky NA, Soon IS, Rabi DM, Ghali WA, Ferris M, Chernoff G, Benchimol EI,
51 Panaccione R, Ghosh S, Barkema HW, Kaplan GG. Increasing incidence and
52 prevalence of the inflammatory bowel diseases with time, based on systematic
53 review. *Gastroenterology*. 2012 Jan;142(1):46-54.
54
55
56
57
58
59
60

1
2
3 39. Riddell RH, Goldman H, Ransohoff DF, Appelman HD, Fenoglio CM, Haggitt RC,
4 Ahren C, Correa P, Hamilton SR, Morson BC, et al. Dysplasia in inflammatory bowel
5 disease: standardized classification with provisional clinical applications. *Hum Pathol*.
6 1983 Nov;14(11):931-968.
7

8
9
10 40. Okayasu I, Hatakeyama S, Yamada M, Ohkusa T, Inagaki Y, Nakaya R A novel
11 method in the induction of reliable experimental acute and chronic ulcerative colitis in
12 mice. *Gastroenterology*. 1990 Mar;98(3):694-702.
13

14
15
16 41. Eaden JA, Abrams KR, Mayberry JF. The risk of colorectal cancer in ulcerative
17 colitis: a meta-analysis. *Gut*. 2001 Apr;48(4):526-535.
18

19
20 42. Sokol H, Pigneur B, Watterlot L, Lakhdari O, Bermúdez-Humarán LG, Gratadoux
21 JJ, Blugeon S, Bridonneau C, Furet JP, Corthier G, Grangette C, Vasquez N, Pochart
22 P, Trugnan G, Thomas G, Blottière HM, Doré J, Marteau P, Seksik P, Langella P.
23 *Faecalibacterium prausnitzii* is an anti-inflammatory commensal bacterium identified
24 by gut microbiota analysis of Crohn disease patients. *Proc Natl Acad Sci U S A*. 2008
25 Oct 28;105(43):16731-16736.
26

27
28 43. Silverberg MS, Satsangi J, Ahmad T, Arnott ID, Bernstein CN, Brant SR, Caprilli
29 R, Colombel JF, Gasche C, Geboes K, Jewell DP, Karban A, Loftus EV Jr, Peña AS,
30 Riddell RH, Sachar DB, Schreiber S, Steinhart AH, Targan SR, Vermeire S, Warren
31 BF. Toward an integrated clinical, molecular and serological classification of
32 inflammatory bowel disease: report of a Working Party of the 2005 Montreal World
33 Congress of Gastroenterology. *Can J Gastroenterol*. 2005 Sep;19 Suppl A:5A-36A
34

35
36 44. Sadlack B, Merz H, Schorle H, Schimpl A, Feller AC, Horak I. Ulcerative colitis-
37 like disease in mice with a disrupted interleukin-2 gene. *Cell*. 1993 Oct 22;75(2):253-
38 261.
39

40
41 45. Franke A, McGovern DP, Barrett JC, Wang K, Radford-Smith GL, Ahmad T, Lees
42 CW, Balschun T, Lee J, Roberts R, Anderson CA, Bis JC, Bumpstead S, Ellinghaus
43 D, Festen EM, Georges M, Green T, Haritunians T, Jostins L, Latiano A, Mathew CG,
44 Montgomery GW, Prescott NJ, Raychaudhuri S, Rotter JI, Schumm P, Sharma Y,
45 Simms LA, Taylor KD, Whiteman D, Wijmenga C, Baldassano RN, Barclay M,
46 Bayless TM, Brand S, Büning C, Cohen A, Colombel JF, Cottone M, Stronati L,
47 Denson T, De Vos M, D'Inca R, Dubinsky M, Edwards C, Florin T, Franchimont D,
48 Geary R, Glas J, Van Gossom A, Guthery SL, Halfvarson J, Verspaget HW, Hugot
49 JP, Karban A, Laukens D, Lawrance I, Lemann M, Levine A, Libioulle C, Louis E,
50 Mowat C, Newman W, Panés J, Phillips A, Proctor DD, Regueiro M, Russell R,
51 Rutgeerts P, Sanderson J, Sans M, Seibold F, Steinhart AH, Stokkers PC, Torkvist L,
52 Kullak-Ublick G, Wilson D, Walters T, Targan SR, Brant SR, Rioux JD, D'Amato M,
53 Weersma RK, Kugathasan S, Griffiths AM, Mansfield JC, Vermeire S, Duerr RH,
54 Silverberg MS, Satsangi J, Schreiber S, Cho JH, Annese V, Hakonarson H, Daly MJ,
55 Parkes M. Genome-wide meta-analysis increases to 71 the number of confirmed
56
57
58
59
60

1
2
3 Crohn's disease susceptibility loci. *Nat Genet.* 2010 Dec;42(12):1118-1125.
4

5
6 46. Baert F, Noman M, Vermeire S, Van Assche G, D' Haens G, Carbonez A,
7 Rutgeerts P. Influence of immunogenicity on the long-term efficacy of infliximab in
8 Crohn's disease. *N Engl J Med.* 2003 Feb 13;348(7):601-608.
9

10
11 47. Colombel JF, Sandborn WJ, Reinisch W, Mantzaris GJ, Kornbluth A,
12 Rachmilewitz D, Lichtiger S, D'Haens G, Diamond RH, Broussard DL, Tang KL, van
13 der Woude CJ, Rutgeerts P; SONIC Study Group. Infliximab, azathioprine, or
14 combination therapy for Crohn's disease. *N Engl J Med.* 2010 Apr 15;362(15):1383-
15 1395.
16

17
18 48. Cooper HS, Murthy SN, Shah RS, Sedergran DJ. Clinicopathologic study of
19 dextran sulfate sodium experimental murine colitis. *Lab Invest.* 1993 Aug;69(2):238-
20 249.
21

22
23 49. Ekobom A, Helmick C, Zack M, Adami HO. Ulcerative colitis and colorectal cancer.
24 A population-based study. *N Engl J Med.* 1990 Nov 1;323(18):1228-1233.
25

26
27 50. Schroeder KW, Tremaine WJ, Ilstrup DM. Coated oral 5-aminosalicylic acid
28 therapy for mildly to moderately active ulcerative colitis. A randomized study. *N Engl J*
29 *Med.* 1987 Dec 24;317(26):1625-1629.
30

31
32 51. Rioux JD, Xavier RJ, Taylor KD, Silverberg MS, Goyette P, Huett A, Green T,
33 Kuballa P, Barmada MM, Datta LW, Shugart YY, Griffiths AM, Targan SR, Ippoliti AF,
34 Bernard EJ, Mei L, Nicolae DL, Regueiro M, Schumm LP, Steinhart AH, Rotter JI,
35 Duerr RH, Cho JH, Daly MJ, Brant SR. Genome-wide association study identifies
36 new susceptibility loci for Crohn disease and implicates autophagy in disease
37 pathogenesis. *Nat Genet.* 2007 May;39(5):596-604.
38

39
40 52. Sands BE, Anderson FH, Bernstein CN, Chey WY, Feagan BG, Fedorak RN,
41 Kamm MA, Korzenik JR, Lashner BA, Onken JE, Rachmilewitz D, Rutgeerts P, Wild
42 G, Wolf DC, Marsters PA, Travers SB, Blank MA, van Deventer SJ. Infliximab
43 maintenance therapy for fistulizing Crohn's disease. *N Engl J Med.* 2004 Feb
44 26;350(9):876-85.
45

46
47 53. Colombel JF, Sandborn WJ, Rutgeerts P, Enns R, Hanauer SB, Panaccione R,
48 Schreiber S, Byczkowski D, Li J, Kent JD, Pollack PF. Adalimumab for maintenance
49 of clinical response and remission in patients with Crohn's disease: the CHARM trial.
50 *Gastroenterology.* 2007 Jan;132(1):52-65.
51

52
53 54. Hampe J, Franke A, Rosenstiel P, Till A, Teuber M, Huse K, Albrecht M, Mayr G,
54 De La Vega FM, Briggs J, Günther S, Prescott NJ, Onnie CM, Häsler R, Sipos B,
55 Fölsch UR, Lengauer T, Platzer M, Mathew CG, Krawczak M, Schreiber S. A
56 genome-wide association scan of nonsynonymous SNPs identifies a susceptibility
57 variant for Crohn disease in ATG16L1. *Nat Genet.* 2007 Feb;39(2):207-211.
58
59
60

- 1
2
3
4 55. Bouma G, Strober W. The immunological and genetic basis of inflammatory
5 bowel disease. *Nat Rev Immunol*. 2003 Jul;3(7):521-533.
6
7
8 56. Lichtiger S, Present DH, Kornbluth A, Gelernt I, Bauer J, Galler G, Michelassi F,
9 Hanauer S. Cyclosporine in severe ulcerative colitis refractory to steroid therapy. *N*
10 *Engl J Med*. 1994 Jun 30;330(26):1841-1845.
11
12 57. Abraham C, Cho JH. Inflammatory bowel disease. *N Engl J Med*. 2009 Nov
13 19;361(21):2066-2078.
14
15
16
17 58. Summers RW, Switz DM, Sessions JT Jr, Bechtel JM, Best WR, Kern F Jr,
18 Singleton JW. National Cooperative Crohn's Disease Study: results of drug treatment.
19 *Gastroenterology*. 1979 Oct;77(4 Pt 2):847-869
20
21
22
23 59. Satsangi J, Silverberg MS, Vermeire S, Colombel JF. The Montreal classification
24 of inflammatory bowel disease: controversies, consensus, and implications.
25 *Gut*. 2006 Jun;55(6):749-53.
26
27
28
29 60. Elson CO, Sartor RB, Tennyson GS, Riddell RH. Experimental models of
30 inflammatory bowel disease. *Gastroenterology*. 1995 Oct;109(4):1344-1367.
31
32
33 61. Greenstein AJ, Janowitz HD, Sachar DB. The extra-intestinal complications of
34 Crohn's disease and ulcerative colitis: a study of 700 patients. *Medicine (Baltimore)*.
35 1976 Sep;55(5):401-412.
36
37 62. Fujino S, Andoh A, Bamba S, Ogawa A, Hata K, Araki Y, Bamba T, Fujiyama Y.
38 Increased expression of interleukin 17 in inflammatory bowel disease. *Gut*. 2003
39 Jan;52(1):65-70.
40
41
42 63. Sartor RB. Microbial influences in inflammatory bowel diseases.
43 *Gastroenterology*. 2008 Feb;134(2):577-594.
44
45
46
47 64. Manichanh C, Rigottier-Gois L, Bonnaud E, Gloux K, Pelletier E, Frangeul L,
48 Nalin R, Jarrin C, Chardon P, Marteau P, Roca J, Dore J.
49 Reduced diversity of faecal microbiota in Crohn's disease revealed by a
50 metagenomic approach. *Gut*. 2006 Feb;55(2):205-211.
51
52
53 65. Fuss IJ, Neurath M, Boirivant M, Klein JS, de la Motte C, Strong SA, Fiocchi C,
54 Strober W. Disparate CD4+ lamina propria (LP) lymphokine secretion profiles in
55 inflammatory bowel disease. Crohn's disease LP cells manifest increased secretion
56 of IFN-gamma, whereas ulcerative colitis LP cells manifest increased secretion of IL-
57
58
59
60

1
2
3 5. J Immunol. 1996 Aug 1;157(3):1261-1270.
4
5

6
7 66. Rutgeerts P, Geboes K, Vantrappen G, Beyls J, Kerremans R, Hiele M.
8 Predictability of the postoperative course of Crohn's disease.
9 Gastroenterology. 1990 Oct;99(4):956-963.
10

11
12 67. Present DH, Korelitz BI, Wisch N, Glass JL, Sachar DB, Pasternack BS.
13 Treatment of Crohn's disease with 6-mercaptopurine. A long-term, randomized,
14 double-blind study. N Engl J Med. 1980 May 1;302(18):981-987.
15
16

17
18 68. Swidsinski A, Ladhoff A, Pernthaler A, Swidsinski S, Loening-Baucke V, Ortner M,
19 Weber J, Hoffmann U, Schreiber S, Dietel M, Lochs H. Mucosal flora in inflammatory
20 bowel disease. Gastroenterology. 2002 Jan;122(1):44-54.
21

22
23 69. van Dullemen HM, van Deventer SJ, Hommes DW, Bijl HA, Jansen J, Tytgat GN,
24 Woody J. Treatment of Crohn's disease with anti-tumor necrosis factor chimeric
25 monoclonal antibody (cA2). Gastroenterology. 1995 Jul;109(1):129-135.
26
27

28
29 70. Azer SA. Overview of molecular pathways in inflammatory bowel disease
30 associated with colorectal cancer development. Eur J Gastroenterol Hepatol. 2013
31 Mar;25(3):271-281.
32

33
34 71. Azer SA, AIOlayan TI, AIGhamdi MA, AISanea MA. Inflammatory bowel disease:
35 An evaluation of health information on the internet. World J Gastroenterol. 2017 Mar
36 7;23(9):1676-1696.
37

38
39 72. Börner K, Maru JT, Goldstone RL. The simultaneous evolution of author and
40 paper networks. Proc Natl Acad Sci U S A. 2004 Apr 6;101 Suppl 1:5266-73.
41
42

43
44 73 Sinatra R, Deville P, Szell M, Wang D, Barabasi AL. A century of
45 physics. Nature Physics 2015; 11(10): 791-796.
46
47

48
49 74. Wren JD, Georgescu C, Giles CB, Hennessey J. Use it or lose it: citations predict
50 the continued online availability of published bioinformatics resources. Nucleic Acids
51 Res. 2017 Apr 20;45(7):3627-3633.
52
53

54
55 75. Shanahan DR. Auto-correlation of journal impact factor for consensus research
56 reporting statements: a cohort study. PeerJ. 2016 Mar 31;4:e1887.
57
58
59
60

- 1
2
3
4 76. Royle P, Kandala NB, Barnard K, Waugh N. Bibliometrics of systematic reviews: analysis of citation rates and journal impact factors. *Syst Rev*. 2013 Sep 12;2:74.
5
6
7
8 77. Falagas ME, Kouranos VD, Michalopoulos A, Rodopoulou SP, Batsiou
9 MA, Karageorgopoulos DE. Comparison of the distribution of citations received by
10 articles published in high, moderate, and low impact factor journals in clinical
11 medicine. *Intern Med J*. 2010 Aug;40(8):587-591.
12
13 78. García-Aroca MÁ, Pandiella-Dominique A, Navarro-Suay R, Alonso-Arroyo
14 A, Granda-Orive JI, Anguita-Rodríguez F, López-García A. Analysis of Production,
15 Impact, and Scientific Collaboration on Difficult Airway Through the Web of Science
16 and Scopus (1981-2013). *Anesth Analg*. 2017 Jun;124(6):1886-1896.
17
18 79. Tanner-Smith EE, Polanin JR. Brief alcohol intervention trials conducted by higher
19 prestige authors and published in higher impact factor journals are cited more
20 frequently. *J Clin Epidemiol*. 2016 Feb 6.
21
22
23 80. Jagsi R, Guancial EA, Worobey CC, Henault LE, Chang Y, Starr R, Tarbell
24 NJ, Hylek EM. The "gender gap" in authorship of academic medical literature--a 35-
25 year perspective. *N Engl J Med*. 2006 Jul 20;355(3):281-287.
26
27
28 81. Long MT, Leszczynski A, Thompson KD, Wasan SK, Calderwood AH. Female
29 authorship in major academic gastroenterology journals: a look over 20 years.
30 *Gastrointest Endosc*. 2015;81(6):1440-1447.
31
32
33 82. Diamond SJ, Thomas CR Jr, Desai S, Holliday EB, Jagsi R, Schmitt C, Enestvedt
34 BK. Gender Differences in Publication Productivity, Academic Rank, and Career
35 Duration Among U.S. Academic Gastroenterology Faculty. *Acad*
36 *Med*. 2016 Aug;91(8):1158-1163.
37
38
39 83. Nicholson JM, Ioannidis JP. Research grants: Conform and be funded. *Nature*.
40 2012 Dec 6;492(7427):34-36.
41
42 84. Lauer MS, Danthi NS, Kaltman J, Wu C. Predicting Productivity Returns on
43 Investment: Thirty Years of Peer Review, Grant Funding, and Publication of Highly
44 Cited Papers at the National Heart, Lung, and Blood Institute. *Circ Res*. 2015 Jul
45 17;117(3):239-243.
46
47
48
49 85. Cheng K, Dodson TB, Egbert MA, Susarla SM. Which Factors Affect Citation
50 Rates in the Oral and Maxillofacial Surgery Literature? *J Oral Maxillofac*
51 *Surg*. 2017 Apr 1. pii: S0278-2391(17)30361-0.
52
53
54
55
56
57
58
59
60

1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

86. Connelly TM, Devane L, Kelly JC, Wrafter P, Messaris E. The 100 classic papers in ulcerative colitis: a bibliometric analysis. *Expert Rev Gastroenterol Hepatol.* 2016 Aug 22:1-9. [Epub ahead of print]

For peer review only

Glossary

Articles are scientific written composition representing a substantial advance in the understanding of a topic or problem. They raise questions, provide thoughtful, critical analysis and aim at establishing new directions.

Basic research is defined as fundamental research, which aims at improving scientific theories and our understanding of a phenomenon. Basic research may use animal models and include in vivo and in-vitro studies that target advances of fundamental knowledge.

Clinical research is defined as research applied to a clinical condition/disease with the aim to test an intervention or make a change to a phenomenon. Basic research usually fuels clinical research.

Reports are defined as brief articles with conclusions, results, and recommendations. They report on a substantial advance in an area/topic or a problem and aim at reporting findings and standardization of practice.

Review and meta-analysis are defined as an article reviewing the progress of knowledge in a particular topic, critically analysing the current status of knowledge and presenting an understanding of the subject by discussing related literature. A review should identify gaps in the literature and highlight future directions for further research. **A meta-analysis** is defined as a statistical analysis that combines the results from different scientific studies to provide conclusive evidence.

1
2
3 **Figure Legend**
4

5 **Figure 1A:** Number of citations of papers published before the year 2000 (mean±SD)
6

7 **Figure 1B:** Number of citations of papers published after the year 2000 (mean±SD)
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

For peer review only

Table 1 Top cited papers in inflammatory bowel disease identified by searching the Web of Science, summarized by year of publication and category

Article type	Year of publication: no of articles [References]							
	1950-1958	1959-1967	1968-1976	1977-1985	1986-1994	1995-2003	2004-2012	Total (%)
Article				1 [39]				1 [2%]
Review/ Meta-analysis			1 [61]			5 [25,36,41,55,60]	8 [27,34,35,45,33,57,38,63]	14 [28%]
Report							2 [43,59]	2 [4%]
Research	1 [28]		1 [23]	3 [37,58,67]	8 [22,44,40,48,49,56,50,66]	10 [20,21,26,24,31,46,62,69,65,68]	10 [29,30,32,51,52,42,54,47,53,64]	33 [66%]
Total (%)	1 [2%]	0 [0%]	2 [4%]	4 [8%]	8 [16%]	15 [30%]	20 [40%]	50 [100%]

Table 2 Top-cited papers in inflammatory bowel disease (IBD) identified by searching the Web of Science, summarized by category and topic

Topics on IBD	Category: no of articles [References]				Total (%)
	Article	Review/ Meta-analysis	Report	Research	
Epidemiology, prevalence		2 [35,38]			2 [4%]
CD genetic susceptibility and NOD2 mutation		2 [34,45]		4 [20,21,51,54]	6 [12%]
Animal models for IBD		1 [60]		4 [22,44,40,48]	5 [10%]
Pathogenesis of IBD		7 [25,27,36,55,33,57,63]		8 [29,32,42,62,65,68,66,64]	15 [30%]
Classification, index of disease activity	1 [39]		2 [43,59]	2 [23,37]	5 [10%]
Risk of developing colorectal cancer		1 [41]		1 [49]	2 [4%]
Extra-intestinal complications		1 [61]			1 [2%]
Infliximab in CD				6 [24,31,30,46,52,47]	6 [12%]
Corticosteroids in UC				1 [28]	1 [2%]
Drug treatment and cyclosporine in UC				2 [56,58]	2 [4%]
Adalimumab in CD				1 [53]	1 [2%]
5-aminosalicylic acid in				1 [50]	1 [2%]

UC					
6-mercaptopurine in CD				1 [67]	1 [2%]
Monoclonal antibodies, anti-tumor necrosis factor in CD				2 [26,69]	2 [4%]
Total (%)	1 [2%]	14 [28%]	2 [4%]	33 [66%]	50 [100%]

For peer review only

1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47

Table 3. The journals that published the top-cited inflammatory bowel disease (IBD) articles included in the study, the journal impact factor, and the number of papers published and reference number.

Journal*	2016-Journal Impact Factor (JIF)	Number of papers published [References]
<i>New England Journal of Medicine</i>	72.406	12 [25,26,31,30,46,49,56,52,47,50,67,57]
<i>Gastroenterology</i>	18.392	12 [23,36,35,40,58,60,53,69,38,68,63,66]
<i>Nature</i>	40.137	4 [20,21,27,33]
<i>Nature Genetics</i>	27.959	4 [34,51,45,54]
<i>The Lancet</i>	47.831	2 [24,37]
<i>Proceedings of the National Academy of Sciences of the United States of America</i>	9.661	2 [32,42]
<i>Cell</i>	30.410	2 [22,44]
<i>Gut</i>	16.658	4 [59,64,41,62]
<i>British Medical Journal</i>	20.785	1 [28]
<i>Science</i>	37.205	1 [29]
<i>Human Pathology</i>	3.014	1 [39]
<i>Laboratory Investigation</i>	4.857	1 [48]
<i>Canadian Journal of Gastroenterology and Hepatology</i>	2.147	1 [43]
<i>Nature Reviews Immunology</i>	39.932	1 [55]
<i>Medicine (Baltimore)</i>	1.804	1 [61]
<i>Journal of Immunology</i>	4.856	1 [65]

- Gastroenterology related journals (Gastroenterology, and Gut) only published 16 (32%) articles out of the top highly cited 50 articles

Table 4 Authors and co-authors of two or more articles of the top-cited articles in inflammatory bowel disease identified by searching the Web of Science

Author's name*	Number [References]		Author's Name*	Number [References]	
	First author	Coauthor		First author	Coauthor
Hugot, JP	1 [20]	2 [34,45]	Daly, MJ	-	5[29,34,51,45,33]
Podolsky, DK	1 [25]	3 [28,27,31]	Steinhart, AH	-	5[29,34,43,51,45]
Targan, SR	1 [26]	7 [29,31,34,43,51,45,33]	Griffiths, A	-	4[29,34,51,45]
Hanauer, SB	1 [24]	6 [21,26,31,30,56,53]	Dassopoulos, T	-	2[29,34]
Xavier, RJ	1 [27]	3 [34,51,33]	Bitton, A	-	3[29,34,33]
Duerr, RH	1 [29]	4 [21,34,45,33]	Datta, LW	-	3[29,34,51]
Present, DH	2 [31,67]	3 [26,30,56]	Kistner, EO	-	2[29,34]
Rutgeerts, P	1 [30]	9 [26,24,31,34,46,45,52,47,53]	Rotter, JI	-	5[29,34,51,45,33]
Fiocchi, C	1 [36]	1 [65]	Schumm, LP	-	5[29,34,51,45,52]
Barrett, JC	1 [34]	2 [45,33]	Lee, J	-	2[45,33]
Riddell, RH	1 [39]	2 [43,60]	Lees, CW	-	2[45,33]
Loftus, EV Jr	1 [35]	1 [43]	Sandborn, WJ	-	3[30,47,53]
Franke, A	1 [45]	2 [33,54]	Barmada, MM	-	3[29,34,51]
Silverberg, MS	1 [43]	5 [29,34,51,45,33]	Nicolae, DL	-	4[21,29,34,51]
Rioux, JD	1 [51]	4 [29,34,45,33]	Sands, BE	-	3[31,30,52]
Lichtiger, S	1 [56]	1 [47]	Belaiche, J	-	2[20,34]
Colombel, JF	2 [47,53]	5 [20,24,30,43,45]	Laukens, D	-	3[34,45,33]
Abraham, C	1 [57]	2 [29,33]	Lawrance, I	-	2[45,33]
Becktel, JM	-	2 [23,58]	Louis, E	-	3[34,33,45]

1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47

Singleton,JW	-	2 [23,58]	Vos,M	-	3[34,45,33]
Kern,F Jr	-	2 [23,58]	Vermeire,S	-	5[34,46,43,45,33]
Van Deventer,SJ	-	4 [26,31,52,69]	Satsangi,J	-	4[34,43,45,33]
Mayer,L	-	3 [26,24,31]	Bernstein,CN	-	2[43,52]
Braakman,T	-	2 [26,31]	Tremelling,M	-	2[34,33]
DeWoody,KL	-	2 [26,31]	Mansfield,J	-	3[34,45,33]
Schaible,TF	-	2 [26,31]	Jewell,D	-	2[34,43]
Feagan,BG	-	3 [24,30,52]	Mathew,CG	-	4[34,45,33,54]
Lichtenstein,GR	-	2 [24,30]	Parkes,M	-	3[34,45,33]
Schreiber,S	-	7 [24,43,45,33,54,53,68]	Georges,M	-	3[34,45,33]
Rachmilewitz,D	-	4 [24,30,52,47]	Karban,A	-	2[43,45]
Wolf,DC	-	2 [24,52]	Gossum,A	-	2[34,45]
Olson,A	-	2 [24,30]	Franchimont,D	-	3[34,45,33]
Taylor,KD	-	5 [29,34,51,45,33]	Newman,W	-	2[45,33]
Bayless, TM	-	2 [21,45]	Regueiro,M	-	5[29,34,51,45,33]
Cho, JH	-	7 [21,29,34,51,45,33,57]	Kornbluth,A	-	2[56,47]

*Author's name= family name, abbreviations of first or first and second names.

Table 5 Grading the top-cited articles in inflammatory bowel disease according to the Oxford Centre for Evidence-based Medicine – Levels of Evidence.

Level	Domain	Characteristics and description	Articles number [References]
1a	Therapeutic/ Prevention, Aetiology/Harm	Systematic reviews of RCTs (with consistent results from individual studies)	1 (33)
	Prognosis	Systematic reviews with homogeneity of inception cohort studies	
	Diagnosis	Systematic reviews with homogeneity of Level 1 diagnostic studies	
	Differential diagnosis/symptom prevalence study	Systematic reviews with homogeneity of prospective cohort studies.	
1b	Therapeutic/ Prevention, Aetiology/Harm	Individual RCT (with narrow confidence intervals)	12 [26,24,30,56,58,52,47,53,50,66,67, 59]
	Prognosis	Individual inception cohort study with >80% follow-up	
	Diagnosis	Validating cohort study with good reference standards	
	Differential diagnosis/symptom prevalence study	Prospective cohort study with good follow-up	
2a	Therapeutic/ Prevention, Aetiology/Harm	Systematic review of cohort studies (with consistent results from individual studies)	2 [34,63]

1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47

	Prognosis	Systematic review with homogeneity of either retrospective cohort studies or untreated control groups in RCT	
	Diagnosis	Systematic review with homogeneity of Level > 2 diagnostic studies	
	Differential diagnosis/symptom prevalence study	Systematic review with homogeneity of 2b and better studies	
2b	Therapeutic/ Prevention, Aetiology/Harm	Individual cohort study (including low quality RCT; e.g., <80% follow-up)	3 [31,46,49]
	Prognosis	Retrospective cohort study or follow-up untreated control patients in an RCT	
	Diagnosis	Exploratory cohort study with good reference standards	
	Differential diagnosis/symptom prevalence study	Retrospective cohort study or poor follow-up	
2c	Therapeutic/ Prevention, Aetiology/Harm	Outcome studies (analysis of large registries)	3 [38,60,61]
	Prognosis	Outcomes research	
	Diagnosis		
	Differential diagnosis/symptom	Ecological studies	

	prevalence study		
3a	Therapeutic/ Prevention, Aetiology/Harm	Systemic reviews of case-control studies (with consistent results from individual studies)	9 [25,27,36,35,41,43,55,45,57]
	Prognosis		
	Diagnosis	Systematic reviews with homogeneity of 3b and better studies	
	Differential diagnosis/symptom prevalence study	Systematic reviews with homogeneity of 3b and better studies	
3b	Therapeutic/ Prevention, Aetiology/Harm	Individual case-control study	15 [20,21,22,28,29,44,40,32,51,42,54,62,64,65,68]
	Prognosis		
	Diagnosis	Non consecutive study, or without consistently applied reference standards	
	Differential diagnosis/symptom prevalence study	Non consecutive cohort study or very limited population	
4	Therapeutic/ Prevention, Aetiology/Harm	Case series (and poor quality cohort and case-control studies)	5 [23,39,37,48,69]
	Prognosis	Case-series (and poor quality prognostic cohort studies)	
	Diagnosis	Case-control study, poor or non-	

1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47



		independent reference standard	
	Differential diagnosis/symptom prevalence study	Case-series or superseded reference standards	
5	Therapeutic/ Prevention, Aetiology/Harm	Expert opinion without explicit critical appraisal or based on physiology, or bench research.	0 [0]
	Prognosis	Expert opinion without explicit critical appraisal or based on physiology, or bench research.	
	Diagnosis	Expert opinion without explicit critical appraisal or based on physiology, or bench research.	
	Differential diagnosis/symptom prevalence study	Expert opinion without explicit critical appraisal or based on physiology, or bench research.	

Peer Review Only

1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47

For peer review only

1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60



209x296mm (300 x 300 DPI)

Appendix 1.

Top-cited articles on inflammatory bowel disease identified by searching the Web of Science database^a

Rank	Authors, Year [Reference]	Article (<i>Journal</i>)	2016-JIF	Category	Number of citations, Web of Knowledge	Average citation per year ^b	Rank of the article in the journal publishing it ^c	Origin: First author's organization, location (country)
1	Hugot et al, 2001 ²⁰	Association of NOD2 leucine-rich repeat variants with susceptibility to Crohn's disease. (<i>NATURE</i>).	40.137	Basic research	3,555	209.1	134	Fondation Jean Dausset CEPH (France)
2	Ogura et al, 2001 ²¹	A frameshift mutation in NOD2 associated with susceptibility to Crohn's disease. (<i>NATURE</i>).	40.137	Basic research	3,285	193.2	159	The University of Michigan Medical School, Michigan (United States).
3	Kuhn et al, 1993 ²²	Interleukin-10-deficient mice develop chronic enterocolitis. (<i>CELL</i>)	30.410	Basic research	2,982	119.3	67	Institute for Genetics, University of Cologne, (Germany)
4	Best et al, 1976 ²³	Development of a Crohns-disease activity index-National cooperative Chrons-disease study (<i>Gastroenterology</i>).	18.392	Clinical research	2,533	60.3	2	Hines Veterans Administration Cooperative Studies Support Center, University of Colorado Medical Center, Denver, Colorado, (United States).
5	Hanauer et al, 2002 ²⁴	Maintenance infliximab for Crohn's disease: the ACCENT I randomized trial (<i>Lancet</i>)	47.831	Clinical research	2,442	152.6	46	University of Chicago Medical Center, Chicago, IL (United States).
6	Podolsky, 2002 ²⁵	Inflammatory bowel disease. (<i>New England Journal of Medicine</i>)	72.406	Review	2,423	151.4	163	Massachusetts General Hospital and Harvard Medical School, Boston,

								Massachusetts (United States).
7	Targan et al, 1997 ²⁶	A short-term study of chimeric monoclonal antibody cA2 to tumor necrosis factor alpha for Crohn's disease (<i>New England Journal of Medicine</i>)	72.406	Clinical research	2,364	112.6	169	Cedars-Sinai Medical Center, Los Angeles, California (United States)
8	Xavier and Podolsky, 2007 ²⁷	Unravelling the pathogenesis of inflammatory bowel disease (<i>NATURE</i>)	40.137	Review	2,036	185.1	450	Massachusetts General Hospital, Harvard Medical School, Boston, Massachusetts (United States).
9	Truelove and Witts, 1955 ²⁸	Cortisone in ulcerative colitis- Final report on a therapeutic trial (<i>British Medical Journal</i>).	20.785	Clinical research	1,871	29.7	20	Nuffield Department of Clinical Medicine, Oxford (United Kingdom)
10	Duerr et al, 2006 ²⁹	A genome-wide association study identifies IL23R as an inflammatory bowel disease gene. (<i>SCIENCE</i>).	37.205	Clinical research	1,862	155.2	530	Department of Medicine, School of Medicine, University of Pittsburgh, Pittsburgh, PA (United States).
12	Rutgeerts et al, 2005 ³⁰	Infliximab for induction and maintenance therapy for ulcerative colitis (<i>New England Journal of Medicine</i>)	72.406	Clinical research	1,834	141.1	290	University Hospital Gasthuisberg, Leuven, (Belgium).
12	Present et al, 1999 ³¹	Infliximab for treatment of fistulas in patients with Crohn's disease (<i>New England Journal of Medicine</i>)	72.406	Clinical research	1,730	91.0	321	Mount Sinai Medical Center, New York, NY, (United States)

13	Frank et al, 2007 ³²	Molecular-phylogenetic characterization of microbial community imbalances in human inflammatory bowel diseases. (<i>Proceedings of the National Academy of Sciences of the United States of America</i>)	9.661	Basic research	1,650	150.0	172	University of Colorado, Boulder, CO (United States)
14	Jostins et al, 2012 ³³	Host-microbe interactions have shaped the genetic architecture of inflammatory bowel disease. (<i>Nature</i>)	40.137	Review Meta-analysis	1,643	273.8	683	Wellcome Trust Sanger Institute, Wellcome Trust Genome Campus, Hinxton, Cambridge, (United Kingdom)
15	Barrett et al, 2008 ³⁴	Genome-wide association defines more than 30 distinct susceptibility loci for Crohn's disease. (<i>Nature Genetics</i>)	27.959	Review Meta-analysis	1,631	163.1	25	Wellcome Trust Centre for Human Genetics, University of Oxford, Roosevelt Drive, Oxford (United Kingdom)
16	Loftus, 2004 ³⁵	Clinical epidemiology of inflammatory bowel disease: Incidence, prevalence, and environmental influences (<i>Gastroenterology</i>)	18.392	Review	1,566	111.9	10	Mayo Clinic, Rochester, Minnesota, (United States)
17	Fiocchi, 1998 ³⁶	Inflammatory bowel disease: Etiology and pathogenesis (<i>Gastroenterology</i>)	18.392	Review	1,540	77.0	12	University Hospitals of Cleveland Case Western Reserve University School of Medicine, Ohio (United States)
18	Harvey and Bradshaw, 1980 ³⁷	A simple index of Crohns-disease activity (<i>Lancet</i>)	47.831	Clinical research	1,466	38.6	166	Bristol Royal Infirmary and Frenchay Hospital, Bristol (United Kingdom)
19	Molodeck	Increasing incidence and prevalence	18.392	Review	1,438	239.7	19	University of Calgary,

	y et al, 2012 ³⁸	of the inflammatory bowel diseases with time, based on systematic review. (<i>Gastroenterology</i>).						Calgary, Alberta, (Canada).
20	Riddell et al, 1983 ³⁹	Dysplasia in inflammatory bowel disease- Standardized classification with provisional clinical applications (<i>Human Pathology</i>)	3.014	Article	1,398	39.9	2	National Foundation for Ileitis and Colitis, New York, (United States).
21	Okayasu et al, 1990 ⁴⁰	A novel method in the induction of reliable experimental acute and chronic ulcerative-colitis in mice (<i>Gastroenterology</i>)	18.392	Basic research	1,396	49.9	24	School of Medicine, Tokyo Medical and Dental University, (Japan).
22	Eaden et al, 2001 ⁴¹	The risk of colorectal cancer in ulcerative colitis: a meta-analysis. (<i>Gut</i>).	16.658	Review Meta-analysis	1,388	81.6	1	Leicester General Hospital, Gwendolen Road, Leicester (United Kingdom)
23	Sokol et al, 2008 ⁴²	Faecalibacterium prausnitzii is an anti-inflammatory commensal bacterium identified by gut microbiota analysis of Crohn disease patients. <i>Proceedings of the National Academy of Sciences of the United States of America</i>)	9.661	Basic research	1,384	138.4	247	Institut National de la Recherche Agronomique U910, Domaine de Vilvert, Jouy-en-Josas, (France).
24	Silverberg et al, 2005 ⁴³	Toward an integrated clinical, molecular and serological classification of inflammatory bowel disease: report of a Working Party of the 2005 Montreal World Congress of Gastroenterology. (<i>Canadian Journal of Gastroenterology and Hepatology</i>)	2.147	Report	1,373	105.6	1	Mount Sinai Hospital IBD Centre, University of Toronto, Toronto, Ontario (Canada)

25	Sadlack et al, 1993 ⁴⁴	Ulcerative colitis-like disease in mice with a disrupted interleukin-2 gene (<i>CELL</i>)	30.410	Basic research	1,358	54.32	387	Institute of Virology and Immunobiology, University of Würzburg, (Germany)
26	Franke et al, 2010 ⁴⁵	Genome-wide meta-analysis increases to 71 the number of confirmed Crohn's disease susceptibility loci. (<i>Nature Genetics</i>)	27.959	Review Meta-analysis	1,321	165.1	63	Institute of Clinical Molecular Biology, Christian-Albrechts-University Kiel, Kiel, (Germany).
27	Baert et al, 2003 ⁴⁶	Influence of immunogenicity on the long-term efficacy of infliximab in Crohn's disease. (<i>New England Journal of Medicine</i>)	72.406	Clinical research	1,297	86.5	562	University Hospital Gasthuisberg, Leuven, (Belgium).
28	Colombel et al, 2010 ⁴⁷	Infliximab, azathioprine, or combination therapy for Crohn's disease (<i>New England Journal of Medicine</i>)	72.406	Clinical research	1,294	161.7	565	Hôpital Claude Huriez and Centre d'Investigation Clinique, Centre Hospitalier Universitaire de Lille, Université Lille Nord de France, Lille, (France).
29	Cooper et al, 1993 ⁴⁸	Clinicopathologic study of dextran sulfate sodium experimental murine colitis. (<i>Laboratory Investigation</i>)	4.857	Basic research	1,219	48.8	4	Hahnemann University, Philadelphia, Pennsylvania. (United States)
30	Ekbom et al, 1990 ⁴⁹	Ulcerative colitis and colorectal cancer. A population-based study. (<i>New England Journal of Medicine</i>)	72.406	Clinical research	1,168	41.7	684	University Hospital, Uppsala, (Sweden).

31	Schroeder et al, 1987 ⁵⁰	Coated oral 5-aminosalicylic acid therapy for mildly to moderately active ulcerative colitis. A randomized study (<i>New England Journal of Medicine</i>)	72.406	Clinical research	1,156	37.3	695	Mayo Clinic, Rochester, MN (United States)
32	Rioux et al, 2007 ⁵¹	Genome-wide association study identifies new susceptibility loci for Crohn disease and implicates autophagy in disease pathogenesis. (<i>Nature Genetics</i>)	27.959	Basic research	1,152	104.7	89	Université de Montréal and the Montreal Heart Institute, Research Center, Montreal, Quebec (Canada).
33	Sands et al, 2004 ⁵²	Infliximab maintenance therapy for fistulizing Crohn's disease. (<i>New England Journal of Medicine</i>)	72.406	Clinical research	1,146	81.8	706	Massachusetts General Hospital, and Harvard Medical School, Boston (United States)
34	Colombel et al, 2007 ⁵³	Adalimumab for maintenance of clinical response and remission in patients with Crohn's disease: the CHARM trial. (<i>Gastroenterology</i>).	18.392	Clinical research	1,124	102.2	32	Hôpital Claude Huriez, Centre Hospitalier Universitaire de Lille, Rue Michel Polonovski, Lille, (France)
35	Hampe et al, 2007 ⁵⁴	A genome-wide association scan of nonsynonymous SNPs identifies a susceptibility variant for Crohn disease in ATG16L1. (<i>Nature Genetics</i>)	27.959	Basic research	1,123	102.1	92	Institute for Clinical Molecular Biology, Christian-Albrechts University Kiel, University Hospital Schleswig-Holstein, (Germany).

36	Bouma and Strober, 2003 ⁵⁵	The immunological and genetic basis of inflammatory bowel disease. (<i>Nature Reviews Immunology</i>)	39.932	Review	1,116	74.4	35	National Institutes of Health, and National Institutes of Allergy and Infectious Diseases, Bethesda, Maryland (United States)
37	Lichtiger et al, 1994 ⁵⁶	Cyclosporine in severe ulcerative colitis refractory to steroid therapy. (<i>New England Journal of Medicine</i>)	72.406	Clinical research	1,104	46.0	755	Mount Sinai School of Medicine, New York (United States).
38	Abraham et al, 2009 ⁵⁷	Inflammatory bowel disease. (<i>New England Journal of Medicine</i>)	72.406	Review	1,091	121.2	772	Yale University School of Medicine, New Haven, CT (United States)
39	Summers et al, 1979 ⁵⁸	National Cooperative Crohn's Disease Study: results of drug treatment (<i>Gastroenterology</i>)	18.392	Clinical research	1,059	27.1	37	Division of gastroenterology, University of Iowa Medical Center, Iowa City, Virginia, (United States).
40	Satsangi, et al 2006 ⁵⁹	The Montreal classification of inflammatory bowel disease: controversies, consensus, and implications (<i>Gut</i>).	16.658	Report	1,054	87.8	7	Gstrointestinal Unit, Western General Hospital, University of Edinburg, (United Kingdom).
41	Elson, et al, 1995 ⁶⁰	Experimental models of inflammatory bowel disease. (<i>Gastroenterology</i>).	18.392	Review	957	41.6	40	Department of Medicine, University of Alabama Hospital at Birmingham, AL, (United States).

42	Greenstein et al, 1976 ⁶¹	The extra-intestinal complications of Crohn's disease and ulcerative colitis: a study of 700 patients. <i>Medicine (Baltimore)</i> .	1.804	Review	945	22.5	10	Department of Surgery, Mount Sinai School of Medicine and the City University of New York, New York, (United States.)
43	Fujino et al, 2003 ⁶²	Increased expression of interleukin 17 in inflammatory bowel disease. (<i>Gut</i>).	16.658	Basic research	931	62.1	12	Shiga University of Medical Science, Seta-Tukinowa, Otsu, (Japan).
44	Sartor, 2008 ⁶³	Microbial influences in inflammatory bowel diseases. (<i>Gastroenterology</i>).	18.392	Review	925	92.5	44	Department of Medicine, Center for Gastrointestinal Biology and Disease, University of North Carolina at Chapel Hill, Chapel Hill, North Carolina, (United States).
45	Manichanh et al, 2006 ⁶⁴	Reduced diversity of faecal microbiota in Crohn's disease revealed by a metagenomic approach. (<i>Gut</i>).	16.658	Basic research	913	76.1	13	Unité d'Ecologie et de Physiologie du système Digestif, INRA-UEPSD, 78350 Jouy-en-Josas, (France)
46	Fuss et al, 1996 ⁶⁵	Disparate CD4+ lamina propria (LP) lymphokine secretion profiles in inflammatory bowel disease. Crohn's disease LP cells manifest increased secretion of IFN-gamma, whereas ulcerative colitis LP cells manifest increased secretion of IL-5. (<i>Journal of Immunology</i>)	4.856	Basic research	893	40.6	68	National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, MD, (United States)
47	Rutgeerts	Predictability of the postoperative	18.392	Clinical	884	31.6	50	Department of Medicine,

	et al, 1990 ⁶⁶	course of Crohn's disease. (<i>Gastroenterology</i>).		research				University Hospital Gasthuisberg, University of Leuven, (Belgium).
48	Present et al, 1980 ⁶⁷	Treatment of Crohn's disease with 6-mercaptopurine. A long-term, randomized, double-blind study. (<i>New England Journal of Medicine</i>)	72.406	Clinical research	874	23.0	1150	Lenox Hill Hospital and the Mount Sinai School of Medicine of City University of New York (United States)
49	Swidsinski et al, 2002 ⁶⁸	Mucosal flora in inflammatory bowel disease. (<i>Gastroenterology</i>).	18.392	Basic research	873	54.6	52	Charité Humboldt Universität, Berlin, (Germany).
50	Vandullem en et al, 1995 ⁶⁹	Treatment of Crohn's disease with anti-tumor necrosis factor chimeric monoclonal antibody (cA2). (<i>Gastroenterology</i>).	18.392	Clinical research	871	37.9	53	Academic Medical Center, Amsterdam, (The Netherlands).

^a The search was conducted in April, 2018 by searching the Web of Knowledge.

^b The average citation per year = total number of citation / number of years since publication.

^c This ranking was identified by searching each journal for a top-cited article and identifying its ranking based on the number of citations received in comparison to the number of citations received by other articles published in that journal.

1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46

For peer review only

BMJ Open

What can we learn from top-cited articles in inflammatory bowel disease? A bibliometric analysis and assessment of the level of evidence

Journal:	<i>BMJ Open</i>
Manuscript ID	bmjopen-2017-021233.R2
Article Type:	Research
Date Submitted by the Author:	31-May-2018
Complete List of Authors:	Azer, Samy; King Saud University, Medical Education; Australian Professional Teaching, Azer, Sarah; St Vincent Hospital
Primary Subject Heading:	Gastroenterology and hepatology
Secondary Subject Heading:	Gastroenterology and hepatology, Medical education and training, Medical publishing and peer review
Keywords:	Inflammatory bowel disease (IBD), Ulcerative colitis (UC), Crohn's disease (CD), Bibliometric analysis, Top-cited articles, Quality of evidence

SCHOLARONE™
Manuscripts

1
2
3 Amended version
4
5
6
7
8

9
10 **What can we learn from top-cited articles in**
11 **inflammatory bowel disease? A bibliometric analysis**
12 **and assessment of the level of evidence**
13
14

15
16
17
18 Samy A. Azer¹ and Sarah Azer²
19

20
21 Dr Azer is a Consultant Gastroenterologist and Professor of Medical
22 Education and the chair of Curriculum Development and Research Unit,
23 College of Medicine, King Saud University, Riyadh, Saudi Arabia¹
24
25

26
27
28 Registrar, St Vincent Hospital, University of Melbourne, Victoria,
29 Australia²
30
31

32
33
34 Correspondence and requests for reprints should be addressed to:

35 Professor Samy Azer

36 Curriculum Development and Research Unit,

37 College of Medicine, King Saud University

38 P O Box 2925, Riyadh 11461

39 Saudi Arabia

40 Telephone: (966) 11-4699178

41 Fax: (966) 11-4699174
42
43

44 Email:azer2000@optusnet.com.au
45
46
47

48
49
50
51
52 SHORT TITLE: Top-cited Inflammatory Bowel Disease
53
54

ABSTRACT

Background and Objectives: Despite increasing number of publications in inflammatory bowel disease (IBD) no bibliometric analysis has been conducted to evaluate the significance of highly-cited articles. Our objectives were to identify the top-cited articles in IBD, assessing their characteristics, and determining the quality of evidence provided by these articles.

Design and outcome measures: IBD and related terms were used in searching the Web of Science to identify English language articles. The 50 top-cited articles were analyzed by year, journal impact factor (JIF), authorship, females in authorship, institute, country, and grants received. The level of evidence was determined using the Oxford Centre for Evidence-Based Medicine guidelines.

Results: The number of citations varied from 871 to 3555 with a total of 74638, and a median 1339.50, (IQR= 587). No correlations were found between the number of citations and number of years since publication ($r=0.042$, $p=0.771$), JIF ($r= 0.186$, $p=0.196$), number of authors ($r= 0.061$, $p=0.674$), females in authorship ($r=0.064$, $p=0.661$), number of institutes ($r= 0.076$, $p=0.602$), number of countries ($r= 0.101$, $p=0.483$), or number of grants ($r= - 0.015$, $p=0.915$). The first authors were from the United States ($n= 24$), United Kingdom ($n= 6$), Germany ($n=5$), France ($n=5$), Belgium ($n=3$), and Canada ($n=3$). The levels of evidence were 12 articles at level 1b, 9 articles at level 3a, and 15 articles at level 3b and fewer were at other levels.

Conclusions: Research papers represented 66% of articles. The majority of items have reasonably high levels of evidence; which may have contributed to the higher number of citations. The study also shows a gender gap in authorship in this area.

Key words

Inflammatory bowel disease (IBD), Ulcerative colitis (UC), Crohn's disease (CD), Top-cited articles, Bibliometric analysis, Quality of evidence, Number of authors, Female authors, Grants/funds, Institutes, Countries.

Strengths and limitations of the study

- More than one method was used in searching the Web of Science to maximize the yield of the search.
- The articles represent a historic perspective on key discoveries in the area of inflammatory bowel disease.
- A number of characteristics including journal impact factor, number of authors, number of females in authorship, number of institutes, number of countries involved, and grants received have been studied against citations received.
- The level of evidence for each article has been evaluated.
- The search was limited to articles in the English language, raising the possibility of failing to include top-cited articles in other languages.

INTRODUCTION

The number of citations received by an article has been used for several years by universities and grant funding bodies in assessing the quality of research produced by researchers, ranking research performance and in making decisions regarding professional promotion and grant applications [1-4]. Thomson Reuters gather the names of these authors in the Highly Cited Researchers database where they are acknowledged for the quality of their work and the size of their research input in a particular area [5]. Although the number of citations cannot explain why researchers cited a particular paper nor reflect the quality of the research and the outcomes identified in a manuscript, the number of citations and the reputation of contribution to research in a particular field cannot be ignored. This is particularly important when there is a pattern of consistency and progressive input into a discipline over years (a life experience), and a demonstration from publication records and citation history of collaboration with other researchers from other institutes at local and international levels. Hence the credits given to an author or a group of authors and the impact of the work in a particular area can be proportionally related to the citation records [6]. The greater the citation history over years, the more influential they are in their specialty [7]. In this study, we hypothesized that examining the most cited in IBD may provide more insight into the significance of these articles and the level of evidence they present [8]. Considering the fact that there are over 91,000 articles on IBD in the literature as per our preliminary search of Web of Science, it is important to consider the characteristics of highly cited articles.

1
2
3 Inflammatory bowel disease comprises ulcerative colitis (UC) and Crohn's disease
4 (CD); both pursue a relapsing and remitting course over years. While the two
5
6 diseases share several similarities, they have a number of differences with regard to
7
8 structures involved, pathogenesis, clinical presentation, and management
9
10 approaches. UC was first reported briefly in mid 1800 [9], while CD was reported in
11
12 *the Journal of the American Medical Association (JAMA)* later by Crohn, Ginzburg
13
14 and Oppenheimer in 1932 [10]; describing it as a chronic inflammatory bowel disease
15
16 of the ileum. Later, it was discovered that CD can involve any part of the
17
18 gastrointestinal tract from the lips to the anal margin but the ileocolonic disease
19
20 represents the common presentation. Since then both diseases have been
21
22 extensively researched in their different aspects.
23
24
25
26
27
28

29 We assumed that these articles may be a cornerstone in IBD, and may enable
30
31 researchers in understanding a range of aspects related to IBD. Therefore, the
32
33 bibliometric analysis of these articles including journal impact factor, authorship,
34
35 females in authorship, institute, country and grants received may explain key features
36
37 of a successful or influential article in IBD. The aims of the present research were (1)
38
39 identify the top-cited articles in IBD, and analyze their characteristics and (2) assess
40
41 the quality of evidence provided by articles.
42
43
44
45

46 **METHODS**

47 **Study Design**

48
49
50 The Web of Science database was searched for the identification of the top-cited
51
52 articles and tracking the citation records of each publication. Although Scopus and
53
54
55
56
57
58
59
60

1
2
3 Google Scholar also provide citation records, it was decided to limit the search to
4
5 Web of Science database. Compared to other databases, the Web of Science is
6
7 regularly updated and the 2015 Journal Citation Reports (JCRs) included more than
8
9 6,500 journals across 150 disciplines. Although Google Scholar database is freely
10
11 available, it was not used because it is difficult to search, and it cites textbooks,
12
13 monographs, conference proceedings, as well as non-peer reviewed publications
14
15 [11]. It is also not possible to track the yearly records of citations attracted by each
16
17 article since publication. Scopus database was not used because it is not extensive in
18
19 its coverage and its records only go back to 1996 [12]. Furthermore, several other
20
21 researchers have used Web of Science to identify top-cited articles [13,14,15]
22
23
24
25

26
27 To achieve the aims of this study we planned to identify the highly cited articles in IBD
28
29 and assess if there were any correlation between the number of citations and any of
30
31 the parameters characterizing these highly cited articles. We also aim to grade each
32
33 article against the level of evidence hierarchy as per the Oxford Centre for Evidence-
34
35 Based Medicine (OCEBM-2011 Levels of Evidence and the accompanying Table of
36
37 Evidence Glossary) [16,17].
38
39
40

41 **Searching the Web of Science database**

42
43
44 On 15 and 16 April 2018, the authors searched the Web of Science database to
45
46 retrieve top-cited articles in inflammatory bowel disease. The search words used
47
48 were the following: “Inflammatory bowel disease”, “Ulcerative colitis”, “Crohn’s
49
50 disease”, “IBD”, “Experimental colitis”, “Animal models for Colitis”, “Animal models for
51
52 inflammatory bowel disease”, “Pathology IBD”, “Pathology UC”, “Pathology CD”,
53
54
55
56
57
58
59
60

1
2
3 “Pathogenesis IBD”, “Pathogenesis UC”, “Pathogenesis CD”, “Treatment IBD”,
4
5 “Treatment UC”, “Treatment CD”, “Investigation IBD” and “Regional ileitis”. To
6
7 increase the yield of the search, we used the full terms- inflammatory bowel disease,
8
9 ulcerative colitis, and Crohn’s disease for the abbreviations IBD, UC, and CD,
10
11 respectively. These search words were identified from the terminology used in
12
13 gastroenterology journals and the proceedings of major conferences on inflammatory
14
15 bowel disease and gastroenterology such as the British Society of Gastroenterology
16
17 (BSG), the American Gastroenterological Association (AGA), American College of
18
19 Gastroenterology (ACG), Canadian Association of Gastroenterology (CAG), Scottish
20
21 Society of Gastroenterology (SSG), and Gastroenterological Society of Australia
22
23 (GESA). For each search word, the results were arranged using a link on the Web of
24
25 Science system, “sort-by” – “Time Cited- highest to lowest”. The results showed the
26
27 articles organized in a descending order with the articles most frequently cited at the
28
29 top. A copy of the results was printed out for further analysis. The findings from each
30
31 search word were then arranged on one Excel sheet (Microsoft Excel 2010, Microsoft
32
33 Corp, Redmond, WA) in descending order based on the number of citations.
34
35 Duplicate articles and articles not in the English language were excluded. In addition
36
37 to the absolute number of citations, we calculated the average citations per year for
38
39 each article. The average number of citations per year is the ratio calculated from the
40
41 number of citations obtained by an article divided by the number of years since
42
43 publication [18].
44
45
46
47
48
49
50
51

52 Using the above mentioned search words, we conducted another search of major
53
54 gastroenterology journals and the 2016-JCR under the category “Gastroenterology
55
56
57
58
59
60

1
2
3 and Hepatology". This category comprises 76 journals at the time of conducting the
4 search; of these seven journals were in languages other than English and were not
5 searched. Gastroenterology journals publishing articles not in the English language
6 were excluded because neither the author nor the assistant researchers are
7 competent in the Spanish, Italian or German languages. Since the language
8 recommended by the journal publishing this work is English and its readers are most
9 likely interested in research publications in the English language, we decided not to
10 search these journals.
11

12 Interestingly, after identifying the list of top-cited articles in IBD, and again checking
13 these seven non-English journals, none had a paper with a citation higher than the
14 paper ranked number 50 on the list.
15

16 These key words were also used in searching the websites of major general
17 medicine, surgery and research journals including the *New England Journal of*
18 *Medicine, Lancet, the British Medical Journal, the Journal of the American Medical*
19 *Association, Annals of Internal Medicine, Archives of Medicine, PLOS Medicine,*
20 *Annals of Surgery, Archives of Surgery, British Journal of Surgery, American Journal*
21 *of Surgical Pathology, Nature, Science, Nature Reviews Cancer, Nature Genetics,*
22 *Nature Medicine, Cell, Nature Reviews Microbiology, Immunity, Nature Reviews*
23 *Immunology, Nature Reviews Molecular Cell Biology, and Journal of Immunology.*
24

25 A list identifying the 50 top-cited articles was reviewed again and checked regarding
26 authorship, year of publication, title of the article, journal publishing the work, the
27 Journal Impact Factor (JIF) at the time of the search, the number of citations and the
28 institution of the first author (Appendix 1).
29

Inclusion And Exclusion Criteria

The inclusion criteria were: papers focusing on IBD (ulcerative colitis or Crohn's disease) written in the English language. The exclusion criteria were: (i) articles on inflammatory bowel disease in languages other than English, (ii) articles that focused on other diseases and inflammatory bowel disease was not the main focus, and (iii) studies that focus on other types of colitis and not inflammatory bowel disease.

Assessing Articles

The full text of the identified 50-top cited articles was obtained and a copy was given to each researcher. The following information was collected for each article: (i) the authors' names, the number of authors, their affiliations, and the number of females contributing to authorship, (ii) the number of institutes involved in the publication, (iii) the city and country of the origin of the publication, (iv) the total number of citations obtained up to the day of searching the database, and the number of yearly citations since publication, (v) the year of publication and the calculated number of years since publication, and (vi) the number of funds/grants stated in the publication and the Web of Science.

We have not used the classification provided by the Web of Science regarding study type because we noted that the Web of Science groups publications as original research, articles, practical guides and reviews and identifies them as articles or reviews. For consistency and the purpose of this study, the top-cited articles were grouped into four types - article, review paper/meta-analysis, report, and research. A definition of each type is given in the glossary (Appendix 2). Two researchers

1
2
3 independently allocated each of the top-cited articles under its type as per the
4 definition given. Any differences between the researchers were discussed in a
5 meeting until a decision was reached.
6
7
8
9

10 The topics covered by the top-cited articles were identified by each researcher
11 independently and were discussed in a meeting to harmonize the grouping into a
12 logical, simple and practical way. Articles that covered more than one topic were
13 classified on the basis of the aim of the study and the main outcomes. For other
14 evaluations of an article including the number of authors, the number of females
15 represented in authorship, the number of institutes, and countries contributing to the
16 work, and the number of grants/funds received we checked the original article for
17 such details. Institute was defined as the university where an author belonged. If an
18 author belonged to two universities, this was considered to be two different institutes.
19 Regarding the identification of females in the authorship we noted that several
20 journals use abbreviations of the first and second name rather than the full name. In
21 order to identify the females in these articles we tried to search the Google database
22 to find the university, personal website of the author, their LinkedIn or ResearchGate
23 accounts. We also tried to identify them by searching the Google Scholar database
24 and identify their account, where we can find other publications under their name and
25 the full first name. In two papers, despite our efforts, we failed to identify the gender
26 of five authors and we contacted the corresponding authors. We received a response
27 from one correspondence, making us unable to identify the gender of three authors in
28 the second paper.
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

Evaluating the Journals

The publishing journals of the top 50 articles in IBD were identified and evaluated in regard to the following: (i) the 2016-Journal Impact Factor (JIF) of each journal, and (ii) the ranking order of each article in comparison to other articles published in that journal. This was based on the number of citations obtained in comparison to the citation numbers received by other articles published in the journal. For example, an article ranked number one, in its publishing journal, means that the article received the highest number of citations in comparison to all other articles published in that journal. This evaluation aimed at assessing the position order of articles identified among the 50 top-cited articles in IBD in regard to their ranking among other articles published in the journal. Such assessment highlights the significance of the inflammatory bowel disease articles among other topics published in gastroenterological journals as well as general medicine journals such as *The New England Journal of Medicine*, *The Lancet*, *the British Medical Journal*, *Medicine*, and top research journals such as *Nature*, *Nature Genetics*, *Science*, *Cell*, and top journals in immunology such as *Nature Reviews Immunology* (Appendix 1).

Assessing Level of Evidence

Two researchers independently used the Oxford Centre for Evidence-Based Medicine (OCEBM-2011 Levels of Evidence and the accompanying Table of Evidence Glossary) [16,17] to rank each article regarding level of evidence. In 1998 this hierarchical of evidence was first produced to make the process of finding relevant evidence feasible. Since then the levels have been reviewed and amended, and the

1
2
3 version used in this research is the currently available version. This evaluation aimed
4
5 at identifying the level of evidence of each article and assessing whether the highly
6
7 cited articles have received higher scores in regard to level of evidence as per the
8
9 Oxford hierarchy. The assessment required extensive review of each article since
10
11 quality descriptors exist for different types of studies and level of evidence vary
12
13 depending on therapeutic, prevention, prognostic, diagnostic, or prevalence design
14
15 [13,14].
16
17
18
19

20 **Statistical Analysis**

21
22
23 Pearson's correlation coefficient (r) was calculated to determine if the high citation
24
25 numbers obtained was related to the age of the article. Other correlations were
26
27 between the number of citations and the number of authors, the percentage of
28
29 females in authorship, the number of institutes, the number of countries involved, the
30
31 number of grants received, and the Journal Impact Factor (JIF) of the journals in
32
33 which articles were published. Because of the assumption that researchers usually
34
35 cite recently published articles, it was decided to compare the mean yearly citations
36
37 received of articles published before the year 2000 and compare them with those
38
39 published after the year 2000. All analyses were conducted using SPSS Software
40
41 (IBM SPSS Statistics Premium version 22.0 for Mac OS-SPSS Inc., Chicago, IL,
42
43 USA) and the results were reported at total, mean, median, IQR, and percentage.
44
45
46 The inter-rater agreement between evaluators was calculated using the Fleiss kappa
47
48 scale [19].
49
50
51
52
53
54
55
56
57
58
59
60

Patient and Public involvement

This study did not involve patients or the public.

RESULTS

Top-Cited Papers Identified

The 50 top-cited articles in IBD identified by searching the Web of Science [20-69] have been summarized in Appendix 1. The articles are listed in an order from 1 to 50 with the highest absolute citation number is ranked 1 and the article with the lowest citation ranked 50 as per the day of the search.

Table 1 summarizes the year of publication and article type. The articles were published over 57 years (from 1955 to 2012). During the period from 1955 to 1976, only 3 articles (6%) were published. However, the number increased significantly from 1977 to 1994 making a total of 12 (24%) articles. The number of publications increased significantly to 35 (70%) during the years from 1995 to 2012. No correlation was found between the number of citations of these papers and the number of years since published (Pearson correlation (r) = 0.042, p = 0.771). To assess if there were differences between old articles (published before the year 2000) and those published after the year 2000, it was decided to study the mean number of citations received by top-cited articles in each year after their publications. The year 2000 was taken as a midpoint for comparison because the majority of articles identified were published in the period after the year 1986, and hence the year 2000 could represent such point. As shown from Figures 1A and 1B, the mean numbers of citations were higher for articles published after the year 2000 compared to those published before

1
2
3 the year 2000. Approximately one fourth of the top-cited papers were reviews/meta-
4 analysis (n= 14, 28%), two-thirds were research papers (n= 33, 66%), and the
5
6 remaining were an article (n= 1, 2%) and two reports (n=2, 4%).
7
8
9

10 Table 2 summarizes the distribution of IBD topics covered in the top-cited articles.

11
12 These can be summarized as follows: epidemiology and prevalence (n=2, 4%),
13
14 Crohn's disease genetic susceptibility and NOD2 mutation (n=6, 12%), Animal
15
16 models (n= 5, 10%), Pathogenesis of IBD (n= 15, 30%), classification and index of
17
18 disease activity (n= 5, 10%), risk of developing colorectal cancer (n= 2, 4%), extra-
19
20 intestinal complications (n= 1, 2%), Infliximab in Crohn's disease (n= 6, 12%),
21
22 corticosteroids in ulcerative colitis (n=1, 2%), drug treatment and cyclosporine in
23
24 ulcerative colitis (n= 2, 4%), adalimumab in Crohn's disease (n=1, 2%), 5-
25
26 aminosalicylic acid in ulcerative colitis (n=1, 2%), 6-mercaptopurine in Crohn's
27
28 disease (n=1, 2%), and monoclonal antibiotics, and anti-tumour necrosis factor in
29
30 Crohn's disease (n=2, 4%). As shown in Appendix 1, 14 (28%) were basic research
31
32 and 19 (38%) were clinical research. The level of evidence is discussed later in the
33
34 results.
35
36
37
38
39
40

41 The articles were published in the following journals: *New England Journal of*
42
43 *Medicine* (n= 12, 24%), *Gastroenterology* (n= 12, 24%), *Nature* (n=4, 8%), *Nature*
44
45 *Genetics* (n=4, 8%), *The Lancet* (n= 2, 4%), *Proceedings of the National Academic of*
46
47 *Sciences of the United States of America* (n=2, 4%), *Cell* (n= 2, 4%), and *Gut* (n= 4,
48
49 8%). See Table 3 for more details about the journals publishing these articles.
50
51
52
53
54
55
56
57
58
59
60

1
2
3 Looking at the ranking of the top-cited articles in IBD in the journals they were
4 published in could provide a better picture about the influence of these articles. This
5 influence would be clearly demonstrated when the journal has a relatively higher
6 Journal Impact Factor. The ranking is based on the number of citations received by
7 an article compared to the number of citations received by other articles that were
8 published in that journal. The article by Best et al (1976) [23] is ranked number 4 in
9 the list, and also ranked number 2 among all articles published in *Gastroenterology*
10 (2016-JIF = 18.392). The article by Eaden et al [41] is ranked number 22 in the list
11 and also ranked number 1 among all articles published in *Gut* (2016-JIF= 16.658).
12 The ranking of other articles in List and their rankings in the journals in which they
13 were published are shown in Appendix 1.
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28

29 The first authors of the top-cited articles were from the United States (n= 24, 48%),
30 the United Kingdom (n=6, 12%), Germany (n= 5, 10%), France (n= 5, 10%), Belgium
31 (n= 3, 6%), Canada (n= 3, 6%), Japan (n=2, 4%), Sweden (n=1, 2%), and the
32 Netherlands (n=1, 2%).
33
34
35
36
37
38

39 Table 4 summarises the 70 authors who have published two papers or more in the
40 top-cited IBD. Of these 18 authors were the first author and coauthors of more than
41 two papers in total, all the remaining, 52 were coauthors of more than two papers.
42
43
44
45

46 Top authors were Rutgeers, P (n=10 papers), Targan, SR (n=8 papers), Schreiber, S
47 (n=7 papers), Cho, JH (n=7 papers), Colombel, JF (n=7 papers), Hanauer, SB (n=7
48 papers), Silverberg, MS (n=6 papers), and each of the following authors have 5
49 papers: Podolsky, DK, Rioux, JD, Daly MJ, Steinhart, AH, Rotter, JI, Schumm, LP,
50 Taylor, KD, Vermeire, S, Duerr, RH, and Regueiro, M.
51
52
53
54
55
56
57
58
59
60

1
2
3 The leadership of universities and institutes that have contributed to the creation of
4 these publications were Massachusetts General Hospital and Harvard Medical
5 School, Boston, Massachusetts, the United States, Mount Sinai School of Medicine,
6 New York, the United States, Mayo Clinic, Rochester, Minnesota, the United States,
7 Cedars-Sinai Medical Center, Los Angeles, California, the United States, University of
8 Chicago Medical Center, Chicago, Illinois, the United States, University of Pittsburgh,
9 Pittsburgh, Pennsylvania, the United States, University Hospital of Cleveland Case
10 Western Reserve University School of Medicine, Ohio, the United States, Wellcome
11 Trust Centre for Human Genetics, University of Oxford, Roosevelt Drive, Oxford, the
12 United Kingdom, Wellcome Trust Sanger Institute, Wellcome Trust Genome Campus,
13 Cambridge, the United Kingdom, and Institute of Virology and Immunobiology,
14 University of Würzburg, Germany. See Appendix 1 for more detail.

31 **Characteristics of the Top-Cited Articles**

32
33
34 These articles were created by 667 authors, median 7.0, minimum 1, maximum 106,
35 IQR 9.5; the females in authorship were 111, median 1.0, minimum 0, maximum 20,
36 IQR 2. It is worth mentioning here that it was difficult to identify the gender of some
37 authors in two papers because the full first and middle names were not shown and it
38 was difficult to find more information or clues to make a decision. We contacted the
39 corresponding authors of these two articles; we received information for one article
40 but we had no response from the corresponding author of the second article. Thus
41 the gender of three authors could not be identified. The number of institutes involved
42 were 436, median 3.0, minimum 1, maximum 88, IQR 9; the countries involved were
43 141, median 1.0, minimum 1, maximum 16, IQR 2.75; and the number of grants/funds
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

1
2
3 were 328, median 1.0, minimum 0, maximum 94, IQR 2.75. No correlations were
4
5 found between the number of citations and the Journal Impact Factor (JIF) (Pearson
6
7 correlation ($r = 0.186$; $p=0.196$), the number of authors ($r =0.061$; $p= 0.674$), number
8
9 of females in authorship ($r =0.064$; $p= 0.661$), the number of institutes involved (r
10
11 $=0.076$; $p= 0.602$), the number of countries involved ($r =0.101$; $p= 0.483$), and the
12
13 number of grants received ($r= - 0.015$; $p=0.915$).
14
15

16 17 18 **Level of Evidence**

19
20
21 Table 5 summarizes the grading of articles according to the Oxford Center for
22
23 evidence-based medicine. The table shows that most articles were graded at levels
24
25 1b and 3a and 3b evidence (12 papers had level 1b evidence, 9 papers at level 3a,
26
27 and 15 papers had level 3b evidence). Five articles had a level of evidence of 4 and
28
29 no article at level 5. The remaining articles were at levels 1a, 2a, 2b and 2c. The
30
31 overall agreement between the evaluators was acceptable; Fleiss kappa= 0.8252;
32
33 95% CI 0.79-0.85.
34
35

36 37 38 **DISCUSSION**

39
40
41 This study aimed at identifying the characteristics of the top 50 most frequently cited
42
43 papers in IBD and assessing the quality of evidence provided. The papers covered a
44
45 number of key topics related to IBD including: epidemiology and prevalence,
46
47 pathogenesis and genetic susceptibility, animal models, clinical classification and
48
49 indices of disease activity, risks of developing colorectal cancer, extra-intestinal
50
51 complications, and use of infliximab, adalimumab, monoclonal antibodies and anti-
52
53 tumour necrosis factor, and 6- mercaptopurine in CD, and use of 5-aminosalicylic
54
55
56
57
58
59
60

1
2
3 acid, corticosteroids, and cyclosporine in treating UC. While these topics cover key
4 issues related to IBD, topics related to molecular biology, surgical management,
5 patient education, nutritional aspects, radiological and other investigations were not
6 represented in the top-cited articles list [70,71].
7
8
9
10
11

12
13 The assessment of the characteristics of the top 50 highly cited articles identified in
14 this study reveals the following:
15
16

17
18 First, the lack of correlations between the number of citations and the number of
19 years since publication may indicate that the high-citations is not caused by ageing of
20 these articles. In fact, only 15 articles (30%) were published in the period from 1955
21 to 1994 (39 years), while the majority, 35 (70%) were published in the last 17 years.
22
23 No papers were published after 2012. This article also shows that the mean number
24 of citations of articles published before the year 2000 were much lower than those of
25 articles after the year 2000. This may be related to the tendency of researchers to cite
26 recently published research and new findings [72] and papers that they have read
27 [18]. Also the number of citations and the papers' age might be attributed to the
28 changes in citation behaviour over time. For example, in the 50s and 60s, the authors
29 used to cite fewer papers compared to what was practiced over the last 20 years [73].
30
31 The higher citations have been found to be the strongest predictor of current online
32 availability after a long time since publication. Therefore, the higher citation could be
33 a protective mechanism for continued availability of a publication despite aging and
34 hence continuing citation [74].
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

1
2
3 Second, the lack of a correlation between the number of citations and the Journal
4 Impact Factor (JIF). The JIF has been widely used in ranking and evaluating journals.
5
6 It stands as a proxy for the relative importance of a journal with its field [75]. Although
7
8 the top-cited articles identified were published in journals with high impact factors, the
9
10 impact factors of some journals were not necessarily the highest in their fields. For
11
12 example, *Laboratory Investigation*, *Canadian Journal of Gastroenterology and*
13
14 *Hepatology*, *Medicine (Baltimore)*, and *Journal of Immunology* had JIFs in the range
15
16 of 1.804 to 4.857. With this information in mind one may postulate that the high JIF is
17
18 not necessarily related to the higher citation numbers received. Two recent works
19
20 showed that the JIF is not an accurate indicator of citations an average article
21
22 receives, articles published in low impact factor journals can still be highly cited and
23
24 vice versa [76,77].
25
26
27
28
29
30

31 Third, the study showed negative correlation between the number of citations and the
32
33 number of authors, the number of female authors, or the number of institutes. The
34
35 number of authors and females in authorship varied from one to 106 and from zero to
36
37 20, respectively. Also the number of institutes involved varied from one to 88. The
38
39 question that can be raised in this regards; are we expecting an increase in number
40
41 of citations as the number of authors or the number institutes involved increased?
42
43 The work of Garcia-Aroca et al [78] shows that collaboration between authors
44
45 increases their impact and increases citation rates. However, they showed that
46
47 publishing in English in certain journals and collaborating with certain authors and
48
49 institutes increase the visibility of the manuscripts published on the subject. Hence it
50
51 is the quality of collaboration rather than the absolute number of these parameters.
52
53
54
55
56
57
58
59
60

1
2
3 Recently Tanner-Smith and Polanin showed that studies conducted by more
4 established authors (have higher h-indices) and reported in more prestigious journal
5 outlets are more likely to be cited by other scholars, even after controlling for various
6 proxies of study quality [79].
7
8
9
10

11
12
13 Although the proportion of women in authorship of original research in the United
14 States in general has significantly increased in the last four decades, women still
15 compose a minority of the authors of original research [80]. In the field of
16 gastroenterology, the percentage of the United States female physician authors of
17 original research in the field has relatively increased over time, yet the senior author
18 position remains lower than expected [81,82].
19
20
21
22
23
24
25
26
27

28 Fourth, the study showed no correlation between the number of citations and the
29 number of funds/grants received. This finding is not surprising. Recently it was shown
30 that too many of the United States authors of most influential papers in science do not
31 receive NH funding [83]. Another group of researchers found no association between
32 grant percentile ranking and grant outcome as assessed by number of top-10%
33 articles per dollar million spent [84].
34
35
36
37
38
39
40
41

42 The United States, the United Kingdom, Germany, France, Belgium, and Canada
43 contributed to the majority of these articles. The leadership of universities from these
44 countries in gastrointestinal research particularly IBD is no surprise, top universities
45 identified from this study were Massachusetts General Hospital and Harvard Medical
46 School, Boston, Massachusetts, the United States, Mount Sinai School of Medicine,
47 New York, the United States, Mayo Clinic, Rochester, Minnesota, the United States,
48
49
50
51
52
53
54
55
56
57
58
59
60

1
2
3 Cedars-Sinai Medical Center, Los Angeles, California, the United States, University of
4
5 Chicago Medical Center, Chicago, Illinois, the United States. Other institutes and
6
7 research centres that had lead these studies are shown in Appendix 1.
8
9

10
11 All articles were published in the English language. The most productive journals
12
13 were the *New England Journal of Medicine*, and *Gastroenterology* with a total of 24
14
15 articles. Others were *Nature*, *Nature Genetics*, *the Lancet*, and *Proceedings of the*
16
17 *National Academy of Sciences of the United States of America*, *Cell*, *Gut*, *British*
18
19 *Medical Journal*, *Science*, and *Nature Reviews Immunology* making a total of 20
20
21 articles. While these journals have a relatively high JIF, other journals published one
22
23 article each and had a relatively low JIF compared to journals included in their
24
25 categories. For example, *Human Pathology* listed number 22 under the category of
26
27 Pathology, and *Canadian Journal of Gastroenterology and Hepatology*, listed number
28
29 74 under the category Gastroenterology and Hepatology. The high level of evidence
30
31 as outlined in the top-cited articles could be an important contributing factor to the
32
33 higher number of citations received by these articles [85].
34
35
36
37
38

39 After the submission of our study we came across the study by Connelly et al [86] on
40
41 top 100 articles on IBD. While they indicated that their findings covered the period
42
43 between 1955-2012 which is consistent with our findings, our study has examined a
44
45 range of parameters including correlation of citation numbers with JIF, number of
46
47 years since publication, number of authors, females in authorship, institutes, and
48
49 number of countries and grants, which were not addressed by Connelly's work. Also
50
51 we have examined the level of evidence of highly cited articles.
52
53
54
55
56
57
58
59
60

CONCLUSIONS

Our list of top-cited articles in IBD highlights key contributions that based the foundation of research and examination of different aspects of the disease over 57 years. This scholarly contribution came from universities and research centres in the United States, the United Kingdom, Germany, France, Belgium and Canada. The findings may be consistent with the concept that it is not the absolute number of collaborators that makes an impact on the citation number or the influence of a publication but rather the quality of such collaboration with regard to the researchers involved, their institutes, and the ongoing contribution to the advances of research. The relatively small number of females in the authorship reflects the gender gap and the fact that women still compose a minority of the authors of original research and reviews in gastroenterology. The higher level of evidence demonstrated in most top-cited articles may have contributed to the higher number of citations received by these articles.

1
2
3 **Acknowledgement:** The author would like to thank Diana Sanad for her assistance
4
5 and reviewing the manuscript.
6
7

8
9 **Funding support:** This work was funded by the College of Medicine, Research
10
11 Center Deanship of Scientific Research, King Saud University, Riyadh, Saudi Arabia.
12
13

14 **Ethical approval:** Not applicable to this study.
15

16
17 **Contributorship Statement:** SAA and SA shared equally the different roles and
18
19 responsibilities to complete the submitted article including, the research idea, the
20
21 search of databases, the evaluation of data collected, the statistical analysis, the
22
23 interpretation of findings, the creation of tables and figures, writing the manuscript
24
25 and the approved the final version of the manuscript.
26
27

28
29 **Competing interests:** There are no competing interests for any author
30

31
32 **Provenance and peer review:** Not commissioned; externally peer reviewed
33

34
35 **Data sharing:** No further data available to share
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

REFERENCES

1. MacMaster FP, Swansburg R, Rittenbach K. Academic Productivity in Psychiatry: Benchmarks for the H-Index. *Acad Psychiatry*. 2017 Apr 18. [Epub ahead of print]
2. Susarla HK, Dhar V, Karimbux NY, Tinanoff N. Do Standard Bibliometric Measures Correlate with Academic Rank of Full-Time Pediatric Dentistry Faculty Members? *J Dent Educ*. 2017 Apr;81(4):427-432.
3. Milone MT, Bernstein J. On Track to Professorship? A Bibliometric Analysis of Early Scholarly Output. *Am J Orthop (Belle Mead NJ)*. 2016 Mar-Apr;45(3):E119-23.
4. Azer SA, Holen A, Wilson I, Skokauskas N. Impact factor of medical education journals and recently developed indices: Can any of them support academic promotion criteria? *J Postgrad Med*. 2016 Jan-Mar;62(1):32-39. doi: 10.4103/0022-3859.173202.
5. Jones AW. Impact of JAT publications 1981-2003: the most prolific authors and the most highly cited articles. *J Anal Toxicol*. 2004 Oct;28(7):541-545.
6. Patsopoulos NA, Ioannidis JP, Analatos AA. Origin and funding of the most frequently cited papers in medicine: database analysis. *BMJ* 2006;332:1061–1064.
7. Garfield E. Fortnightly review: how can impact factors be improved? *BMJ* 1996;313:411–413.
8. Azer SA. Exploring the Top-Cited and Most Influential Articles in Medical Education. *J Contin Educ Health Prof*. 2016 Summer;36 Suppl 1:S32-41.
9. Wilks S. Morbid appearances in the intestines of Miss Bankes. *Med Times Gazette* 1859;2:264-265.
10. Crohn BB, Ginzburg L, Oppenheimer GD. Regional ileitis: a pathologic and clinical entity. *JAMA* 1932;99:1323-1329.
11. Van Noorden R, Maher B, Nuzzo R. The top 100 papers. *Nature*. 2014;514(7524):550.

- 1
2
3
4 12. Kulkarni AV, Aziz B, Shams I, Busse JW. Comparisons of citations in Web of
5 Science, Scopus, and Google Scholar for articles published in general medical
6 journals. *JAMA*. 2009 Sep 9;302(10):1092-1096.
7
- 8 13. Powell AGMT, Bevan V, Brown C, Lewis WG. Altmetric Versus Bibliometric
9 Perspective Regarding Publication Impact and Force. *World J Surg*. 2018 Mar 13.
10
11
12
- 13 14. Yi F, Ma J, Ni W, Chang R, Liu W, Han X, Pan D, Liu X, Qiu J. The top
14 cited articles on glioma stem cells in Web of Science. *Neural Regen Res*. 2013 May
15 25;8(15):1431-8. doi: 10.3969/j.issn.1673-5374.2013.15.011.
16
- 17 15. Mu Y, Li N, Guan L, Wang C, Shang S, Wang Y. Therapies for children with
18 cerebral palsy: A Web of Science-based literature analysis. *Neural Regen Res*. 2012
19 Nov 25;7(33):2632-9. doi: 10.3969/j.issn.1673-5374.2012.33.009.
20
21
- 22 16. Azer SA. Top-Cited Articles in Problem-Based Learning: A Bibliometric Analysis
23 and Quality of Evidence Assessment. *J Dent Educ*. 2017 Apr;81(4):458-478.
24
25
- 26 17. Oxford Centre for Evidence-based Medicine – Levels of Evidence (March 2009).
27 Available at: [http://www.cebm.net/oxford-centre-evidence-based-medicine-levels-](http://www.cebm.net/oxford-centre-evidence-based-medicine-levels-evidence-march-2009)
28 [evidence-march-2009](http://www.cebm.net/oxford-centre-evidence-based-medicine-levels-evidence-march-2009) [Accessed 20 May 2017].
29
30
- 31 18. Azer SA. The top-cited articles in medical education: a bibliometric analysis. *Acad*
32 *Med* 2015;90(8):1147-1161.
33
34
35
- 36 19. D'Antiga L, Betalli P, De Angelis P, et al. Interobserver agreement on endoscopic
37 classification of oesophageal varices in children. *J Pediatr Gastroenterol Nutr*
38 2015;61(2):176-181.
39
40
- 41 20. Hugot JP, Chamaillard M, Zouali H, Lesage S, Cézard JP, Belaiche J, Almer S,
42 Tysk C, O'Morain CA, Gassull M, Binder V, Finkel Y, Cortot A, Modigliani R, Laurent-
43 Puig P, Gower-Rousseau C, Macry J, Colombel JF, Sahbatou M, Thomas G.
44 Association of NOD2 leucine-rich repeat variants with susceptibility to Crohn's
45 disease. *Nature*. 2001 May 31;411(6837):599-603.
46
47
- 48 21. Ogura Y, Bonen DK, Inohara N, Nicolae DL, Chen FF, Ramos R, Britton H, Moran
49 T, Karaliuskas R, Duerr RH, Achkar JP, Brant SR, Bayless TM, Kirschner BS,
50 Hanauer SB, Nuñez G, Cho JH. A frameshift mutation in NOD2 associated with
51 susceptibility to Crohn's disease. *Nature*. 2001 May 31;411(6837):603-6.
52
53
- 54 22. Kühn R, Löhler J, Rennick D, Rajewsky K, Müller W. Interleukin-10-deficient mice
55 develop chronic enterocolitis. *Cell*. 1993 Oct 22;75(2):263-74
56
57
58
59
60

- 1
2
3 23. Best WR, Becktel JM, Singleton JW, Kern F Jr. Development of a Crohn's
4 disease activity index. National Cooperative Crohn's Disease Study.
5 Gastroenterology. 1976 Mar;70(3):439-44.
6
7
8 24. Hanauer SB, Feagan BG, Lichtenstein GR, Mayer LF, Schreiber S, Colombel JF,
9 Rachmilewitz D, Wolf DC, Olson A, Bao W, Rutgeerts P; ACCENT I Study Group.
10 Maintenance infliximab for Crohn's disease: the ACCENT I randomised trial. Lancet.
11 2002 May 4;359(9317):1541-1549.
12
13 25. Podolsky DK. Inflammatory bowel disease. N Engl J Med. 2002 Aug
14 8;347(6):417-429.
15
16
17 26. Targan SR, Hanauer SB, van Deventer SJ, Mayer L, Present DH, Braakman T,
18 DeWoody KL, Schaible TF, Rutgeerts PJ. A short-term study of chimeric monoclonal
19 antibody cA2 to tumor necrosis factor alpha for Crohn's disease. Crohn's Disease
20 cA2 Study Group. N Engl J Med. 1997 Oct 9;337(15):1029-35.
21
22
23
24 27. Xavier RJ, Podolsky DK. Unravelling the pathogenesis of inflammatory bowel
25 disease. Nature. 2007 Jul 26;448(7152):427-434.
26
27
28 28. Truelove SC and Witts LJ. Cortisone in ulcerative colitis; final report on a
29 therapeutic trial. Br Med J. 1955 Oct 29;2(4947):1041-1048.
30
31
32 29. Duerr RH, Taylor KD, Brant SR, Rioux JD, Silverberg MS, Daly MJ, Steinhart AH,
33 Abraham C, Regueiro M, Griffiths A, Dassopoulos T, Bitton A, Yang H, Targan S,
34 Datta LW, Kistner EO, Schumm LP, Lee AT, Gregersen PK, Barmada MM, Rotter JI,
35 Nicolae DL, Cho JH. A genome-wide association study identifies IL23R as an
36 inflammatory bowel disease gene. Science. 2006 Dec 1;314(5804):1461-1463.
37
38
39 30. Rutgeerts P, Sandborn WJ, Feagan BG, Reinisch W, Olson A, Johanns J,
40 Travers S, Rachmilewitz D, Hanauer SB, Lichtenstein GR, de Villiers WJ, Present D,
41 Sands BE, Colombel JF. Infliximab for induction and maintenance therapy for
42 ulcerative colitis. N Engl J Med. 2005 Dec 8;353(23):2462-76.
43
44
45 31. Present DH, Rutgeerts P, Targan S, Hanauer SB, Mayer L, van Hogezaand RA,
46 Podolsky DK, Sands BE, Braakman T, DeWoody KL, Schaible TF, van Deventer SJ.
47 Infliximab for the treatment of fistulas in patients with Crohn's disease. N Engl J Med.
48 1999 May 6;340(18):1398-405.
49
50
51 32. Frank DN, St Amand AL, Feldman RA, Boedeker EC, Harpaz N, Pace NR.
52 Molecular-phylogenetic characterization of microbial community imbalances in human
53 inflammatory bowel diseases. Proc Natl Acad Sci U S A. 2007 Aug
54 21;104(34):13780-13785
55
56 33. Jostins L, Ripke S, Weersma RK, Duerr RH, McGovern DP, Hui KY, Lee JC,

1
2
3 Schumm LP, Sharma Y, Anderson CA, Essers J, Mitrovic M, Ning K, Cleynen I,
4 Theatre E, Spain SL, Raychaudhuri S, Goyette P, Wei Z, Abraham C, Achkar JP,
5 Ahmad T, Amininejad L, Ananthakrishnan AN, Andersen V, Andrews JM, Baidoo L,
6 Balschun T, Bampton PA, Bitton A, Boucher G, Brand S, Büning C, Cohain A, Cichon
7 S, D'Amato M, De Jong D, Devaney KL, Dubinsky M, Edwards C, Ellinghaus D,
8 Ferguson LR, Franchimont D, Fransen K, Garry R, Georges M, Gieger C, Glas J,
9 Ferguson LR, Franchimont D, Fransen K, Garry R, Georges M, Gieger C, Glas J,
10 Haritunians T, Hart A, Hawkey C, Hedl M, Hu X, Karlsen TH, Kupcinskis L,
11 Kugathasan S, Latiano A, Laukens D, Lawrance IC, Lees CW, Louis E, Mahy G,
12 Mansfield J, Morgan AR, Mowat C, Newman W, Palmieri O, Ponsioen CY, Potocnik
13 U, Prescott NJ, Regueiro M, Rotter JI, Russell RK, Sanderson JD, Sans M, Satsangi
14 J, Schreiber S, Simms LA, Sventoraityte J, Targan SR, Taylor KD, Tremelling M,
15 Verspaget HW, De Vos M, Wijmenga C, Wilson DC, Winkelmann J, Xavier RJ,
16 Zeissig S, Zhang B, Zhang CK, Zhao H; International IBD Genetics Consortium
17 (IIBDGC)., Silverberg MS, Annese V, Hakonarson H, Brant SR, Radford-Smith G,
18 Mathew CG, Rioux JD, Schadt EE, Daly MJ, Franke A, Parkes M, Vermeire S, Barrett
19 JC, Cho JH. Host-microbe interactions have shaped the genetic architecture of
20 inflammatory bowel disease. *Nature*. 2012 Nov 1;491(7422):119-24.
21
22

23
24 34. Barrett JC, Hansoul S, Nicolae DL, Cho JH, Duerr RH, Rioux JD, Brant SR,
25 Silverberg MS, Taylor KD, Barmada MM, Bitton A, Dassopoulos T, Datta LW, Green
26 T, Griffiths AM, Kistner EO, Murtha MT, Regueiro MD, Rotter JI, Schumm LP,
27 Steinhart AH, Targan SR, Xavier RJ; NIDDK IBD Genetics Consortium, Libioulle C,
28 Sandor C, Lathrop M, Belaiche J, Dewit O, Gut I, Heath S, Laukens D, Mni M,
29 Rutgeerts P, Van Gossum A, Zelenika D, Franchimont D, Hugot JP, de Vos M,
30 Vermeire S, Louis E; Belgian-French IBD Consortium; Wellcome Trust Case Control
31 Consortium, Cardon LR, Anderson CA, Drummond H, Nimmo E, Ahmad T, Prescott
32 NJ, Onnie CM, Fisher SA, Marchini J, Ghorji J, Bumpstead S, Gwilliam R, Tremelling
33 M, Deloukas P, Mansfield J, Jewell D, Satsangi J, Mathew CG, Parkes M, Georges
34 M, Daly MJ. Genome-wide association defines more than 30 distinct susceptibility loci
35 for Crohn's disease. *Nat Genet*. 2008 Aug;40(8):955-962.
36
37

38
39 35. Loftus EV Jr. Clinical epidemiology of inflammatory bowel disease: Incidence,
40 prevalence, and environmental influences. *Gastroenterology*. 2004 May;126(6):1504-
41 1517.
42

43
44 36. Fiocchi C. Inflammatory bowel disease: etiology and pathogenesis.
45 *Gastroenterology*. 1998 Jul;115(1):182-205.
46

47
48 37. Harvey RF, Bradshaw JM. A simple index of Crohn's-disease activity. *Lancet*.
49 1980 Mar 8;1(8167):514.
50

51
52 38. Molodecky NA, Soon IS, Rabi DM, Ghali WA, Ferris M, Chernoff G, Benchimol EI,
53 Panaccione R, Ghosh S, Barkema HW, Kaplan GG. Increasing incidence and
54 prevalence of the inflammatory bowel diseases with time, based on systematic
55 review. *Gastroenterology*. 2012 Jan;142(1):46-54.
56
57
58
59
60

1
2
3 39. Riddell RH, Goldman H, Ransohoff DF, Appelman HD, Fenoglio CM, Haggitt RC,
4 Ahren C, Correa P, Hamilton SR, Morson BC, et al. Dysplasia in inflammatory bowel
5 disease: standardized classification with provisional clinical applications. *Hum Pathol*.
6 1983 Nov;14(11):931-968.
7

8
9
10 40. Okayasu I, Hatakeyama S, Yamada M, Ohkusa T, Inagaki Y, Nakaya R A novel
11 method in the induction of reliable experimental acute and chronic ulcerative colitis in
12 mice. *Gastroenterology*. 1990 Mar;98(3):694-702.
13

14
15
16 41. Eaden JA, Abrams KR, Mayberry JF. The risk of colorectal cancer in ulcerative
17 colitis: a meta-analysis. *Gut*. 2001 Apr;48(4):526-535.
18

19
20 42. Sokol H, Pigneur B, Watterlot L, Lakhdari O, Bermúdez-Humarán LG, Gratadoux
21 JJ, Blugeon S, Bridonneau C, Furet JP, Corthier G, Grangette C, Vasquez N, Pochart
22 P, Trugnan G, Thomas G, Blottière HM, Doré J, Marteau P, Seksik P, Langella P.
23 *Faecalibacterium prausnitzii* is an anti-inflammatory commensal bacterium identified
24 by gut microbiota analysis of Crohn disease patients. *Proc Natl Acad Sci U S A*. 2008
25 Oct 28;105(43):16731-16736.
26

27
28 43. Silverberg MS, Satsangi J, Ahmad T, Arnott ID, Bernstein CN, Brant SR, Caprilli
29 R, Colombel JF, Gasche C, Geboes K, Jewell DP, Karban A, Loftus EV Jr, Peña AS,
30 Riddell RH, Sachar DB, Schreiber S, Steinhardt AH, Targan SR, Vermeire S, Warren
31 BF. Toward an integrated clinical, molecular and serological classification of
32 inflammatory bowel disease: report of a Working Party of the 2005 Montreal World
33 Congress of Gastroenterology. *Can J Gastroenterol*. 2005 Sep;19 Suppl A:5A-36A
34

35
36 44. Sadlack B, Merz H, Schorle H, Schimpl A, Feller AC, Horak I. Ulcerative colitis-
37 like disease in mice with a disrupted interleukin-2 gene. *Cell*. 1993 Oct 22;75(2):253-
38 261.
39

40
41 45. Franke A, McGovern DP, Barrett JC, Wang K, Radford-Smith GL, Ahmad T, Lees
42 CW, Balschun T, Lee J, Roberts R, Anderson CA, Bis JC, Bumpstead S, Ellinghaus
43 D, Festen EM, Georges M, Green T, Haritunians T, Jostins L, Latiano A, Mathew CG,
44 Montgomery GW, Prescott NJ, Raychaudhuri S, Rotter JI, Schumm P, Sharma Y,
45 Simms LA, Taylor KD, Whiteman D, Wijmenga C, Baldassano RN, Barclay M,
46 Bayless TM, Brand S, Büning C, Cohen A, Colombel JF, Cottone M, Stronati L,
47 Denson T, De Vos M, D'Inca R, Dubinsky M, Edwards C, Florin T, Franchimont D,
48 Geary R, Glas J, Van Gossom A, Guthery SL, Halfvarson J, Verspaget HW, Hugot
49 JP, Karban A, Laukens D, Lawrance I, Lemann M, Levine A, Libioulle C, Louis E,
50 Mowat C, Newman W, Panés J, Phillips A, Proctor DD, Regueiro M, Russell R,
51 Rutgeerts P, Sanderson J, Sans M, Seibold F, Steinhardt AH, Stokkers PC, Torkvist L,
52 Kullak-Ublick G, Wilson D, Walters T, Targan SR, Brant SR, Rioux JD, D'Amato M,
53 Weersma RK, Kugathasan S, Griffiths AM, Mansfield JC, Vermeire S, Duerr RH,
54 Silverberg MS, Satsangi J, Schreiber S, Cho JH, Annese V, Hakonarson H, Daly MJ,
55 Parkes M. Genome-wide meta-analysis increases to 71 the number of confirmed
56
57
58
59
60

1
2
3 Crohn's disease susceptibility loci. *Nat Genet.* 2010 Dec;42(12):1118-1125.
4

5
6 46. Baert F, Noman M, Vermeire S, Van Assche G, D' Haens G, Carbonez A,
7 Rutgeerts P. Influence of immunogenicity on the long-term efficacy of infliximab in
8 Crohn's disease. *N Engl J Med.* 2003 Feb 13;348(7):601-608.
9

10
11 47. Colombel JF, Sandborn WJ, Reinisch W, Mantzaris GJ, Kornbluth A,
12 Rachmilewitz D, Lichtiger S, D'Haens G, Diamond RH, Broussard DL, Tang KL, van
13 der Woude CJ, Rutgeerts P; SONIC Study Group. Infliximab, azathioprine, or
14 combination therapy for Crohn's disease. *N Engl J Med.* 2010 Apr 15;362(15):1383-
15 1395.
16

17
18 48. Cooper HS, Murthy SN, Shah RS, Sedergran DJ. Clinicopathologic study of
19 dextran sulfate sodium experimental murine colitis. *Lab Invest.* 1993 Aug;69(2):238-
20 249.
21

22
23 49. Ekobom A, Helmick C, Zack M, Adami HO. Ulcerative colitis and colorectal cancer.
24 A population-based study. *N Engl J Med.* 1990 Nov 1;323(18):1228-1233.
25

26
27 50. Schroeder KW, Tremaine WJ, Ilstrup DM. Coated oral 5-aminosalicylic acid
28 therapy for mildly to moderately active ulcerative colitis. A randomized study. *N Engl J*
29 *Med.* 1987 Dec 24;317(26):1625-1629.
30

31
32 51. Rioux JD, Xavier RJ, Taylor KD, Silverberg MS, Goyette P, Huett A, Green T,
33 Kuballa P, Barmada MM, Datta LW, Shugart YY, Griffiths AM, Targan SR, Ippoliti AF,
34 Bernard EJ, Mei L, Nicolae DL, Regueiro M, Schumm LP, Steinhart AH, Rotter JI,
35 Duerr RH, Cho JH, Daly MJ, Brant SR. Genome-wide association study identifies
36 new susceptibility loci for Crohn disease and implicates autophagy in disease
37 pathogenesis. *Nat Genet.* 2007 May;39(5):596-604.
38

39
40 52. Sands BE, Anderson FH, Bernstein CN, Chey WY, Feagan BG, Fedorak RN,
41 Kamm MA, Korzenik JR, Lashner BA, Onken JE, Rachmilewitz D, Rutgeerts P, Wild
42 G, Wolf DC, Marsters PA, Travers SB, Blank MA, van Deventer SJ. Infliximab
43 maintenance therapy for fistulizing Crohn's disease. *N Engl J Med.* 2004 Feb
44 26;350(9):876-85.
45

46
47 53. Colombel JF, Sandborn WJ, Rutgeerts P, Enns R, Hanauer SB, Panaccione R,
48 Schreiber S, Byczkowski D, Li J, Kent JD, Pollack PF. Adalimumab for maintenance
49 of clinical response and remission in patients with Crohn's disease: the CHARM trial.
50 *Gastroenterology.* 2007 Jan;132(1):52-65.
51

52
53 54. Hampe J, Franke A, Rosenstiel P, Till A, Teuber M, Huse K, Albrecht M, Mayr G,
54 De La Vega FM, Briggs J, Günther S, Prescott NJ, Onnie CM, Häsler R, Sipos B,
55 Fölsch UR, Lengauer T, Platzer M, Mathew CG, Krawczak M, Schreiber S. A
56 genome-wide association scan of nonsynonymous SNPs identifies a susceptibility
57 variant for Crohn disease in ATG16L1. *Nat Genet.* 2007 Feb;39(2):207-211.
58
59
60

- 1
2
3
4 55. Bouma G, Strober W. The immunological and genetic basis of inflammatory
5 bowel disease. *Nat Rev Immunol*. 2003 Jul;3(7):521-533.
6
7
8 56. Lichtiger S, Present DH, Kornbluth A, Gelernt I, Bauer J, Galler G, Michelassi F,
9 Hanauer S. Cyclosporine in severe ulcerative colitis refractory to steroid therapy. *N*
10 *Engl J Med*. 1994 Jun 30;330(26):1841-1845.
11
12 57. Abraham C, Cho JH. Inflammatory bowel disease. *N Engl J Med*. 2009 Nov
13 19;361(21):2066-2078.
14
15
16
17 58. Summers RW, Switz DM, Sessions JT Jr, Bechtel JM, Best WR, Kern F Jr,
18 Singleton JW. National Cooperative Crohn's Disease Study: results of drug treatment.
19 *Gastroenterology*. 1979 Oct;77(4 Pt 2):847-869
20
21
22
23 59. Satsangi J, Silverberg MS, Vermeire S, Colombel JF. The Montreal classification
24 of inflammatory bowel disease: controversies, consensus, and implications.
25 *Gut*. 2006 Jun;55(6):749-53.
26
27
28
29 60. Elson CO, Sartor RB, Tennyson GS, Riddell RH. Experimental models of
30 inflammatory bowel disease. *Gastroenterology*. 1995 Oct;109(4):1344-1367.
31
32
33 61. Greenstein AJ, Janowitz HD, Sachar DB. The extra-intestinal complications of
34 Crohn's disease and ulcerative colitis: a study of 700 patients. *Medicine (Baltimore)*.
35 1976 Sep;55(5):401-412.
36
37 62. Fujino S, Andoh A, Bamba S, Ogawa A, Hata K, Araki Y, Bamba T, Fujiyama Y.
38 Increased expression of interleukin 17 in inflammatory bowel disease. *Gut*. 2003
39 Jan;52(1):65-70.
40
41
42 63. Sartor RB. Microbial influences in inflammatory bowel diseases.
43 *Gastroenterology*. 2008 Feb;134(2):577-594.
44
45
46
47 64. Manichanh C, Rigottier-Gois L, Bonnaud E, Gloux K, Pelletier E, Frangeul L,
48 Nalin R, Jarrin C, Chardon P, Marteau P, Roca J, Dore J.
49 Reduced diversity of faecal microbiota in Crohn's disease revealed by a
50 metagenomic approach. *Gut*. 2006 Feb;55(2):205-211.
51
52
53 65. Fuss IJ, Neurath M, Boirivant M, Klein JS, de la Motte C, Strong SA, Fiocchi C,
54 Strober W. Disparate CD4+ lamina propria (LP) lymphokine secretion profiles in
55 inflammatory bowel disease. Crohn's disease LP cells manifest increased secretion
56 of IFN-gamma, whereas ulcerative colitis LP cells manifest increased secretion of IL-
57
58
59
60

1
2
3 5. J Immunol. 1996 Aug 1;157(3):1261-1270.
4
5

6
7 66. Rutgeerts P, Geboes K, Vantrappen G, Beyls J, Kerremans R, Hiele M.
8 Predictability of the postoperative course of Crohn's disease.
9 Gastroenterology. 1990 Oct;99(4):956-963.
10

11
12 67. Present DH, Korelitz BI, Wisch N, Glass JL, Sachar DB, Pasternack BS.
13 Treatment of Crohn's disease with 6-mercaptopurine. A long-term, randomized,
14 double-blind study. N Engl J Med. 1980 May 1;302(18):981-987.
15
16

17
18 68. Swidsinski A, Ladhoff A, Pernthaler A, Swidsinski S, Loening-Baucke V, Ortner M,
19 Weber J, Hoffmann U, Schreiber S, Dietel M, Lochs H. Mucosal flora in inflammatory
20 bowel disease. Gastroenterology. 2002 Jan;122(1):44-54.
21
22

23 69. van Dullemen HM, van Deventer SJ, Hommes DW, Bijl HA, Jansen J, Tytgat GN,
24 Woody J. Treatment of Crohn's disease with anti-tumor necrosis factor chimeric
25 monoclonal antibody (cA2). Gastroenterology. 1995 Jul;109(1):129-135.
26
27

28
29 70. Azer SA. Overview of molecular pathways in inflammatory bowel disease
30 associated with colorectal cancer development. Eur J Gastroenterol Hepatol. 2013
31 Mar;25(3):271-281.
32

33 71. Azer SA, AIOlayan TI, AIGhamdi MA, AISanea MA. Inflammatory bowel disease:
34 An evaluation of health information on the internet. World J Gastroenterol. 2017 Mar
35 7;23(9):1676-1696.
36
37

38
39 72. Börner K, Maru JT, Goldstone RL. The simultaneous evolution of author and
40 paper networks. Proc Natl Acad Sci U S A. 2004 Apr 6;101 Suppl 1:5266-73.
41
42

43 73 Sinatra R, Deville P, Szell M, Wang D, Barabasi AL. A century of
44 physics. Nature Physics 2015; 11(10): 791-796.
45
46

47
48
49 74. Wren JD, Georgescu C, Giles CB, Hennessey J. Use it or lose it: citations predict
50 the continued online availability of published bioinformatics resources. Nucleic Acids
51 Res. 2017 Apr 20;45(7):3627-3633.
52
53

54 75. Shanahan DR. Auto-correlation of journal impact factor for consensus research
55 reporting statements: a cohort study. PeerJ. 2016 Mar 31;4:e1887.
56
57
58
59
60

- 1
2
3
4 76. Royle P, Kandala NB, Barnard K, Waugh N. Bibliometrics of systematic reviews: analysis of citation rates and journal impact factors. *Syst Rev*. 2013 Sep 12;2:74.
5
6
7
8 77. Falagas ME, Kouranos VD, Michalopoulos A, Rodopoulou SP, Batsiou
9 MA, Karageorgopoulos DE. Comparison of the distribution of citations received by
10 articles published in high, moderate, and low impact factor journals in clinical
11 medicine. *Intern Med J*. 2010 Aug;40(8):587-591.
12
13 78. García-Aroca MÁ, Pandiella-Dominique A, Navarro-Suay R, Alonso-Arroyo
14 A, Granda-Orive JI, Anguita-Rodríguez F, López-García A. Analysis of Production,
15 Impact, and Scientific Collaboration on Difficult Airway Through the Web of Science
16 and Scopus (1981-2013). *Anesth Analg*. 2017 Jun;124(6):1886-1896.
17
18 79. Tanner-Smith EE, Polanin JR. Brief alcohol intervention trials conducted by higher
19 prestige authors and published in higher impact factor journals are cited more
20 frequently. *J Clin Epidemiol*. 2016 Feb 6.
21
22
23 80. Jagsi R, Guancial EA, Worobey CC, Henault LE, Chang Y, Starr R, Tarbell
24 NJ, Hylek EM. The "gender gap" in authorship of academic medical literature--a 35-
25 year perspective. *N Engl J Med*. 2006 Jul 20;355(3):281-287.
26
27
28 81. Long MT, Leszczynski A, Thompson KD, Wasan SK, Calderwood AH. Female
29 authorship in major academic gastroenterology journals: a look over 20 years.
30 *Gastrointest Endosc*. 2015;81(6):1440-1447.
31
32
33 82. Diamond SJ, Thomas CR Jr, Desai S, Holliday EB, Jagsi R, Schmitt C, Enestvedt
34 BK. Gender Differences in Publication Productivity, Academic Rank, and Career
35 Duration Among U.S. Academic Gastroenterology Faculty. *Acad*
36 *Med*. 2016 Aug;91(8):1158-1163.
37
38
39 83. Nicholson JM, Ioannidis JP. Research grants: Conform and be funded. *Nature*.
40 2012 Dec 6;492(7427):34-36.
41
42 84. Lauer MS, Danthi NS, Kaltman J, Wu C. Predicting Productivity Returns on
43 Investment: Thirty Years of Peer Review, Grant Funding, and Publication of Highly
44 Cited Papers at the National Heart, Lung, and Blood Institute. *Circ Res*. 2015 Jul
45 17;117(3):239-243.
46
47
48
49 85. Cheng K, Dodson TB, Egbert MA, Susarla SM. Which Factors Affect Citation
50 Rates in the Oral and Maxillofacial Surgery Literature? *J Oral Maxillofac*
51 *Surg*. 2017 Apr 1. pii: S0278-2391(17)30361-0.
52
53
54
55
56
57
58
59
60

1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

86. Connelly TM, Devane L, Kelly JC, Wrafter P, Messaris E. The 100 classic papers in ulcerative colitis: a bibliometric analysis. *Expert Rev Gastroenterol Hepatol.* 2016 Aug 22:1-9. [Epub ahead of print]

For peer review only

Figure Legend

Figure 1A: Number of citations of papers published before the year 2000 (mean±SD)

Figure 1B: Number of citations of papers published after the year 2000 (mean±SD)

For peer review only

1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47

Table 1 Top cited papers in inflammatory bowel disease identified by searching the Web of Science, summarized by year of publication and category

Article type	Year of publication: no of articles [References]							
	1950-1958	1959-1967	1968-1976	1977-1985	1986-1994	1995-2003	2004-2012	Total (%)
Article				1 [39]				1 [2%]
Review/ Meta-analysis			1 [61]			5 [25,36,41,55,60]	8 [27,34,35,45,33,57,38,63]	14 [28%]
Report							2 [43,59]	2 [4%]
Research	1 [28]		1 [23]	3 [37,58,67]	8 [22,44,40,48,49,56,50,66]	10 [20,21,26,24,31,46,62,69,65,68]	10 [29,30,32,51,52,42,54,47,53,64]	33 [66%]
Total (%)	1 [2%]	0 [0%]	2 [4%]	4 [8%]	8 [16%]	15 [30%]	20 [40%]	50 [100%]

Table 2 Top-cited papers in inflammatory bowel disease (IBD) identified by searching the Web of Science, summarized by category and topic

Topics on IBD	Category: no of articles [References]				Total (%)
	Article	Review/ Meta-analysis	Report	Research	
Epidemiology, prevalence		2 [35,38]			2 [4%]
CD genetic susceptibility and NOD2 mutation		2 [34,45]		4 [20,21,51,54]	6 [12%]
Animal models for IBD		1 [60]		4 [22,44,40,48]	5 [10%]
Pathogenesis of IBD		7 [25,27,36,55,33,57,63]		8 [29,32,42,62,65,68,66,64]	15 [30%]
Classification, index of disease activity	1 [39]		2 [43,59]	2 [23,37]	5 [10%]
Risk of developing colorectal cancer		1 [41]		1 [49]	2 [4%]
Extra-intestinal complications		1 [61]			1 [2%]
Infliximab in CD				6 [24,31,30,46,52,47]	6 [12%]
Corticosteroids in UC				1 [28]	1 [2%]
Drug treatment and cyclosporine in UC				2 [56,58]	2 [4%]
Adalimumab in CD				1 [53]	1 [2%]
5-aminosalicylic acid in				1 [50]	1 [2%]

1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47

UC					
6-mercaptopurine in CD				1 [67]	1 [2%]
Monoclonal antibodies, anti-tumor necrosis factor in CD				2 [26,69]	2 [4%]
Total (%)	1 [2%]	14 [28%]	2 [4%]	33 [66%]	50 [100%]

For peer review only

Table 3. The journals that published the top-cited inflammatory bowel disease (IBD) articles included in the study, the journal impact factor, and the number of papers published and reference number.

Journal*	2016-Journal Impact Factor (JIF)	Number of papers published [References]
<i>New England Journal of Medicine</i>	72.406	12 [25,26,31,30,46,49,56,52,47,50,67,57]
<i>Gastroenterology</i>	18.392	12 [23,36,35,40,58,60,53,69,38,68,63,66]
<i>Nature</i>	40.137	4 [20,21,27,33]
<i>Nature Genetics</i>	27.959	4 [34,51,45,54]
<i>The Lancet</i>	47.831	2 [24,37]
<i>Proceedings of the National Academy of Sciences of the United States of America</i>	9.661	2 [32,42]
<i>Cell</i>	30.410	2 [22,44]
<i>Gut</i>	16.658	4 [59,64,41,62]
<i>British Medical Journal</i>	20.785	1 [28]
<i>Science</i>	37.205	1 [29]
<i>Human Pathology</i>	3.014	1 [39]
<i>Laboratory Investigation</i>	4.857	1 [48]
<i>Canadian Journal of Gastroenterology and Hepatology</i>	2.147	1 [43]
<i>Nature Reviews Immunology</i>	39.932	1 [55]
<i>Medicine (Baltimore)</i>	1.804	1 [61]
<i>Journal of Immunology</i>	4.856	1 [65]

- Gastroenterology related journals (Gastroenterology, and Gut) only published 16 (32%) articles out of the top highly cited 50 articles

Table 4 Authors and co-authors of two or more articles of the top-cited articles in inflammatory bowel disease identified by searching the Web of Science

Author's name*	Number [References]		Author's Name*	Number [References]	
	First author	Coauthor		First author	Coauthor
Hugot, JP	1 [20]	2 [34,45]	Daly, MJ	-	5[29,34,51,45,33]
Podolsky, DK	1 [25]	3 [28,27,31]	Steinhart, AH	-	5[29,34,43,51,45]
Targan, SR	1 [26]	7 [29,31,34,43,51,45,33]	Griffiths, A	-	4[29,34,51,45]
Hanauer, SB	1 [24]	6 [21,26,31,30,56,53]	Dassopoulos, T	-	2[29,34]
Xavier, RJ	1 [27]	3 [34,51,33]	Bitton, A	-	3[29,34,33]
Duerr, RH	1 [29]	4 [21,34,45,33]	Datta, LW	-	3[29,34,51]
Present, DH	2 [31,67]	3 [26,30,56]	Kistner, EO	-	2[29,34]
Rutgeerts, P	1 [30]	9 [26,24,31,34,46,45,52,47,53]	Rotter, JI	-	5[29,34,51,45,33]
Fiocchi, C	1 [36]	1 [65]	Schumm, LP	-	5[29,34,51,45,52]
Barrett, JC	1 [34]	2 [45,33]	Lee, J	-	2[45,33]
Riddell, RH	1 [39]	2 [43,60]	Lees, CW	-	2[45,33]
Loftus, EV Jr	1 [35]	1 [43]	Sandborn, WJ	-	3[30,47,53]
Franke, A	1 [45]	2 [33,54]	Barmada, MM	-	3[29,34,51]
Silverberg, MS	1 [43]	5 [29,34,51,45,33]	Nicolae, DL	-	4[21,29,34,51]
Rioux, JD	1 [51]	4 [29,34,45,33]	Sands, BE	-	3[31,30,52]
Lichtiger, S	1 [56]	1 [47]	Belaiche, J	-	2[20,34]
Colombel, JF	2 [47,53]	5 [20,24,30,43,45]	Laukens, D	-	3[34,45,33]
Abraham, C	1 [57]	2 [29,33]	Lawrance, I	-	2[45,33]
Becktel, JM	-	2 [23,58]	Louis, E	-	3[34,33,45]

Singleton,JW	-	2 [23,58]	Vos,M	-	3[34,45,33]
Kern,F Jr	-	2 [23,58]	Vermeire,S	-	5[34,46,43,45,33]
Van Deventer,SJ	-	4 [26,31,52,69]	Satsangi,J	-	4[34,43,45,33]
Mayer,L	-	3 [26,24,31]	Bernstein,CN	-	2[43,52]
Braakman,T	-	2 [26,31]	Tremelling,M	-	2[34,33]
DeWoody,KL	-	2 [26,31]	Mansfield,J	-	3[34,45,33]
Schaible,TF	-	2 [26,31]	Jewell,D	-	2[34,43]
Feagan,BG	-	3 [24,30,52]	Mathew,CG	-	4[34,45,33,54]
Lichtenstein,GR	-	2 [24,30]	Parkes,M	-	3[34,45,33]
Schreiber,S	-	7 [24,43,45,33,54,53,68]	Georges,M	-	3[34,45,33]
Rachmilewitz,D	-	4 [24,30,52,47]	Karban,A	-	2[43,45]
Wolf,DC	-	2 [24,52]	Gossum,A	-	2[34,45]
Olson,A	-	2 [24,30]	Franchimont,D	-	3[34,45,33]
Taylor,KD	-	5 [29,34,51,45,33]	Newman,W	-	2[45,33]
Bayless, TM	-	2 [21,45]	Regueiro,M	-	5[29,34,51,45,33]
Cho, JH	-	7 [21,29,34,51,45,33,57]	Kornbluth,A	-	2[56,47]

*Author's name= family name, abbreviations of first or first and second names.

1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47

Table 5 Grading the top-cited articles in inflammatory bowel disease according to the Oxford Centre for Evidence-based Medicine – Levels of Evidence.

Level	Domain	Characteristics and description	Articles number [References]
1a	Therapeutic/ Prevention, Aetiology/Harm	Systematic reviews of RCTs (with consistent results from individual studies)	1 (33)
	Prognosis	Systematic reviews with homogeneity of inception cohort studies	
	Diagnosis	Systematic reviews with homogeneity of Level 1 diagnostic studies	
	Differential diagnosis/symptom prevalence study	Systematic reviews with homogeneity of prospective cohort studies.	
1b	Therapeutic/ Prevention, Aetiology/Harm	Individual RCT (with narrow confidence intervals)	12 [26,24,30,56,58,52,47,53,50,66,67, 59]
	Prognosis	Individual inception cohort study with >80% follow-up	
	Diagnosis	Validating cohort study with good reference standards	
	Differential diagnosis/symptom prevalence study	Prospective cohort study with good follow-up	
2a	Therapeutic/ Prevention, Aetiology/Harm	Systematic review of cohort studies (with consistent results from individual studies)	2 [34,63]

	Prognosis	Systematic review with homogeneity of either retrospective cohort studies or untreated control groups in RCT	
	Diagnosis	Systematic review with homogeneity of Level > 2 diagnostic studies	
	Differential diagnosis/symptom prevalence study	Systematic review with homogeneity of 2b and better studies	
2b	Therapeutic/Prevention, Aetiology/Harm	Individual cohort study (including low quality RCT; e.g., <80% follow-up)	3 [31,46,49]
	Prognosis	Retrospective cohort study or follow-up untreated control patients in an RCT	
	Diagnosis	Exploratory cohort study with good reference standards	
	Differential diagnosis/symptom prevalence study	Retrospective cohort study or poor follow-up	
2c	Therapeutic/Prevention, Aetiology/Harm	Outcome studies (analysis of large registries)	3 [38,60,61]
	Prognosis	Outcomes research	
	Diagnosis		
	Differential diagnosis/symptom	Ecological studies	

1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47

	prevalence study		
3a	Therapeutic/ Prevention, Aetiology/Harm	Systemic reviews of case-control studies (with consistent results from individual studies)	9 [25,27,36,35,41,43,55,45,57]
	Prognosis		
	Diagnosis	Systematic reviews with homogeneity of 3b and better studies	
	Differential diagnosis/symptom prevalence study	Systematic reviews with homogeneity of 3b and better studies	
3b	Therapeutic/ Prevention, Aetiology/Harm	Individual case-control study	15 [20,21,22,28,29,44,40,32,51,42,54,62,64,65,68]
	Prognosis		
	Diagnosis	Non consecutive study, or without consistently applied reference standards	
	Differential diagnosis/symptom prevalence study	Non consecutive cohort study or very limited population	
4	Therapeutic/ Prevention, Aetiology/Harm	Case series (and poor quality cohort and case-control studies)	5 [23,39,37,48,69]
	Prognosis	Case-series (and poor quality prognostic cohort studies)	
	Diagnosis	Case-control study, poor or non-	

1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47



		independent reference standard	
	Differential diagnosis/symptom prevalence study	Case-series or superseded reference standards	
5	Therapeutic/ Prevention, Aetiology/Harm	Expert opinion without explicit critical appraisal or based on physiology, or bench research.	0 [0]
	Prognosis	Expert opinion without explicit critical appraisal or based on physiology, or bench research.	
	Diagnosis	Expert opinion without explicit critical appraisal or based on physiology, or bench research.	
	Differential diagnosis/symptom prevalence study	Expert opinion without explicit critical appraisal or based on physiology, or bench research.	

Peer review only

1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47

For peer review only

1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60



209x296mm (300 x 300 DPI)

Appendix 1.

Top-cited articles on inflammatory bowel disease identified by searching the Web of Science database^a

Rank	Authors, Year [Reference]	Article (<i>Journal</i>)	2016-JIF	Category	Number of citations, Web of Knowledge	Average citation per year ^b	Rank of the article in the journal publishing it ^c	Origin: First author's organization, location (country)
1	Hugot et al, 2001 ²⁰	Association of NOD2 leucine-rich repeat variants with susceptibility to Crohn's disease. (<i>NATURE</i>).	40.137	Basic research	3,555	209.1	134	Fondation Jean Dausset CEPH (France)
2	Ogura et al, 2001 ²¹	A frameshift mutation in NOD2 associated with susceptibility to Crohn's disease. (<i>NATURE</i>).	40.137	Basic research	3,285	193.2	159	The University of Michigan Medical School, Michigan (United States).
3	Kuhn et al, 1993 ²²	Interleukin-10-deficient mice develop chronic enterocolitis. (<i>CELL</i>)	30.410	Basic research	2,982	119.3	67	Institute for Genetics, University of Cologne, (Germany)
4	Best et al, 1976 ²³	Development of a Crohns-disease activity index-National cooperative Chrons-disease study (<i>Gastroenterology</i>).	18.392	Clinical research	2,533	60.3	2	Hines Veterans Administration Cooperative Studies Support Center, University of Colorado Medical Center, Denver, Colorado, (United States).
5	Hanauer et al, 2002 ²⁴	Maintenance infliximab for Crohn's disease: the ACCENT I randomized trial (<i>Lancet</i>)	47.831	Clinical research	2,442	152.6	46	University of Chicago Medical Center, Chicago, IL (United States).
6	Podolsky, 2002 ²⁵	Inflammatory bowel disease. (<i>New England Journal of Medicine</i>)	72.406	Review	2,423	151.4	163	Massachusetts General Hospital and Harvard Medical School, Boston,

								Massachusetts (United States).
7	Targan et al, 1997 ²⁶	A short-term study of chimeric monoclonal antibody cA2 to tumor necrosis factor alpha for Crohn's disease (<i>New England Journal of Medicine</i>)	72.406	Clinical research	2,364	112.6	169	Cedars-Sinai Medical Center, Los Angeles, California (United States)
8	Xavier and Podolsky, 2007 ²⁷	Unravelling the pathogenesis of inflammatory bowel disease (<i>NATURE</i>)	40.137	Review	2,036	185.1	450	Massachusetts General Hospital, Harvard Medical School, Boston, Massachusetts (United States).
9	Truelove and Witts, 1955 ²⁸	Cortisone in ulcerative colitis- Final report on a therapeutic trial (<i>British Medical Journal</i>).	20.785	Clinical research	1,871	29.7	20	Nuffield Department of Clinical Medicine, Oxford (United Kingdom)
10	Duerr et al, 2006 ²⁹	A genome-wide association study identifies IL23R as an inflammatory bowel disease gene. (<i>SCIENCE</i>).	37.205	Clinical research	1,862	155.2	530	Department of Medicine, School of Medicine, University of Pittsburgh, Pittsburgh, PA (United States).
12	Rutgeerts et al, 2005 ³⁰	Infliximab for induction and maintenance therapy for ulcerative colitis (<i>New England Journal of Medicine</i>)	72.406	Clinical research	1,834	141.1	290	University Hospital Gasthuisberg, Leuven, (Belgium).
12	Present et al, 1999 ³¹	Infliximab for treatment of fistulas in patients with Crohn's disease (<i>New England Journal of Medicine</i>)	72.406	Clinical research	1,730	91.0	321	Mount Sinai Medical Center, New York, NY, (United States)

13	Frank et al, 2007 ³²	Molecular-phylogenetic characterization of microbial community imbalances in human inflammatory bowel diseases. (<i>Proceedings of the National Academy of Sciences of the United States of America</i>)	9.661	Basic research	1,650	150.0	172	University of Colorado, Boulder, CO (United States)
14	Jostins et al, 2012 ³³	Host-microbe interactions have shaped the genetic architecture of inflammatory bowel disease. (<i>Nature</i>)	40.137	Review Meta-analysis	1,643	273.8	683	Wellcome Trust Sanger Institute, Wellcome Trust Genome Campus, Hinxton, Cambridge, (United Kingdom)
15	Barrett et al, 2008 ³⁴	Genome-wide association defines more than 30 distinct susceptibility loci for Crohn's disease. (<i>Nature Genetics</i>)	27.959	Review Meta-analysis	1,631	163.1	25	Wellcome Trust Centre for Human Genetics, University of Oxford, Roosevelt Drive, Oxford (United Kingdom)
16	Loftus, 2004 ³⁵	Clinical epidemiology of inflammatory bowel disease: Incidence, prevalence, and environmental influences (<i>Gastroenterology</i>)	18.392	Review	1,566	111.9	10	Mayo Clinic, Rochester, Minnesota, (United States)
17	Fiocchi, 1998 ³⁶	Inflammatory bowel disease: Etiology and pathogenesis (<i>Gastroenterology</i>)	18.392	Review	1,540	77.0	12	University Hospitals of Cleveland Case Western Reserve University School of Medicine, Ohio (United States)
18	Harvey and Bradshaw, 1980 ³⁷	A simple index of Crohns-disease activity (<i>Lancet</i>)	47.831	Clinical research	1,466	38.6	166	Bristol Royal Infirmary and Frenchay Hospital, Bristol (United Kingdom)
19	Molodeck	Increasing incidence and prevalence	18.392	Review	1,438	239.7	19	University of Calgary,

	y et al, 2012 ³⁸	of the inflammatory bowel diseases with time, based on systematic review. (<i>Gastroenterology</i>).						Calgary, Alberta, (Canada).
20	Riddell et al, 1983 ³⁹	Dysplasia in inflammatory bowel disease- Standardized classification with provisional clinical applications (<i>Human Pathology</i>)	3.014	Article	1,398	39.9	2	National Foundation for Ileitis and Colitis, New York, (United States).
21	Okayasu et al, 1990 ⁴⁰	A novel method in the induction of reliable experimental acute and chronic ulcerative-colitis in mice (<i>Gastroenterology</i>)	18.392	Basic research	1,396	49.9	24	School of Medicine, Tokyo Medical and Dental University, (Japan).
22	Eaden et al, 2001 ⁴¹	The risk of colorectal cancer in ulcerative colitis: a meta-analysis. (<i>Gut</i>).	16.658	Review Meta-analysis	1,388	81.6	1	Leicester General Hospital, Gwendolen Road, Leicester (United Kingdom)
23	Sokol et al, 2008 ⁴²	Faecalibacterium prausnitzii is an anti-inflammatory commensal bacterium identified by gut microbiota analysis of Crohn disease patients. <i>Proceedings of the National Academy of Sciences of the United States of America</i>)	9.661	Basic research	1,384	138.4	247	Institut National de la Recherche Agronomique U910, Domaine de Vilvert, Jouy-en-Josas, (France).
24	Silverberg et al, 2005 ⁴³	Toward an integrated clinical, molecular and serological classification of inflammatory bowel disease: report of a Working Party of the 2005 Montreal World Congress of Gastroenterology. (<i>Canadian Journal of Gastroenterology and Hepatology</i>)	2.147	Report	1,373	105.6	1	Mount Sinai Hospital IBD Centre, University of Toronto, Toronto, Ontario (Canada)

25	Sadlack et al, 1993 ⁴⁴	Ulcerative colitis-like disease in mice with a disrupted interleukin-2 gene (<i>CELL</i>)	30.410	Basic research	1,358	54.32	387	Institute of Virology and Immunobiology, University of Würzburg, (Germany)
26	Franke et al, 2010 ⁴⁵	Genome-wide meta-analysis increases to 71 the number of confirmed Crohn's disease susceptibility loci. (<i>Nature Genetics</i>)	27.959	Review Meta-analysis	1,321	165.1	63	Institute of Clinical Molecular Biology, Christian-Albrechts-University Kiel, Kiel, (Germany).
27	Baert et al, 2003 ⁴⁶	Influence of immunogenicity on the long-term efficacy of infliximab in Crohn's disease. (<i>New England Journal of Medicine</i>)	72.406	Clinical research	1,297	86.5	562	University Hospital Gasthuisberg, Leuven, (Belgium).
28	Colombel et al, 2010 ⁴⁷	Infliximab, azathioprine, or combination therapy for Crohn's disease (<i>New England Journal of Medicine</i>)	72.406	Clinical research	1,294	161.7	565	Hôpital Claude Huriez and Centre d'Investigation Clinique, Centre Hospitalier Universitaire de Lille, Université Lille Nord de France, Lille, (France).
29	Cooper et al, 1993 ⁴⁸	Clinicopathologic study of dextran sulfate sodium experimental murine colitis. (<i>Laboratory Investigation</i>)	4.857	Basic research	1,219	48.8	4	Hahnemann University, Philadelphia, Pennsylvania. (United States)
30	Ekbom et al, 1990 ⁴⁹	Ulcerative colitis and colorectal cancer. A population-based study. (<i>New England Journal of Medicine</i>)	72.406	Clinical research	1,168	41.7	684	University Hospital, Uppsala, (Sweden).

31	Schroeder et al, 1987 ⁵⁰	Coated oral 5-aminosalicylic acid therapy for mildly to moderately active ulcerative colitis. A randomized study (<i>New England Journal of Medicine</i>)	72.406	Clinical research	1,156	37.3	695	Mayo Clinic, Rochester, MN (United States)
32	Rioux et al, 2007 ⁵¹	Genome-wide association study identifies new susceptibility loci for Crohn disease and implicates autophagy in disease pathogenesis. (<i>Nature Genetics</i>)	27.959	Basic research	1,152	104.7	89	Université de Montréal and the Montreal Heart Institute, Research Center, Montreal, Quebec (Canada).
33	Sands et al, 2004 ⁵²	Infliximab maintenance therapy for fistulizing Crohn's disease. (<i>New England Journal of Medicine</i>)	72.406	Clinical research	1,146	81.8	706	Massachusetts General Hospital, and Harvard Medical School, Boston (United States)
34	Colombel et al, 2007 ⁵³	Adalimumab for maintenance of clinical response and remission in patients with Crohn's disease: the CHARM trial. (<i>Gastroenterology</i>).	18.392	Clinical research	1,124	102.2	32	Hôpital Claude Huriez, Centre Hospitalier Universitaire de Lille, Rue Michel Polonovski, Lille, (France)
35	Hampe et al, 2007 ⁵⁴	A genome-wide association scan of nonsynonymous SNPs identifies a susceptibility variant for Crohn disease in ATG16L1. (<i>Nature Genetics</i>)	27.959	Basic research	1,123	102.1	92	Institute for Clinical Molecular Biology, Christian-Albrechts University Kiel, University Hospital Schleswig-Holstein, (Germany).

36	Bouma and Strober, 2003 ⁵⁵	The immunological and genetic basis of inflammatory bowel disease. (<i>Nature Reviews Immunology</i>)	39.932	Review	1,116	74.4	35	National Institutes of Health, and National Institutes of Allergy and Infectious Diseases, Bethesda, Maryland (United States)
37	Lichtiger et al, 1994 ⁵⁶	Cyclosporine in severe ulcerative colitis refractory to steroid therapy. (<i>New England Journal of Medicine</i>)	72.406	Clinical research	1,104	46.0	755	Mount Sinai School of Medicine, New York (United States).
38	Abraham et al, 2009 ⁵⁷	Inflammatory bowel disease. (<i>New England Journal of Medicine</i>)	72.406	Review	1,091	121.2	772	Yale University School of Medicine, New Haven, CT (United States)
39	Summers et al, 1979 ⁵⁸	National Cooperative Crohn's Disease Study: results of drug treatment (<i>Gastroenterology</i>)	18.392	Clinical research	1,059	27.1	37	Division of gastroenterology, University of Iowa Medical Center, Iowa City, Virginia, (United States).
40	Satsangi, et al 2006 ⁵⁹	The Montreal classification of inflammatory bowel disease: controversies, consensus, and implications (<i>Gut</i>).	16.658	Report	1,054	87.8	7	Gstrointestinal Unit, Western General Hospital, University of Edinburg, (United Kingdom).
41	Elson, et al, 1995 ⁶⁰	Experimental models of inflammatory bowel disease. (<i>Gastroenterology</i>).	18.392	Review	957	41.6	40	Department of Medicine, University of Alabama Hospital at Birmingham, AL, (United States).

42	Greenstein et al, 1976 ⁶¹	The extra-intestinal complications of Crohn's disease and ulcerative colitis: a study of 700 patients. <i>Medicine (Baltimore)</i> .	1.804	Review	945	22.5	10	Department of Surgery, Mount Sinai School of Medicine and the City University of New York, New York, (United States.)
43	Fujino et al, 2003 ⁶²	Increased expression of interleukin 17 in inflammatory bowel disease. (<i>Gut</i>).	16.658	Basic research	931	62.1	12	Shiga University of Medical Science, Seta-Tukinowa, Otsu, (Japan).
44	Sartor, 2008 ⁶³	Microbial influences in inflammatory bowel diseases. (<i>Gastroenterology</i>).	18.392	Review	925	92.5	44	Department of Medicine, Center for Gastrointestinal Biology and Disease, University of North Carolina at Chapel Hill, Chapel Hill, North Carolina, (United States).
45	Manichanh et al, 2006 ⁶⁴	Reduced diversity of faecal microbiota in Crohn's disease revealed by a metagenomic approach. (<i>Gut</i>).	16.658	Basic research	913	76.1	13	Unité d'Ecologie et de Physiologie du système Digestif, INRA-UEPSD, 78350 Jouy-en-Josas, (France)
46	Fuss et al, 1996 ⁶⁵	Disparate CD4+ lamina propria (LP) lymphokine secretion profiles in inflammatory bowel disease. Crohn's disease LP cells manifest increased secretion of IFN-gamma, whereas ulcerative colitis LP cells manifest increased secretion of IL-5. (<i>Journal of Immunology</i>)	4.856	Basic research	893	40.6	68	National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, MD, (United States)
47	Rutgeerts	Predictability of the postoperative	18.392	Clinical	884	31.6	50	Department of Medicine,

1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46

	et al, 1990 ⁶⁶	course of Crohn's disease. (<i>Gastroenterology</i>).		research				University Hospital Gasthuisberg, University of Leuven, (Belgium).
48	Present et al, 1980 ⁶⁷	Treatment of Crohn's disease with 6-mercaptopurine. A long-term, randomized, double-blind study. (<i>New England Journal of Medicine</i>)	72.406	Clinical research	874	23.0	1150	Lenox Hill Hospital and the Mount Sinai School of Medicine of City University of New York (United States)
49	Swidsinski et al, 2002 ⁶⁸	Mucosal flora in inflammatory bowel disease. (<i>Gastroenterology</i>).	18.392	Basic research	873	54.6	52	Charité Humboldt Universität, Berlin, (Germany).
50	Vandullem en et al, 1995 ⁶⁹	Treatment of Crohn's disease with anti-tumor necrosis factor chimeric monoclonal antibody (cA2). (<i>Gastroenterology</i>).	18.392	Clinical research	871	37.9	53	Academic Medical Center, Amsterdam, (The Netherlands).

^a The search was conducted in April, 2018 by searching the Web of Knowledge.
^b The average citation per year = total number of citation / number of years since publication.
^c This ranking was identified by searching each journal for a top-cited article and identifying its ranking based on the number of citations received in comparison to the number of citations received by other articles published in that journal.

1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46

For peer review only

Appendix 2

Glossary

Articles are scientific written composition representing a substantial advance in the understanding of a topic or problem. They raise questions, provide thoughtful, critical analysis and aim at establishing new directions.

Basic research is defined as fundamental research, which aims at improving scientific theories and our understanding of a phenomenon. Basic research may use animal models and include in vivo and in-vitro studies that target advances of fundamental knowledge.

Clinical research is defined as research applied to a clinical condition/disease with the aim to test an intervention or make a change to a phenomenon. Basic research usually fuels clinical research.

Reports are defined as brief articles with conclusions, results, and recommendations. They report on a substantial advance in an area/topic or a problem and aim at reporting findings and standardization of practice.

Review and meta-analysis are defined as an article reviewing the progress of knowledge in a particular topic, critically analysing the current status of knowledge and presenting an understanding of the subject by discussing related literature. A review should identify gaps in the literature and highlight future directions for further research. **A meta-analysis** is defined as a statistical analysis that combines the results from different scientific studies to provide conclusive evidence.